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The extensive roll-out of combination antiretroviral therapy (cART) has significantly 
improved the life expectancy for HIV-1 infected individuals in South Africa. Despite 
the inclusion of potent Protease Inhibitors (PIs) in second-line cART, many patients 
still fail treatment. The extent to which PI resistance contributes to treatment failure 
is not completely clear. In this study we report the prevalence of PI mutations 
amongst individuals failing a second-line Lopinavir (LPV/r) inclusive regimen. We 
also investigated if low frequency minority variants at LPV/r failure influence 
Darunavir (DRV/r) failure in a subset of patients using Ultra Deep Pyro-sequencing. 
Structural changes at DRV/r failure were investigated using Homology modeling. 
Models were constructed using the SWISS-MODEL webserver and visualized in 
Chimera v1.8.1. Darunavir was docked into each of the structures using the CLC 
Drug  Discovery  workbench  ™  and  Molecular Dynamics simulations was performed 
using the AMBER12 package. Our study reports a 24% prevalence of PI resistance 
mutations, slightly higher than other studies. A distinct pattern of PI resistance 
mutations was found: M46I+I54V+L76V+V82A, present in 13/37 (35%) of those 
with PI mutations. Darunavir resistance mutations detected following DRV/r failure 
included V11I, V32I, L33F and I54L. There were no minority variants detected at 
LPV/r failure that could have influenced DRV/r failure. Distinct conformational 
changes were evident in both the LPV/r-resistant and DRV/r-resistant model.  
Molecular docking showed that the inhibitory potency of DRV was lowered in the 
mutated DRV/r-resistant model and to a lesser extent in the LPV/r-resistant model. 
These results show that resistance mutations greatly contribute to DRV drug 
susceptibility. This work will contribute to the clinical management of patients failing 






1.1 Origins of HIV/AIDS  
The Acquired Immunodeficiency Syndrome (AIDS) was first identified in 1981 
where the Atlanta based Centre for Disease Control described the occurrence of 
rare opportunistic infections and severely compromised immunity amongst patients 
(CDC, 1981). The disease was prevalent amongst homosexual men, blood 
transfusion recipients, intravenous drug users, children and sexual partners, 
suggesting that the etiological agent was transmitted by body fluids (Freed, 2007). 
Thus   far,  AIDS  has  been  described  by  many  as   the  most   “devastating   infectious  
disease”  yet  to  emerge  (Gottlieb et al., 1981, Barre-Sinoussi et al., 1983, Popovic 
et al., 1984). In 1983, Dr Luc Montagnier and Dr Francois Barre-Sinoussi from the 
Pasteur Institute in France were able to isolate a retrovirus believed to be the 
cause of AIDS, which at the time was named the Lymphadenopathy-Associated 
virus (LAV) (Barre-Sinoussi et al., 1983). In 1984, Dr Robert Gallo isolated a virus 
called the Human–T–Lymphotrophic Virus Type III (HTLV-III) (Gallo et al., 1984). A 
few years later it was then apparent that both LAV and HTLV- III were in fact the 
same virus and was later named the Human Immunodeficiency Virus (HIV).  HIV 
was then established as the causative agent of AIDS and was renamed HIV type 1 
(HIV-1) to distinguish it from a related, but less prevalent AIDS-causing virus, HIV-
2 in 1986 (Clavel et al., 1986).  
HIV belongs to the Lentivirus genus of the Retroviridae family, and is believed to 
be a descendant of the Simian Immunodeficiency Virus (SIV) carried by certain 
non-human primates (Hemelaar, 2012). Like HIV, SIV belongs to the Retroviridae 
family comprising of more than 40 Lentiviruses, having high sequence homology to 
HIV (Sharp and Hahn, 2011). HIV-2 is distantly related to HIV-1, but is closely 
related to SIV, that causes immunodeficiency in macaques (Chakrabarti et al., 
1987, Guyader et al., 1987).  SIVs were found in different primates from Sub-
 2 
Saharan Africa and included African green monkeys, sooty mangabeys, mandrills, 
chimpanzees, and others. SIVcpz which infects chimpanzees is considered the 
origin of HIV-1 while SIVmm which infects sooty mangabeys is thought to cause 
HIV-2 (Silvestri et al., 2007). This provided the first evidence that AIDS had 
emerged in both humans and macaques as a result of a cross-species 
transmission event with Lentiviruses from different primate species (Sharp PM, 
1994).  This transmission was possibly the result of hunting, butchering and the 
consumption of infected raw meat from primates, a common practice at the time 
(Hemelaar et al., 2011). The phylogenetic relationship between SIV and HIV is 
illustrated in Figure 1.1. 
 
Figure 1.1 Maximum-likelihood tree of HIV-1 and HIV-2. The red branches 
represent independent cross-species transmission events from SIV isolated from 
other primates. Different groups of HIV-1 are shown: M (Main), O (Outlier) and N 
(non M/non O) representing independent introductions from chimpanzees 
(SIVcpz). Similarly HIV-2 was introduced from Sooty Mangebeys (SIVsm) on 
several occasions. SIVcol; black and white colobus, SIVdrl; drill, SIVgsn; greater 
spot nosed monkey, SIVlhoest;;   L’Hoest monkey, SIVmac; macaque. SIVmnd; 
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mandrill, SIVmon; Campbells mon monkey, SIVrcm; red-capped monkey, SIVsab; 
Sabaceus monkey, SIVsun; sun-tailed monkey, SIVsyk; Sykes monkey, SIVtan; 
tantalus monkey and SIVver; vervet monkey. The tree was constructed based on 
34 published sequences of the viral polymerase gene accessed from Genbank. 
Taken from Rambaut et al (2001). 
 
 
1.2 Classification of HIV 
The diversity of HIV-1 stems from three independent introductions of the virus from 
chimpanzees to humans (Kandathil et al., 2005) as mentioned in section 1.1. As a 
result, there are four different phylogenetic lineages of HIV, comprising Group M, 
O, N and P (Simon et al., 1998, Ayouba et al., 2001, Plantier et al., 2009, Vallari et 
al., 2011).  The HIV-1 epidemic is primarily due to Group M (Hahn et al., 2000, 
Buonaguro et al., 2007, Hemelaar, 2012) and comprises 11 phylogenetic subtypes 
(A-K) excluding the recombinant forms, while HIV-2 comprises subtypes (A-H) 
(Buonaguro et al., 2007). HIV is classified based on sequences that are derived 
from multiple sub-genomic regions of the same isolate, or from full-length genome 
sequence analysis. As a result phylogenetic relationships between different 
subtypes within the viral genome can be determined. These isolates are referred to 
as inter-subtype recombinant forms and are hypothesized to have originated in 
individuals that have had multiple infections with viruses belonging to two or more 
subtypes (Buonaguro et al., 2007). Once the virus is seen in at least three 
epidemiologically un-related individuals these recombinant forms are referred to as 
Circulating Recombinant Forms (CRFs) (Peeters, 2001). 
 
1.3 Geographical distribution of HIV subtypes 
Molecular epidemiological studies have shown that HIV-1 subtypes exist within 
distinct geographical regions (Bessong, 2008, Hemelaar, 2012). This distribution is 
largely driven by viral migration accompanied by a resulting founder effect or 
possibly the prevalence of a specific route of transmission. Therefore certain 
subtypes predominant within a specific population (Buonaguro et al., 2007). HIV-1 
Group O appears to be endemic to Cameroon and neighboring countries of West 
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Central Africa and is representative of 1-5% of HIV-1 positive patients (Peeters et 
al., 1997). While group N viruses are generally found in parts of Central Africa 
(Plantier et al., 2009). Group M viruses drive the HIV-1 pandemic as they appear to 
have adapted well to new host species and have thus been able to spread around 
the world generating multiple genetic subtypes (Buonaguro et al., 2007).  Subtype 
A is found in Central and Eastern Africa, including Kenya, Uganda, Tanzania, 
Rwanda as well as in the Eastern European countries. Subtype B is the most 
disseminated variant and is representative of the main genetic form in Western and 
Central Europe, including the Americas and Australia. It is also prevalent in South 
East Asia, Northern Africa, the Middle East and has been seen amongst South 
African and Russian homosexual men (Buonaguro et al., 2007). The most 
prevalent HIV-1 subtype is subtype C and is prominent in Sub-Saharan Africa, 
Eastern African countries, India and the Southern region of Brazil (Buonaguro et 
al., 2007). The presence of CRFs within the global pandemic is becoming more 
prevalent than before, accounting for 18% of infections in Southeast Asia (CRF01-
AE) and in West Central Africa (CRF02-AG) (Buonaguro et al., 2007). 
 
1.4 HIV-1 Structure 
HIV-1 has a spherical morphology measuring between 100-120nm in diameter 
(Sierra et al., 2005, Marsden and Zack, 2013). HIV-1 comprises two copies of non-
covalently linked, positive sense single stranded Ribonucleic Acid (ssRNA), tightly 
bound to the Nucleocapsid (p7) and enclosed within a viral protein capsid (p24). 
Also within the capsid is the late assembly protein (p6), viral enzymes: protease 
(PR), reverse transcriptase (RT), integrase (IN), as well as many viral proteins Vpu, 
Vif, Vpr and Nef. The cone shaped capsid is surrounded by the matrix (p17) which 
provides integrity to the virion. As the capsid buds from the host cell, part of the 
host cell membrane is retained by the virus forming an envelope that surrounds the 
capsid. Anchored within the envelope are proteins from the host cell as well as 
approximately 70 copies of glycoprotein 120 and 41, (gp120 and gp41). These 
glycoproteins allow the virus to fuse and attach to target cells thus initiating the 
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infectious replication cycle (Sierra et al., 2005, Marsden and Zack, 2013, Shum et 
al., 2013). The structural features of HIV-1 are shown in Figure 1.2. 
 
Figure 1.2 Structural features of HIV-1 required for the formation of mature 
infectious virions. Taken from Shum et al (2013). 
 








The 9.2kb ssRNA molecules contain nine Open Reading Frames (ORFs). Both 
edges of the Ribonucleic Acid (RNA) molecule contain the LTR (Long Terminal 
Repeat) which are regulatory regions that flank the coding region. As indicated in 
Figure 1.3, each LTR contains a U3, R and a U5 coding region. U3 is a unique 
non-coding region of (200-1200nt) which  forms  the  5’  end  of  the  provirus  following  
reverse transcription and contains binding sites for cellular transcription factors. 
The R region is much shorter (18-250nt) and forms a direct repeat at both sides of 
the genome, as a result   this   region   is   “terminally   redundant”. This region also 
contains the Transactivation response element (TAR) which is important for tat-
mediated transactivation. The U5 is a unique, non-coding region of (75-250nt) and 
comprises the first part of the genome to be reverse transcribed, thus forming the 
3’  end  of   the  provirus  genome (Lodish, 2000).  The gag-pol gene encodes for all 
structural viral proteins which are the matrix, capsid, nucleocapsid (p7), the p6 
protein and the two spacer proteins (p2 and p1). The gag-pol poly-protein is made 
due to a ribosomal frame shift that generates structural proteins (Matrix, Capsid, 
p2, and p6), the Trans-Frame Protein (TFP) and the three viral enzymes. PR, RT 
and IN. The env gene encodes the glycoprotein 160 (gp160) containing the exterior 
gp120 and the transmembrane gp41, two regulatory (Tat and Rev) and four 
accessory (Vif, Vpr, Vpu and Nef) genes. These protein-coding regions are flanked 
by   the  5’  and   the  3’  LTR   that  are  necessary   for   reverse   transcription,   integration  
and gene expression (Sierra et al., 2005). 
 
1.6 HIV-1 replication cycle  
During the HIV-1 replication cycle gp120 binds to a CD4 receptor on the surface of 
the target cell. Upon binding, the gp120 undergoes a conformational change 
resulting in binding to the co-receptors, either Chemokine receptor type 5 (CCR5) 
or Chemokine receptor type 4 (CXCR4) found on the membrane of the target cell. 
This attachment triggers gp41 transmembrane proteins; Heptad Repeat 1 and 2 
(HR1 and HR2) to interact with each other resulting in the formation of a stable six 
helix bundle structure (Melikyan et al., 2000).This completes the fusion of the viral 
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and host cell membranes, permitting the release of the nucleocapsid containing 
viral RNA into the host cell cytoplasm. Following un-coating, the viral RNA is 
reverse transcribed by viral RT into double stranded Deoxyribonucleic acid 
(dsDNA) or proviral Deoxyribonucleic acid (DNA). Viral IN catalyzes the transport 
of the DNA into the nucleus as part of the pre-integration complex. Viral DNA is 
then inserted into the host cell’s chromosomes and the integrated provirus is 
maintained for the entire lifespan of the host cell. Viral RNA is transcribed by host 
cell polymerases from the integrated provirus for translation into protein, following 
RNA splicing for certain viral proteins. New virions then assemble and bud from the 
plasma membrane releasing immature virions. Viral PR then cleaves the poly-
proteins within the virion for the production of mature infectious virus particles 
(Marsden and Zack., 2013). 
 
 
Figure 1.4 Essential steps of the HIV-1 replication cycle (1) HIV-1 virions bind 
to CD4 and a co-receptor on target cells. (2) The viral envelope proteins mediate 
fusion of the viral and host cell membranes, viral RNA is released into the host cell 
cytoplasm. (3) Viral RNA is reverse transcribed into dsDNA by HIV-1 RT. (4) 
dsDNA is translocated into the nucleus, IN catalyzes the integration of the dsDNA 
into the host cells chromosomes (5) Transcription of the HIV-1 genome is mediated 
by host cell polymerases (6) and (7) RNA is exported to the cytoplasm for 
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translation or in-corporation into new virions (8) and (9). New virions then assemble 
and bud from the plasma membrane. (10) Viral PR cleaves HIV poly-proteins into 




1.7 Antiretroviral treatment  
The advent of Antiretroviral Therapy (ART) has transformed HIV-1 infection from a 
once  “devastating  infectious  disease”  to  a  now  treatable  and  manageable  chronic  
disease. Highly active antiretroviral therapy (HAART), also referred to as 
combination Antiretroviral Therapy (cART), is a customized combination of three 
drugs from at least two different classes of Antiretrovirals (ARVs). These drugs are 
prescribed for HIV-1 infection and are based on viral load, CD4 count, as well as 
patient dependent disease symptoms. HAART inhibits various stages in the HIV-1 
replication cycle thereby controlling viral load and delaying the onset of disease 
progression (Marsden and Zack., 2013). Thus far, cART has played a vital role in 
improving the quality of life, and has been able to restore and improve 
immunological functions. Most importantly, cART has significantly reduced HIV-
AIDS related morbidity and mortality within South Africa (SA) and globally 
(Mugavero and Hicks, 2004, Rong et al., 2007, Tanser et al., 2013, Kiepiela P, 
2014). There are different classes of ARVs that constitute cART in SA, namely, the 
Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs), the Nucleoside- 
Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase 
Strand Transfer Inhibitors (INSTIs), and Maturation inhibitors, each of these drugs 
target a specific step in the HIV-1 replication cycle. 
 
1.8 Drug resistance and the role of Minority Variants  
HIV-1 infection in vivo is characterized by rapid viral replication and the generation 
of 1010-1011 virions daily, performed by the error prone HIV-1 RT that lacks proof 
reading functionality (Tang and Shafer, 2012). As a result, an average of one 
mutation per genome per replication cycle is introduced daily (Drake and Holland, 
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1999, Duffy et al., 2008). This combination of viral replication, recombination and 
subsequent evolution results in an extraordinary genetic diversity characterized by 
the co-existence  of  viral  variants  called  “quasispecies”.  The  presence  of  these  viral  
quasispecies imply that circulating viruses are not represented by a unique virus 
genotype,  but  rather  by  a  “swarm”  of  different  yet  genetically  related  viral  variants 
(Domingo et al., 2012).  Thus, within any chronically infected un-treated individual 
there is continual evolution and co-existence of every possible mutation (Coffin, 
1995, Ribeiro et al., 1998). Viral quasispecies are subject to varying selection 
pressures, enabling them to either dominate or decay within the population (Clavel, 
2004). The wild-type variant has a better replicative ability in the absence of 
therapy, while drug resistant variants have a better replicative ability in the 
presence of therapy (Paredes and Clotet, 2010). 
Drug resistance can either be acquired (primary drug resistance) or transmitted 
(secondary drug resistance).  Acquired resistance occurs when drug resistant 
variants gain a selective advantage over the wild-type, and thus increases in 
frequency. Acquired resistance may also lead to the further accumulation of 
mutations and can either increase drug resistance or improve viral fitness 
(Devereux et al., 1999, Izopet et al., 2000, Miller et al., 2000, Birk et al., 2001). If 
treatment is interrupted these mutations decay due to a fitness cost, and are 
replaced by a fitter wild-type virus. These viruses remain incorporated within the 
viral  quasispecies  and  are  referred   to  as  “minority  drug  resistant  variants”.  These  
low frequency variants can re-emerge if ART selective pressure is introduced again 
(Metzner et al., 2005).  
Standard population based sequencing cannot detect variants that occur at <20% 
and therefore minority variants are not detected. This phenomenon is a 
fundamental concept and may account for the common trend of treatment failure 
accompanied by the absence of drug resistance mutations (DRMs). Nevertheless 
these variants are present and more sensitive assays are required for their 
detection. Some minority drug resistant variants have been shown to persist after 
treatment with certain ARVs (Tang and Shafer, 2012), especially the NNRTI drug 
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class. In particular, mutations that are associated with Efavirenz (EFV) and 
Nevirapine (NVP) have been shown to persist at low levels of <20% for as long as 
12-24 months after treatment has stopped (Flys et al., 2005, Palmer et al., 2006, 
Loubser et al., 2006). These minority variants are important to study as they may 
have implications for subsequent therapy with second-generation NNRTIs. A 
pooled analysis from Nicot et al (2012) explained that there is a significant 
association between the presence of NNRTI minor variants and the risk of 
treatment failure (Nicot et al., 2012). 
Transmitted resistance refers to resistant viruses that are transmitted from person 
to person through contact with blood, sexual intercourse or mother to child 
transmission (Wensing et al., 2005).  It is well known that in the absence of 
therapy, the stability of these transmitted variants decreases, and they can easily 
revert back to wild-type or exist as minor variants (Brenner et al., 2004, Bezemer et 
al., 2006). However, if the transmitted variant has a high replication capacity, the 
transmitted variant is likely to persist for extended periods in blood and semen 
(Little et al., 2008). Patients harbouring these variants may have sub-optimal 
treatment responses in comparison to those patients without these variants (Little 
et al., 2008). Given that most ARVs are structurally similar and interact with similar 
target sites, resistance to one drug may inherently result in resistance to other 
drugs within the same drug class. This phenomenon limits the spectrum of ARVs 
that can be used in subsequent salvage regimens, and poses a major threat to the 
clinical efficacy of ART. 
 
1.9 HIV-1 Reverse Transcriptase structure  
HIV-1 RT is an asymmetric heterodimer comprising two subunits, a 66kDa (p66) 
and a 51kDa (p51) subunit. The p51 subunit is composed of the first 440 amino 
acids of the RT gene while the p66 subunit is made up of all 560 amino acids of the 
RT gene.  Both the p66 and the p51 have an identical primary structure, however 
the p51 subunit lacks the 120 amino acid, Ribonucleic acid H (RNase H) domain 
found in the C-terminal region of p66 (Menendez-Arias, 2010). Both of these 
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subunits are derived by cleavage of the gag-pol poly-proteins by viral PR 
(Menendez-Arias, 2010). The polymerase domain contains four sub-domains, 
which are  regarded  as  the  “fingers”  residues  (1-85), (118-155),  the  “palm”  (86-117), 
(156-236),  the  “thumb  “(237-318) as well as connection sub-domain residues (319-
426) (Kohlstaedt et al., 1992, Menendez-Arias, 2013). The p51 sub-domain also 
folds into the same four domains but in different positions relative to each sub-
domain (Sarafianos et al., 1999). This sub-domain is non-enzymatic and has a 
structural role for the stabilization and folding of the p66 subunit. HIV-1 RT plays a 
significant role in the viral life cycle as a DNA polymerase to copy either a DNA or 
RNA template or as an RNaseH, to cleave the RNA portion of the RNA-DNA 
duplex. Both functions are performed together for the conversion of RNA into linear 
dsDNA (Menendez-Arias, 2010). 
 
 
Figure 1.5 Structural components of HIV-1 Reverse Transcriptase, complexed 
with a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Taken from 





1.9.1 HIV-1 Reverse Transcriptase Inhibitors  
Due to the integral role HIV-1 RT plays in the viral lifecycle it has become an 
attractive target in developing ARVs, making RT-inhibitors a major component of 
ARV regimens (Alcaro et al., 2011). Reverse Transcriptase Inhibitors that are 
utilized in clinical settings can either be classified as NRTIs or NNRTIs. NRTIs are 
essentially chain terminators and following phosphorylation by cellular kinases they 
are incorporated by RT into the nascent chain of viral DNA. Deoxynucleotides 
(dNTPs) that contain a terminal hydroxyl group are essential to ensure that the 
DNA helix structure continues to grow, however NRTIs lack this component and 
once incorporated the DNA chain is terminated, inhibiting viral DNA synthesis 
(Menendez-Arias et al., 2011, Tang and Shafer, 2012, Menendez-Arias, 2013). 
NNRTIs, prevent HIV-1 replication by binding to the hydrophobic pocket within the 
RT enzyme near the active site. As a result the flexibility of the enzyme is 
compromised preventing DNA synthesis (Tang and Shafer et al., 2012).  
 
1.9.2 Resistance to Nucleoside Reverse Transcriptase Inhibitors  
Once the drug enters the cell, it is subject to intracellular phosphorylation and 
conversion into triphosphate derivatives, which compete with the natural cellular 
dNTPs for incorporation into the growing DNA strand. There are two mechanisms 
of resistance that has been described (Menendez-Arias, 2013). The first involves a 
discriminatory exclusion pathway where RT retains the ability to recognize the 
natural dNTPs but discriminates and subsequently excludes the NRTI, preventing 
the drug from binding. Mutations that are involved in this pathway are referred to as 
“discriminatory  mutations”   and   include  K65R,  K70EG, L74V, Y115F, Q151M and 
M184V (Tang and Shafer, 2012). Owing to the low genetic barrier of NRTIs, 
resistance emerges quite quickly; a common example includes M184V, which 
selectively impairs the ability of RT to incorporate the NRTIs: Lamivudine (3TC) 
and Emtricitabine (FTC), by steric hindrance (Sarafianos et al., 2009). M184V also 
hyper-sensitizes HIV-1 to Azidothymine (AZT) and Tenofovir (TDF) (Tang and 
Shafer, 2012) but more importantly this mutation reduces viral fitness and is 
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associated with lowering the plasma HIV-1 RNA 0.5 logs lower than that of the 
wild-type virus (Tang and Shafer, 2012). The second mechanism is one involving 
an excision pathway, that selectively removes the NRTI triphosphate that has been 
incorporated into the growing DNA chain (Sarafianos et al., 2009, Tang and 
Shafer, 2012). Chain termination is then bypassed allowing DNA replication to 
continue (Hughes et al., 2008). A common example of the excision mechanism is 
the Adenosine triphosphate (ATP) mediated excision of AZT by pyro-
phosphorylation (Figure 1.6) (Sarafianos et al., 2009). Most of the amino acids that 
are involved in resistance via the excision mechanism are present within the 
fingers or the palm of RT and are in positions that could affect the binding of an 
incoming dNTP (Sarafianos et al., 2009). 
 
 
Figure 1.6 Drug resistance to Nucleoside Reverse Transcriptase Inhibitors 
via the excision and exclusion   “discriminatory”   pathways. Taken from 
Delviks-Frankenberry et al (2010).  
 
 
Other mutations involved in this pathway include the Thymidine Analogue 
Mutations (TAMs) as illustrated in Figure 1.7. These mutations confer resistance to 
AZT, Stavudine (d4T) and partially contribute to Abacavir (ABC) and Didanosine 
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(ddi) resistance (Vandamme et al., 2004). Evolution within these TAM pathways 










Figure 1.7 Schematic of two distinct pathways of Thymidine Analogue 
Mutations. Mutation K70R confers low-level resistance to AZT. Subsequently 
T215Y emerges later in different viral genomes and outgrows the K70R mutant. 
T215Y requires a double nucleotide mutation (ACC –TAC). Persistent replication of 
T215Y in the presence of non-suppressive therapy results in the appearance of the 
TAM 1 pathway. D67N mutation appears in viruses that already harbor K70R, with 
the eventual accumulation of K219E/Q/R and T215F (TAM 2 pathway). Persistent 
replication with TAMs can result in mixed patterns of TAM 1 and 2. Adapted from 
Hu et al (2006).  
 
 
1.9.3 Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors  
A major limitation of NNRTIs is their relatively low genetic barrier, where only a 
single point mutation is required to cause resistance (Tang and Shafer, 2012). High 
level resistance to NVP and EFVs requires between one to two mutations while the 
second-generation NNRTI, Etravirine (ETR) requires two mutations for high-level 
resistance (Tang and Shafer, 2012). Nearly all of the NNRTI resistance mutations 
are present within or adjacent to the NNRTI binding pocket (Ren and Stammers, 
2008).  NNRTI mutations can be divided into three groups, Cluster 1: L100I, 
















K103N, V106A and V108I; Cluster 2: Y181C, Y188L/C/H, and G190S/A and 
Cluster 3: P225H, M230L, and P236L. The first two groups are mutations present 
on the opposite side of the NNRTI binding pocket of RT in the vicinity of p66, while 
the third cluster is present in the p51 subunit (Sarafianos et al., 2009).  NNRTI 
resistance mutations have minimal effects on replication capacity due to the low 
fitness costs they incur (Wirden et al., 2003, Alcaro et al., 2011). However the long 
plasma half-life of these inhibitors may result in periods of monotherapy allowing 
the selection of drug resistant virus. This phenomenon can become problematic 
during periods of non-adherence to multi-drug regimens, where there may be 
intervals of NNRTI monotherapy, as other drugs have a shorter half-life. This, in 
addition to active replication results in resistance evolution (Tang and Shafer, 
2012). 
 
1.10 HIV-1 Protease  
HIV-1 PR belongs to a family of aspartic proteases and is a symmetrically 
assembled homo-dimer containing two identical subunits of 99 amino acids.  The 
dimers are held together by interdigitated β sheets formed at the base of the 
enzyme by the N and C termini of each dimer (Hughes et al., 2008). The substrate 
binding cleft or active site is located in between the two subunits and has the 
signature Aspartate-Threonine-Glycine sequence common to aspartic proteases 
(Brik and Wong, 2003). The active site is covered by two extended β sheet glycine-
rich  loops  known  as  “molecular  flaps”  which  are  highly  flexible  and  are  part  of the 
substrate-binding cavity. The flaps open slightly to enable substrates into the active 
site and subsequently close keeping the substrate in place by hydrogen bonds and 







1.10.1 HIV-1 Protease Inhibitors  
Extensive characterization of the structural components of HIV-1 PR and its 
substrates have led to the advent of PIs (Wensing et al., 2010). PIs bind to the 
active site of viral PR and have an integral function in the inhibition of cleavage of 
post-translational proteins thereby preventing the production of mature infectious 
virus (Wensing et al., 2010, Fun et al., 2012). Thus far, nine PIs have been 
clinically approved for use by the Food and Drug Association (FDA) and include 
Saquinavir (SQV), Indinavir (IDV), Ritonavir, Nelfinavir (NFV), Amprenavir (APV), 
Lopinavir (LPV), Atazanavir (ATV), Tiprinavir (TPV) and Darunavir (DRV). All PIs 
with the exception of TPV are competitive peptidometric inhibitors containing a 
hydroxyl-ethylene core that prohibits cleavage by PR (Turner et al., 1998, Wensing 
et al., 2010). Since the advent of PIs several strategies have been implemented to 
improve the clinical outcome of these drugs, such as the co-administration of PIs 
with a sub-optimal dose of Ritonavir. Ritonavir is an inhibitor of the cytochrome 
P450 3A4 enzyme that considerably improves the bioavailability and half-life of PIs, 
resulting in a higher PI plasma concentrations (Wensing et al., 2010, Fun et al., 
2012). 
  
1.10.2 Resistance to Protease Inhibitors  
Resistance to all PIs has been noted and the genetic basis of resistance well 
documented (Wensing et al., 2010). Resistance to PIs occurs in a sequential 
process resulting in the accumulation of primary and secondary mutations.  
Primary  or  “major  mutations”  arise  first  due  to  an  amino  acid  substitution  within  the  
substrate-binding cleft of viral PR resulting in an overall enlargement of the 
catalytic site. As a result the binding efficiency of the PI is diminished leading to a 
reduction in drug susceptibility and thus drug resistance. In addition binding of the 
natural substrate to PR is also compromised resulting in decreased viral replication 
capacity (Nijhuis et al., 1999). Examples of primary mutations include D30N, V32I, 
M46IL, G48VM, I50VL, I54VTAML, L76V, V82ATFS, I84V, N88S and L90M. 
Secondary   “minor  mutations”   emerge   later   and   can   only   cause   resistance   in   the  
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presence of major mutations; however they play a critical role in improving viral 
replication and are  also   referred   to  as   “compensatory”  mutations   (Wensing et al., 
2010).  PI mutations have also been observed in gag where they are commonly 
found in or close to the cleavage sites. These mutations are thought to adapt the 
virus to the altered substrate binding cleft of the mutant drug resistant viral PR (Fun 
et al., 2012).  
 
Figure 1. 8. Three-dimensional structure of HIV-1 viral Protease.  Mutated 
residues are shown with their  C-α atoms with spheres.  Major mutations (red) and 
minor mutations (blue), semi- transperant solvent accessible surfaces are shown in 
red. Within the active site, a stick model of DRV is bound. Taken from Pokorna et 
al (2009).  
 
 
1.11 HIV-1 Integrase structure 
HIV-1 IN is a 288 amino acid protein of 32kDa encoded by the end of the pol gene 
and forms part of the gag-pol polypeptide precursor, from which it is released by 
viral PR during cleavage (Suzuki et al, 2012).  HIV-1 IN consists of three 
independent structural and functional domains that are connected by flexible 
linkers as indicated in Figure 1.9: the N terminal Domain (NTD), the catalytic core 
domain (CCD), and the C terminal domain (CTD). Each of these domains either 
directly or indirectly contribute to the IN-DNA interaction. The NTD is well 
conserved and encompasses residues (1-49) and is linked to the CCD (50-212) 
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through a linker segment of amino acids (47-55), that has the HH-CC (2 Histidine’s 
and 2 Cysteine’s) motif.  This motif makes up the Zinc binding site and possibly 
favors protein multimerization, a fundamental process in integration (Delelis et al., 
2008, Suzuki et al., 2012). The CCD is composed of a mixture of α helices and β 
sheets and comprises a triad of aspartic (D) and glutamic acid (E) residues termed 
the DDE motif, which is important for the catalytic activity (Suzuki et al., 2012). This 
domain is well conserved and is important for binding of the viral DNA extremities 
via residues Q148, K156 and K159 (Delelis et al., 2008, Suzuki et al., 2012). The 
CTD amino acids (212-288) bind non-specifically to DNA and are involved in the 
stability of the complex with DNA. The CTD displays the greatest degree of genetic 







Figure 1.9 Three independent domains of HIV-1 Integrase, the N-Terminal 
Domain (NTD), the Catalytic Core Domain (CCD) and the C-Terminal Domain 
(CTD) (Taken from Low & Muesing et al (2006).  
 
1.11.1 HIV-1 Integrase function  
Retroviral mediated integration occurs via three biochemically distinct steps 
(Craige et al., 2001). Firstly, IN specifically recognizes the viral attachment sites in 
the  5’  and  the  3’  LTRs  of  newly synthesized viral DNA ends. This allows for the  3’  
processing of viral DNA, HIV-1 IN catalyzes the removal of two nucleotides 
adjacent   to   the   highly   conserved   CA   dinucleotide   from   the   3’   end   of   the   LTR  
region. As a   result   the   DNA   is   chemically   activated   through   the   formation   of   3’  
hydroxyl  radicals  (3  ‘OH)  at  the  terminal  ends  of  viral  DNA,  allowing  its  participation 
in   the   subsequent   reaction.   The   second   step   involves   the   insertion   of   the   3’  
processed, activated viral DNA strand into the target DNA via a single trans-
N-Terminus C-Terminal Domain C-Terminus 
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esterification  reaction  referred  to  as  the  “strand  transfer  step”. The viral DNA ends 
are brought into close proximity with the target DNA by IN, allowing a nucleophilic 
attack by the 3’OH  radical  on  the  target  DNA  (Suzuki et al., 2012). Following which, 
IN  ligates  both  the  3’  OH  radical  terminal  of  the viral DNA to the 5‘  phosphoryl  ends  
of the target DNA and a new phosphor-diester bond is established. Intermediate 
DNA products with un-repaired gaps between the non-ligated  5’ends  of  viral  DNA  
as  well  as  the  3’  ends  of  target  DNA  are  formed. These un-repaired gaps result in 
the short duplication of target DNA sequences flanking both ends; this is followed 
by the formation of imperfect inverted repeats upon sealing of the nick. Following 
the ligation reaction the gaps in the intermediate DNA products are repaired to 
yield fully functional integrated provirus. This step creates an intermediate product 
where   the  DNA   is   joined   to   the   target  DNA  by   the  3’  ends  of  both  strands.  DNA  
repair  is  therefore  required  to  seal  the  nick  between  the  5’  end  of  the  viral  DNA and 
the  3’  end  of  the  target  DNA,  in  order  to  complete  the  provirus formation (Suzuki et 
al., 2012). This reaction is shown in Figure 1. 10.  
 
 
Figures 1.10 The role of HIV-1 integrase (IN) during retroviral integration. The 
process is initiated by IN recognition of both ends of viral DNA and the subsequent 
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removal  of  2/3  nucleotides   from  each  of   the  3’  ends,  a  process   referred   to  as   “3’  
processing”.  Integrase captures the target DNA (chromosomal DNA) which is then 
cleaved  in  a  “staggered  manner”  via  the  exposed  hydroxyl  group  on  the  viral  DNA  
ends.   The   3’   end   of   the   viral   DNA   and   the   5’   end   of   the   target DNA is 
simultaneously linked during the “strand   transfer” step. In infected cells, the 
excision   of   the  mispaired   5’   viral   DNA   ends   and   the   incorporation   of   the   single  
strand gaps are carried out by unknown cellular enzymes. Taken from Suzuki et al 
(2012).  
 
1.11.2 HIV-1 Integrase Inhibitors 
Viral integration is a key process for retroviral replication hence the use of HIV-1 
INSTIs has become popular for antiviral activity. Raltegravir (RAL) was the first 
INSTI approved for use by the FDA in 2007 for treatment naïve and experienced 
patients. However it was only made available  
in SA in 2011 and is recommended as a component of a patient specific third line 
treatment (Gary Maartens, 2011). Dolutegravir (DTG) and Elvitegravir (EVG) are 
new investigational INSTIs still in clinical trials (Abram et al., 2013). Both RAL and 
EVG have shown good efficacy in vitro and in clinical studies (Ceccherini-
Silberstein et al., 2010). (Gary Maartens, 2011). Raltegravir has a low genetic 
barrier where only a single point mutation is required to cause resistance. 
Therefore it is not surprising that resistance to this drug has also emerged. 
Resistance associated with RAL is characterized by the presence of three major 
signature IN mutations Y143RC, Q148HRK and N155H (Malet et al., 2008, Abram 
et al., 2013).  Secondary accessory mutations further increase the level of 
resistance and often restores replication capacity. These mutations occur at the 
CTD residue S230, suggesting a direct role for the other domains in IN enzymatic 
function (Mbisa et al., 2011, Parczewski et al., 2012).  Natural polymorphisms 
within IN; T97A, E138K, V151I, G163R, V165I, V201I, I203M and T206S, can 
influence the rate at which resistance develops and can either increase resistance, 
restore viral fitness or contribute to both (Rhee et al., 2008, Mbisa et al., 2011, 
Parczewski et al., 2012). However more work is needed to confirm the roles of 
these polymorphisms.  
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Primary resistance to EVG is characterized by mutations T66I, E92Q, T97A, 
S147G, Q148R, N155H, and less commonly T66AK, E92G, and Q148HK (Quashie 
et al., 2012).  Dolutegravir is a relatively novel INSTI and no major DTG associated 
drug resistance mutations have been identified as yet. Although it is known that the 
accumulation of multiple mutations is required for resistance due to the drugs 
higher genetic barrier. Nevertheless substitutions associated with this drug include 
E92, L101, T124, S153, and G193 (Quashie et al., 2012). 
 
1.12 Highly Active Antiretroviral Therapy in South Africa 
The National Treatment Program was implemented in SA in 2004 (Kiepiela P, 
2014). South Africa currently has the largest ART program in the world with an 
estimated 1.79 million people on ART; approximately 85% have access through 
the public sector, 4% through non-governmental community treatment programs 
and 11% from the private sector (Johnson, 2012).  Kwa-Zulu Natal (KZN) has the 
highest prevalence of HIV-1 infection globally, but fortunately has been able to 
provide the highest number of HIV-1 testing per province as of 2014, as well as the 
highest number of sites that are accredited to provide ART (Massyn et al, 2014). 
South Africa utilizes standardized first and second-line regimens based on drug 
tolerability and safety efficacy for each patient. Current guidelines in SA are 
illustrated in Figure 1.11 (Department of Health, 2013). Despite the intervention of 
ART programs and their role in reducing HIV-1 burden, various obstacles limit its 
use including, drug toxicity, adverse effects, treatment adherence issues, co-
infection with other pathogens, individual pharmacokinetics and drug resistance 
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Figure l.11 Schematic of the current South African Antiretroviral guidelines for HIV-1 infection (Adapted from the 
Department of Health (2013). 
Second Line Therapy 2 NRTIs + 1 PI 
 
Adults and Adolescents 
Failing on a TDF 
based 1st line regimen 
 
AZT+3TC+ LPV/r 
Failing on a d4T 
based 1st line regimen  
 
TDF+3TC/FTC and LPV/r 
Dyslipedia or diarrhea 
associated with LPV 
 
Switch LPV to ATV/r 
Infants and Children  
Failing first line 
ABC+3TC+LPV/r or 
d4T+3TC+LPV/r 
Consult with expert for advice  
 











If HIV RNA >1000 copies/ml on 2nd line for >1 year, repeat viral load after 6 months 
and monitor adherence, drug interaction, tolerability and psychological problems If 
patients present with VL <1000cpm - Continue with second-line LPV/r treatment, or 
if  VL >1000cpm - Specialist referral and genotypic testing requested. Patient 
placed on salvage regimens with DRV/RAL/ETR. 
 
 
First Line Therapy- 2NRTIs +1 NNRTI 
 
Regimens  
New Adult Patients including pregnant women TDF+3TC/FTC + EFV/FDC 
FDC Preferred 
Adolescents ABC+ 3TC+ EFV 
Contraindication to EFV – psychiatric co-morbidity  TDF + FTC/3TC+ NVP 
Contraindication to TDF-  
Renal disease & Anemia or use of Nephrotoxic drugs 
AZT+3TC+EFV or NVP 
Contraindication to TDF & AZT 
Renal disease & Anemia/ use of nephrotoxic 
drugs/aminoglycosides 
d4T + 3TC+EFV or NVP 
Contraindication to TDF, AZT, d4T  
Renal disease/Anemia/ peripheral neuropathy use of 
nephrotoxic drugs 
ABC+3TC+EFV or NVP 
Currently on d4T regimen  TDF + 3TC/FTC+ EFV 
FDC preferred 
Infants and children <3 years  
< 3kg  
ABC+3TC+LPV/r 
Infants and children 3 years and older or above 10kg ABC+3TC +EFV 
 
If patients present with a viral load >1000 copies per ml then switch to second line LPV treatment  
 
 
Regardless of CD4 count, ART is given to  
 Patients presenting with all types of Tuberculosis (TB) 
 Pregnant or breastfeeding women 








Regardless of CD4 count, ART is given to patients  
 With advanced HIV-1 disease (WHO Stage 3 
& 4) 
 Patients  with  CD  4  <200  cells/μl  are  fast  
tracked  
 
Patients presenting with 
 CD  4  <  500μl/ml  irrespective  of  clinical  stage  of  
disease  
 Priority  given  to  patients  with  CD4  <  350cells/μl 
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1.13 Second-line Antiretroviral Therapy 
The PI Lopinavir is a first-generation PI that was approved in 2000, and was one of 
the first PIs to be co-formulated with Ritonavir as Kaletra™ (Chandwani and 
Shuter, 2008). Lopinavir is currently marketed as Aluvia™  and is administered in 
combination with two NRTIs, constituting the second-line regimen in SA, as 
previously mentioned (Department of Health, 2013). This drug has demonstrated 
high efficacy in both treated and naïve patients (Chandwani and Shuter, 2008). 
Despite the relatively high genetic barrier, resistance to LPV/r is characterized by 
mutations L10IRV, K20M, L24I, V32I, L33F, M46IL, I47AV, I50V, F53L, 
I54VLAMTS, L63P, A71VY, G73S, L76V, V82AFTS, I84V, and L90M (Kempf et al., 
2002, Tang and Shafer et al., 2012). Nonetheless, LPV/r has still shown good 
efficacy in the presence of five or less primary resistance mutations; however the 
presence of additional mutations compromises its efficacy (Kempf et al., 2002). 
Genotypic analysis of first-line failures in SA suggests that the majority of patients 
remained susceptible to a second-line treatment of AZT, ddi and LPV/r (Marconi et 
al., 2008, Orrell et al., 2009, Wallis et al., 2010). Some studies have shown good 
virological outcomes with a LPV/r inclusive second-line therapy, when used in 
conjunction with adherence counseling 
 (Hosseinipour et al., 2010, Johnston et al., 2012, Garone et al., 2013, Schoffelen 
et al., 2013).  However, some patients experience mortality due to the high toxicity 
of LPV/r, threatening the drugs long-term use (Osinusi-Adekanmbi et al., 2014). A 
few studies have reported on second-line failure in Africa (Pujades-Rodriguez et 
al., 2011, Levison et al., 2011, Wallis et al., 2011) . Amongst these studies, the first 
major PI mutations were seen at least six months after treatment (Osinusi-
Adekanmbi et al., 2014). Treatment failure in most studies were attributed to 
adherence issues, delayed start in second-line treatment and mortality associated 
with LPV/r (Wallis et al., 2011, Ajose et al., 2012, Garone et al., 2013, Osinusi-
Adekanmbi et al., 2014, Van Zyl et al, 2013). 
With the numerous challenges that resource limited settings experience, it is 
imperative to preserve and maximize second-line treatment options (Garone et al., 
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2013 ). Despite patients failing second-line treatment, little has been reported on 
the PI resistance mutations seen in HIV-1 subtype C (Wallis et al., 2011). Thus far 
some studies have shown infrequent or a low prevalence of major PI drug 
resistance mutations (Riddler et al., 2008, El-Khatib et al., 2010, Wallis et al., 2011, 
Ajose et al., 2012, Levison et al., 2012, Osinusi-Adekanmbi et al., 2014,). A similar 
trend has been reported for HIV-1 infection with B viruses (Riddler et al., 2008).  
 
1.14 Third-line Antiretroviral Therapy  
South Africa is one of the only countries in Sub-Saharan Africa that has access to 
third-line ART for patients that have failed both first and second-line treatment 
(Department of Health, 2013). Antiretroviral drugs, DRV/r, ETR, RAL and 
Maraviroc (MVC) are registered in SA for use in third-line treatment. There are no 
stipulations regarding the choice of third-line drugs however, decisions are made 
by an expert panel on the basis of a genotypic resistance test (Meintjes et al., 
2014). Nonetheless there are some guidelines to assist in the design of these 
regimens such as: adherence counselling prior to initiating third-line treatment; first 
generation NNRTIs should not be included as they do not impair viral fitness; 3TC 
is recommended as this mutation selects for M184V which impairs viral replication; 
other drugs that can be considered include RAL, ETR, and or Rilpivirine (RPV). 
However, RAL is favoured as it is an entirely new drug class with no risk of cross-
resistance; MVC is extremely expensive and can only be used following a tropism 
test which shows that the patient has tropism for the CCR5 co-receptor; the use of 
double boosted PIs and the use of a PI with the broadest resistance profile 
(currently DRV) is preferred (Meintjes et al., 2014).  
Darunavir, previously known as TMC114, is commercially known as PREZISTA™  
and gained   FDA   “accelerated   approval”   in   2006,   following results from various 
clinical trials (Wolfe and Hicks, 2009). Darunavir is a specifically engineered HIV-1 
PI that has a greater binding affinity within the active site of viral PR than other 
known PIs (Wolfe and Hicks, 2009, Tang and Shafer, 2012). Like other PIs, DRV is 
also co-administered with a low dosage of Ritonavir. Darunavir is structurally 
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similar to APV but shows a greater binding avidity and binds almost 1000 times 
tighter than Ritonavir, SQV or NFV (King et al., 2004). This drug has become 
popular for use, owing to a number of favourable properties such as its high 
tolerability, dosing flexibility, high potency and high genetic barriers for resistance. 
Three major structural attributes are responsible for the high genetic barrier i) The 
Pico molar binding affinity to wild-type PR binding site ii) the ability to form 
numerous backbone to backbone hydrogen bonds with the PR substrate binding 
cleft and iii) the ability to adopt a conformation that fits within the substrate 
envelope of viral PR (Saskova et al., 2009).   
POWER 1 and 2 studies (Performance of TMC114 when evaluated in Highly 
Treatment Experienced patients with PI resistance) evaluated the use of DRV/r in 
triple class (NRTI/NNRTI/PI) experienced adults with viral loads >1000cpm 
harbouring at least one primary PI DRM. Promising results with significant 
reductions in viral load and improvements in CD4 were shown (Katlama et al., 
2007). Another   trial,   “The  Antiretroviral  Therapy with TMC114 Examined In naïve 
Subjects (ARTEMIS), evaluated DRV/r versus LPV/r efficacy in treatment naïve 
patients and confirmed a virological failure rate lower than 12% in the DRV/r 
patients compared to 17.1% for LPV/r patients during the 96 week analysis 
(Aratesh K, 2005).   
 
1.14.1 Darunavir resistance profile 
Data from a pooled 24 week POWER 1 and 2 trials identified 11 DRV/r resistance 
associated mutations as currently listed by the International Aids Society (IAS) this 








Table 1.1 Darunavir resistance associated mutations. Those highlighted in blue 
indicate DRV/r mutations associated with virological failure. Adapted from de 
Meyer et al (2008).  
 
Protease Codons      11      32      33      47  50     54      73       76    84      89   
 Consensus                 V       V         L         I  I        I       G         L       I          I 
 DRV/r                         I         I          F        V V     L/M    S         V       V        M 
 
Owing to the high genetic barrier of DRV/r, more than three DRMs in addition to a 
number of background resistance associated mutations are required for DRV/r 
resistance (de Meyer et al., 2008). Studies on subtype B have shown that the 
prevalence of DRV/r mutations within routine clinical settings is low (Mitsuya et al., 
2007, Wolfe and Hicks, 2009). 
 
1. 15 Genetic variability in HIV-1  
 HIV-1 naturally varies in genetic content by 35% between subtypes (Wainberg and 
Brenner, 2012). This variability is strongly associated with differences in genes 
coding for viral enzymes.  Inter-subtype differences in PR and RT are between 10-
12% at the nucleotide level and 5-6% at the amino acid level (Gonzalez et al., 
2003). This variability strongly drives the spectrum of mutations that emerge under 
drug selection pressure (Gonzalez et al., 2003). Three factors that influence which 
drug resistance mutations develop in different subtypes are: (i) Inter-subtype 
differences in codon usage - associated with differences in nucleotide and 
mutational motifs and refers to the number of transitions and trans-versions 
required for ARV resistance. Viral isolates may encode different amino acid 
substitutions, thus influencing the rate and type of resistance mutations that may 
emerge. ii) Inter-subtype amino acid differences - associated with minor structural 
changes in drug targets; as a result different mutations may emerge under the 
same drug pressure, (iii) Inter-subtype differences at the nucleotide level at regions 
surrounding nucleotides involved in drug resistance (Tang and Shafer, 2012).  
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1.15.1 Variability in subtype C  
Subtype C has several distinct genomic features that contribute to its high genetic 
variability, and include a prematurely truncated rev ORF, an extra NF Kappa β 
binding site in the LTR and an enlarged Vpu protein (Ndung'u et al., 2001, Gordon 
et al., 2003). It has also been shown that subtype C PR has a higher enzyme 
activity than PR from other subtypes (Velazquez-Campoy et al., 2001). Despite this 
level of genetic diversity in subtype C, these viruses are conserved at the amino 
acid level as a large proportion of amino acid substitutions are silent and result in 
no overall change in the amino acid sequence. However, the presence of these 
naturally occurring polymorphisms amongst the different HIV-1 subtypes is still 
debatable. Various studies have reported the possible contribution of these 
polymorphisms to drug resistance as indicated in Table 1.2 (Bessong et al., 2008, 
Bandaranayake et al., 2010, Wainberg and Brenner, 2012).  
 
Table 1.2   Some genetic differences that predispose across the different 








I13V TPV  13% 90-98% Subtypes 
A, G and CRF02 
4-78% in other 
Non B 
K20I ATV 2% 93-98% Subtype 
G, CRF02 
1-3.5% in 
Subtype A, F, 
CRF01 
M36I ATV, IDV, 
NFV, 
TPV 
13% 81-99% Non B 
Subtypes 
- 
H69K TPV 2% 96-97% Subtype 
A, C, G, CRF01/02 
2% in Subtype 
F 
V82I ATV 2% 87% in Subtype G 1-6% in Non B 
I93L ATV 33% 94% in Subtype C 5-40% in Non 
B 
 
The presence of these genetic signatures and polymorphisms in PR are regarded 
as compensatory mutations in subtype B, and could influence the susceptibility to 
PIs. As a result this could create a major barrier for the clinical success of cART, 
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as patients with non-B subtypes may fail treatment quicker than those with B 
viruses (Santos and Soares, 2010). 
The preferential selection of K65R by subtype C viruses is a common example of 
this variability (Brenner et al., 2006, Doualla-Bell et al., 2006, Invernizzi et al., 
2013). This selection is based on a template-dependent mechanism as illustrated 
in Figure 1.12. The nucleotide sequence at codons 64-65-66 differs between 
subtype B and C. Viral isolates of subtype C contain a homo-polymeric stretch of 
adenine bases that cause RT to pause during the synthesis of dsDNA from ssDNA 
templates. This process is template specific but independent of the RT enzyme 
(Lessells et al., 2012). Subsequent mis-alignment of the template and the primer 
leads to the AAG to AGG change resulting in the K65R mutation (Coutsinos et al., 
2011). As a result K65R is predominately found in subtype C viruses (Brenner et 
al., 2006, Doualla-Bell et al., 2006, Invernizzi et al., 2013). For subtype B, there is a 
distinct pausing at codon 67 facilitating the generation of D67N and TAMs as 
opposed to K65R (Coutsinos et al., 2011). 
 
 
Figure 1.12 Schematic of the template dependent mechanism of subtype C 
versus subtype B viruses to select for the K65R mutation and the D67N 





It is therefore imperative that patients are carefully monitored upon the initiation of 
HAART, as it is important to bear in mind that ARVs are designed to particularly 
target subtype B viruses, and differences in treatment responses should be 
expected (Doualla-Bell et al., 2006, Toor et al., 2011, Wainberg and Brenner, 2012, 
Sui et al., 2014). 
  
1.16. Drug resistance testing  
For clinicians to design efficient regimens, prior knowledge of mutations conferring 
resistance to a particular drug is required (Meintjies et al., 2014). This is achieved 
by resistance testing whose primary goal is to provide a list of detailed mutations 
and drug susceptibility profiles for patients receiving ARVs. There are two types of 
resistance testing, firstly phenotypic assays, which investigates drug susceptibility 
by directly measuring viral growth rate relative to a wild-type reference virus in the 
presence of varying concentrations of drug, while genotypic testing assesses the 
genetic composition of HIV-1 variants indicating the presence of resistance 
mutations. This involves sequencing of virus populations from plasma, the resultant 
nucleotide sequence encompasses the complete 99 amino acids of HIV-1 PR and 
the   5’   polymerase-coding region of HIV-1 RT, both of which are viral enzymes 
targeted by ARVs.  Additionally viral IN and gp41 testing can also be performed if 
required. Drug resistance algorithms such as the IAS and the Stanford Drug 
resistance database are used to interpret differences between patient derived 
sequences and a wild-type reference strain, usually subtype B.  This results in the 
generation of a list of mutations that aid in predicting drug susceptibility (Harrigan 
and Cote, 2000).  Genotypic resistance testing has proven to be useful in a number 
of clinical studies, in that it can improve both virological and immunological 
outcomes of ART (Harrigan and Cote, 2000, Medeiros et al., 2007, Paredes i 
Deiros et al 2009). Genotyping is generally preferred over phenotyping due to the 
relatively shorter turnaround time, its cost effectiveness and its ability to identify 
evolving resistance (Harrigan and Cote, 2000, Tang and Shafer, 2012). 
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Unfortunately with phenotypic testing the effects of antagonistic mutations can be 
obscured. A common example is the presence of K65R and M184V; the 
phenotypically the 3TC resistance mutation will be detected however seeing as 
K65R reduces TDF susceptibility two fold, the presence of the TDF resistance will 
be obscured due to the presence of M184V which increases TDF susceptibility two 
fold. Nevertheless phenotyping has proved useful in testing the susceptibility of 
recently approved drugs (Tang and Shafer, 2012).  
 
1.16.1 Drug resistance testing in South Africa 
In many parts of the world, resistance testing is recommended for patients that are 
newly diagnosed with HIV-1 or for patients failing first-line treatment (Vandamme et 
al., 2004). However, for resource-constrained settings like SA, routine testing 
includes only a six monthly viral load test, while resistance testing is only 
performed for those patients failing second-line therapy (Department of Health., 
2013). Unfortunately this has numerous implications for patients, in that they are 
given first-line treatment without prior knowledge of baseline mutations and 
possible transmitted drug resistance. Both of these may increase in frequency in 
the presence of drug selection pressure and hence compromise the efficacy of 
subsequent treatment. Some retrospective and prospective studies have 
demonstrated that the presence of drug resistance mutations prior to starting a 
regimen is an independent predictor of the success of that regimen (DeGruttola et 
al., 2000, Demeter and Haubrich, 2001, Hanna and D'Aquila, 2001). A German 
study showed that almost 10% of the drug naïve patients harbored pre-existing 
mutations within RT, suggesting that prior knowledge of these mutations before 
treatment are useful for designing effective regimens (Harrigan and Cote, 2000). 
Additionally, patients failing their first-line regimen are placed onto second-line 
therapy comprising a PI and recycled NRTIs. Given that the PI component may 
work relatively well in suppressing viral replication, patients may have already 
mounted NRTI resistance, causing them to fail treatment quicker. Despite the 
inability to frequently conduct resistance testing, these settings face several other 
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challenges. Many patients are left on failing first-line regimens for extended periods 
of time, resulting in the accumulation of mutations. Levison et al (2011) showed 
that the accumulation of RT mutations is detrimental to the success of subsequent 
second-line therapy (Levison et al., 2011). Thus, resistance testing is an important 
tool for making informed treatment decisions and guiding patient management 
within a clinical setting. 
 
1.17 DNA sequencing 
The advent of DNA sequencing has revolutionized considerably over the past 50 
years encompassing a variety of new platforms (Figure 1.13). Many were 
developed in first world countries where resources and funds are more readily 
available. Despite this, many of these applications are slowly filtering their way 





Figure 1.13 Timeline depicting the evolution of DNA sequencing since 1965 
(Adapted from   Quinones- Mateu et al (2014).  
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1.18 Sanger sequencing versus Ultra Deep Pyro-Sequencing   
Standard resistance genotyping employs the Sanger based method for 
sequencing. However it is well known that this method can only detect >20% of the 
virus population and viruses occurring at < 20% are missed (Halvas et al., 2010, 
Stelzl et al., 2011). Figure 1.14 reiterates the ability of deep sequencing to detect 
more variants than Sanger sequencing. Fortunately, evolution of other sequencing 
methods such as, Next generation sequencing (NGS) can detect these low 
frequency variants and have been adopted in many studies. Quiñones-Mateu et al 
(2014) reported that the past 13 years has seen the highest number of scientific 
publications for HIV-1 studies employing deep sequencing, while in 2013 alone 57 
HIV-1 studies using Ultra Deep Pyro-Sequencing (UDPS) were published 
(Quinones-Mateu et al., 2014). 
 
Figure 1.14 Neighbour-joining phylogenetic trees. Differences between Sanger 
and Ultra Deep Pyro-sequencing (UDPS). A) Trees for 12 HIV-1 infected 
individuals, comprising 105bp fragments corresponding to the HIV-1 V3 region of 
the gp120 envelope. B) Phylogenetic tree for deep sequencing reads, (frequency 
<1%) for the same 105bp fragments. Coloured dots indicate each unique variant. 
Bootstrap resampling (1000 data sets) of the multiple alignments tested the 
statistical robustness of the trees, an asterisk indicates percentage values >75% 
 33 
and (s/nt) - represents the substitutions per nucleotide (Quinones-Mateu et al., 
2014). 
 
1.19 Detection of minority variants  
There are numerous methods to detect minor variants: point mutation assays, 
phenotypic assays and sequencing assays.  
 
1.19.1. Point mutation assays  
Point mutation assays are highly sensitive and can detect minor variants present 
within the viral quasispecies (Gianella and Richman, 2010). An inherent 
disadvantage of most of these assays is that only a single point mutation at a time 
can be detected, and other polymorphisms in nearby codons are missed (Gianella 
and Richman, 2010). Examples of these assays include Allele Specific PCR (AS-
PCR) and the LigAmp assay (Table 1.3).   
1.19.2 Sequencing assays 
Sequencing assays offer the ability to analyse the entire sequence context 
identifying genetic linkage of each mutation and has become one of the most 
widely used techniques in a research setting. There are different methods which 
can be used and include; clonal sequence analysis, single genome analysis (SGA) 
and UDPS.   
 
1.19.2.1 Clonal sequence analysis  
The desired Polymerase Chain Reaction (PCR) amplified product is inserted into a 
vector comprising an antibiotic resistance gene, and a colour selection marker 
such as the LacZ gene which is used to provide blue white screening using X-gal is 
employed. Source DNA is generally obtained by pooling products of parallel PCRs. 
The final recombinant construct is then transformed into bacterial cells and plated 
onto solid media with an antibiotic that restricts growth of bacteria without the 
plasmid. After selection of recombinant clones using blue-white screening, 
recombinant DNA is extracted and subsequently sequenced. The number of 
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colonies examined predicts the sensitivity of the assay (Paredes i Deiros et al 
2009, Gianella and Richman, 2010).  
 
1.19.2.2 Single Genome Analysis 
For SGA, many single viral genomes from a plasma sample are obtained. After an 
RNA extraction and complementary DNA (cDNA) synthesis using specific or 
random primers, the cDNA is serially diluted 1:3 to a maximum dilution of 1:187. 
Thereafter ten individual real-time PCR (RT-PCR) amplifications are performed for 
each of the cDNA dilutions. In accordance with Poisson’s distribution, the cDNA 
dilution that yields PCR products in three of the ten reverse transcription-PCRs 
contains one copy of cDNA per positive PCR about 80% of the time.  As a result 70 
PCRs are performed using the cDNA dilution that yields approximately 30% 
positive reactions. These reactions are then screened by Agarose gel 
electrophoresis and sequenced using direct dideoxyterminator sequencing. DNA 
sequences that are derived from 20-40 single genomes are analysed per sample 
(Gianella and Richman, 2010).  
 
1.19.2.3 Ultra Deep Pyro-Sequencing  
Ultra Deep Pyro-sequencing is an emulsion-based massively parallel sequencing 
technology, particularly suited for an in-depth analysis of a population of 
heterogeneous genomes such as retroviruses. DNA library fragments are 
immobilized onto micron sized capture beads, respective enzymes and reagents 
are placed in a water mixture, which is injected into small cylindrical plastic 
containers containing synthetic oil. A combination of these materials together with 
vigorous mixing creates droplets around the beads resulting in micro-reactors.  
Each of these micro-reactors will ideally contain only one bead with a unique 
fragment of DNA. Any competing and contaminating sequences are excluded, the 
enzyme component in the reaction causes the isolated DNA fragments to be 
amplified into millions of copies during the emulsion PCR (emPCR). This parallel 
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amplification of fragments results in a copy number of several million per bead. The 
emulsion is then broken and the amplified fragments remain bound to the beads. 
The clonally amplified beads are enriched and loaded layer by layer onto a 
PicoTiter plate (PTP). After the addition of sequencing enzymes individual 
nucleotides are flown across the plate in a fixed order. The addition of one or more 
nucleotides that are complementary to the template strand results in a chemi-
luminescent signal that is recorded by a Charge Coupled Device (CCD) camera, 
these light signals are processed and subsequently transmitted to a computer 
generating a report with the identified DNA sequences for each clone (Paredes i 
Deiros et al 2009, Gianella and Richman, 2010, Avidor et al., 2013, Quinones-
Mateu et al., 2014). With recent technological improvements, the use of UDPS for 

























Table 1.3 Comparison between different methods for detecting minority 




1.19.2.4 Deep sequencing platforms 
There are four deep sequencing platforms currently available, 454  ™   (454   Life  
Sciences/Roche, Branford, CT),   Illumina   ™   (Illumina,   Inc, San Diego, CA), Ion 
Torrent™  (Ion  Torrent/Life  Technologies, South San Francisco, CA) and  PacBio™  
(Pacific Biosciences, Menlo Park, CA)  (Rothberg JM et al, 2011, Quinones-Mateu 
et al, 2014). Comparisons of these platforms are shown in Table 1.4. Each of these 
Method  Point Mutation Assays Sequencing Assays 
Assays  AS-PCR  LigAmp Clonal 
Sequence 
Analysis  
SGA  UDPS 

































-One allele per 
experiment can 







-One allele per 
experiment 

































1 1 Multiple Multiple 300-400bp 
Linked 
mutations  
No  No Yes Yes Yes 
Sensitivity 
(%) 
0.01-<1 <1-12 <1-10 <1-10 <1 
Cost  * ** *** **** * 
Labor 
intensity  
** ** * ***** ******* 
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platforms can generate a vast amount of valuable sequencing data, but differ from 
each other in terms of the quantity and quality of data produced. Many factors must 
be considered when selecting a deep sequencing platform most importantly, the 
desired applications that are required, resource availability, costs incurred for 
reagents and consumables to perform experiments, existing infrastructure as well 
as personnel to perform the assays (Quinones-Mateu et al., 2014).  
 
Table 1. 4 Comparisons between the four most popular sequencing platforms 
as of 2014. The 454™ (GS Junior and GS FLX+ systems), Illumina™ (MiSeq v2 
and HiSeq 2500 systems), Ion Torrent™ (Ion Personal Genome Machine, 318 v2 
chip, Ion Proton™ chip systems, and Pacific Biosciences™ (PacBio RS II SMRT). 
Adapted from Quinones-Mateu et al (2014).  
 
Platform 454™ Illumina™ Ion  torrent™ PacBio™ 
 454 GS 
Junior 
GS FLX+ MiSeq Hi Seq PGM Proton RS II 
Amplification 
method  
Emulsion PCR on 
beads 
Bridge PCR in situ Emulsion PCR on 
beads 
No PCR required 









Advantages  Long reads, Maturity Easy work flow, 
Maturity 






Short reads, Long run Homo-polymer, mis-
reads 




Indels Substitution Indels Indels  
Error rate  ~1% ~0.1% ~1% ~13% 
Read length 
(bp) 
400 700 250 125 400 200 8500 
Run time 
(hours) 
10 20 39 276 7 4 2 
 
Reads that are generated by UDPS provides an efficient tool for studying viral 
diversity, HIV transmission and disease progression (Quinones-Mateu et al, 2014). 
Interestingly, a number of studies have reported the use of UDPS for the detection 
of minority HIV-1 drug resistant variants at levels as low as 0.1-1% (Wang et al., 
2007, Johnson et al., 2008, Archer et al., 2012, Dudley et al., 2012, Xiaobai et al., 
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2014). Majority   of   these   studies   have   employed   the   454™   sequencing   platform 
while others have used platforms like Illumina™  and  Ion  Torrent™. 
 
1.19.2.5 Applications of Ultra Deep Pyro-Sequencing   
As previously mentioned, studies have shown that UDPS can detect minority drug 
resistance variants occurring at < 20% of the circulating virus population which are 
often missed by bulk sequencing (Dudley et al., 2012, Fisher et al., 2012, Nicot et 
al., 2012, Avidor et al., 2013, Garcia-Diaz et al., 2013, Mohamed et al., 2014). The 
detection of drug resistant minority variants has been employed in various clinical 
settings (Fisher et al., 2014). A study by Avidor et al (2013) found PI DRM V32I 
(12.8%) in a single patient that had failed DRV/r treatment. This mutation was 
unfortunately missed by bulk sequencing at the time of testing and as a result the 
patient continued DRV/r treatment for 19 months, until this mutation was detected 
much later by bulk sequencing (Avidor et al., 2013). A study by Le et al (2009) 
described a correlation between minority variants and historical ARV use in 
treatment experienced patients (Le et al., 2009). 
Others studies have shown that minor variants can predict ARV failure to NNRTI-
inclusive regimens (Simen et al., 2009), as well as identify possible ETR resistance 
at low frequencies. (Varghese et al., 2009). This data is useful for resource limited 
settings, where patient treatment histories are not always readily available. 
Patients harboring these variants are exposed to almost twice the risk of virological 
failure upon initiating treatment. These variants may increase in the presence of 
drug therapy, and can also result in cross-resistance to other drugs within the 
same drug class (Kapoor et al., 2004, Simen et al., 2009, Varghese et al., 2009, 
Nicot et al., 2012).  This suggests that these variants may act as predictors of 
treatment failure despite adequate adherence levels. However, more work will be 
required to fully elucidate the role of minority variants in HIV-1 subtype C infected 




1.20 Computational methods to study HIV-1 Protease 
The structure of HIV-1 PR is fundamental for the design of PIs. As a result, various 
computational methods such as (i) homology modeling (ii) molecular docking and 
(iii) molecular dynamics simulations have been employed (Schwede et al., 2003, 
Hao et al., 2012). This information has been used to understand HIV-1 PR drug 
resistance and the implications it may have for new and improved ARVs. Most PIs 
are substrate-based inhibitors that bind with great specificity to the active site of 
viral PR. Slight structural changes within the active site, the flaps or other regions 
not in direct contact with the inhibitor can compromise the drug-binding interaction 
(Schwede et al., 2003, Hao et al., 2012). 
1.20.1 Homology modeling 
Homology modeling is an effective method to reliably generate three-dimensional 
(3D) models of a protein from the amino acid sequence at the atomic level. It relies 
on the identification of one or more known protein structures (template) that is likely 
to resemble the structure of the target sequence. This is followed by an alignment 
that maps residues in the target sequence to residues in the template sequence 
(Marti-Renom et al., 2000). There are essentially five steps that are performed (i) 
template selection, (ii) alignment (iii) model building (iv) energy minimization (v) 
model evaluation and (vi) model validation. Various software packages are 
available for model construction, two popular packages include Modellar (Sali and 
Blundell, 1993), and SWISS-MODEL (Nayeem et al., 2006). 
SWISS-MODEL was used in this study and is a fully automated protein modeling 
server, that comprises three integrated components; (i) the pipeline- which is a 
suite of software tools and databases for automated protein structure modeling, (ii) 
the workspace, which is a web based graphical user workbench, and lastly (iii) the 
repository which is a continuously updated database of homology models for a set 
of organism proteomes (Schwede et al., 2003). In order to visualize the resultant 
3D structure, programs such as UCSF Chimera (Pettersen et al., 2004), SWISS-
 40 
pdb-Viewer (Guex and Peitsch, 1997), or The Pymol Molecular Graphics System 
2002 (DeLano Scientific, San Carlos, CA, USA) are amongst the many that can be 
used.  
1.20.2 Molecular docking  
Molecular docking is used to predict the preferred orientation of one molecule 
(receptor) to a second molecule (ligand) when bound to each other in order to form 
a stable complex (Lengauer and Rarey, 1996). There are three approaches 
describing the ligand-receptor   interaction.   First:   the   “lock   and   key”   theory   as  
proposed by Fisher et al (1890) where both the ligand and the receptor are treated 
as rigid bodies. Second the induced fit theory created by Koshland et al (1958) 
which states that the active site of a protein is continuously reshaped due to the 
ligand-protein interactions implying that the ligand and the receptor are treated as 
flexible during docking (Lengauer and Rarey, 1996).  It has also been documented 
that proteins can undergo much larger conformational changes, and is shown by a 
recent model referred  to  as  a  “conformation  ensemble”,  proposed  by  Boyong  et  al  
(2003). This model describes proteins as a pre-existing ensemble of 
conformational states; the plasticity of the protein permits a switch from one state 
to another (Lengauer and Rarey, 1996). Each of these models focuses on a 
particular aspect of the recognition process; the lock and key theory introduces the 
principle of 3D complementarity, the induced fit model explains how the 
complementarity is achieved and the ensemble model depicts the conformational 
complexity of proteins. When structures are treated as flexible, binding events are 
determined more accurately as opposed to rigid models (Jenwitheesuk and 
Samudrala, 2003). In addition, the number of possible conformations increases 
exponentially requiring a large amount of computing power.  
 
Various algorithms have been designed to deal with such conformations and are 
usually incorporated into molecular docking software packages. Examples of some 
of these software packages include AutoDock, Glide, FlexX, CDocker, LigandFit, 
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MCDock, Dock 6.0, GOLD, and a relatively new package known as the CLC drug 
discovery Workbench TM (CLC, Bio, Qiagen, Valencia, CA). This software employs 
algorithms from a previously well-known package “  Molegro  Virtual  Docker”.  The 
CLC Workbench enables the use of a variety of components to study the molecular 
mechanisms of proteins while the drug discovery component can be used for 
molecular docking,  
 
The docking simulation involves two important aspects (i) the search algorithm and 
(ii) the docking scoring function –the docking function used by the CLC workbench 
is the PLANTS (Protein-Ligand ANT System) (Korb et al., 2009) score which has a 
good balance between accuracy and computational evaluation time. This score 
mimics the potential energy change, when the protein and the ligand bind together. 
As a result the ligands can be ranked in terms of binding stability; generally ligands 
with a low energy score have a better stability and are used for further in vitro 
testing. This is represented by the simple equation (Score = Starget -Sligand + Sligand).  
Previous studies have employed molecular docking studies to investigate the level 
of drug susceptibility for a range of PIs (Toor et al., 2011, Saxena, 2013). A study 
by Toor et al (2011), demonstrated that in the presence of certain DRMs, binding 
scores differed and correlated with drug susceptibility scores in accordance with 
the Stanford drug resistance algorithms (Toor et al., 2011). Docking is extensively 
used in the pharmaceutical industry for the design and discovery of novel inhibitors 
(Sousa et al., 2006). 
 
1.20.3 Molecular Dynamics  
A Molecular Dynamics (MD) simulation is a computational method that calculates 
the time dependent behavior of a molecular system, predicting the physical motion 
of atoms and molecules  
(Lipkowitz, 1990). These simulations provide an insight of the fluctuations and 
conformational changes that occur amongst proteins and nucleic acids. The 
resultant trajectory of the molecule is  determined  using  Newton’s   laws  of  motion 
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(Lipkowitz, 1990). During the simulation, the molecule is set into motion by heating 
to a specific temperature to overcome potential energy barriers and achieve more 
stable conformations at high temperatures. The force on each particle (Fi) is 
determined, first as a function of time, which is equal to the negative gradient of the 
potential energy (Fi= - ) where U is the potential energy function and r is the 
position  of   the  particle.  By  Newton’s   second   law  of  motion,   the  acceleration  of a 
particle is determined by dividing the force acting on it by the mass (M) of a particle 
(ai=- ). The change in velocities of the particle is equal to the integral of 
acceleration (a) over time and the change in position is equal to the integral of 
velocity over time. (dv= ∫ 𝑎𝑑𝑡), (dv= ∫ 𝑣𝑑𝑡 ). The kinetic energy can be described in 
terms of both the velocities and momenta of the particles, where (N) is the number 
of particles. K(v)= Σ miVi and K(p)= Σ . As a result, the total energy in the 
system is referred to as Hamiltonian (H), which is the sum of the kinetic and 
potential energies; H (q.p)=K (p)+ U (q), where q is the set of Cartesian 
coordinates, p is the momenta of the particles and U (q) refers to the potential 
energy function. The velocities (vi) is the first derivative of the positions with 
respect to time. vi (t)= 𝑞𝑖  (𝑡) where 𝑞𝑖(𝑡), refers to the atomic positions at a time 
(t).  Using the initial coordinates of the system, atoms move to new positions and 
new velocities at time (t) can be determined, thereby generating new 
conformations (Jensen, 1999, Parul Sharma, 2012). 
 
Software packages that can be used to perform these MD simulations include 
packages like, Assisted Model Building with Energy Refinement (AMBER), 
(Chemistry of HARvard Macromolecular Mechanics (CHARMM), and GROningen 
Machine for Chemical Simulations (GROMACS). For this study, AMBER (Case et 
al, 2005) was used for the analysis. AMBER incorporates a set of programs that 
uses force fields to perform MD simulations of chemical structures. The AMBER 
package comprises four programs; Antechamber, tleap, Sander and Process 
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Trajectory (PTRAJ). Antechamber automates the process of parameterization and 
is used to build topology files required for the simulation, tleap is used to prepare 
the system for the simulation programs. Sander is a central simulation program 
that is used to perform energy minimization and MD. PTRAJ is used to perform the 
analysis of the simulation results and provides outputs that can be used for other 
downstream analysis such as the calculation of the Root Mean Square Deviation 
(RMSD) values and the determination of binding affinities for complexes (Marcos 
Vinícius R. Garcia et al., 2012).  
 
MD simulations have been used to study the dynamics and flexibility of HIV-1 PR 
flaps that may be influenced by the presence of mutations (Liu et al., 2008, 
Agniswamy et al., 2012, Naicker et al., 2013). A previous study was able to use 
MD simulations to show a unique binding mode within an open conformation of the 
PR flaps, here the inhibitor was found laying roughly perpendicular to the usual 
active site binding pocket. As a result they were able to identify a new binding site 
for DRV that may have implications for improved drug design (Zhang et al., 2014). 
In another study MD simulations was used to show that that the flap region of the 
subtype C PR has more fluctuations over time in comparison to a subtype B PR. 
Other structural modifications were also identified that could result in the reduced 
susceptibility to PIs (Naicker et al., 2013). It is therefore an important tool for 
investigating the implications of resistance mutations to drug binding interactions 






1.21 Project rationale and aims 
Aims:  
1. To investigate the prevalence of protease, reverse transcriptase and 
integrase resistance mutations present in patients failing a Protease 
Inhibitor inclusive regimen. 
2. To use homology modeling to construct models for LPV/r-resistant and 
DRV/r-resistant isolates, to compare the effects of Darunavir treatment on 
HIV-1 Protease.   
3. To utilize Molecular Dynamics and molecular docking simulations to 




1. To genotype PR and RT using an in house assay as well as the HIV-1 
Viroseq Genotyping system, for all patients failing LPV/r. 
2. To genotype PR, RT and IN for patients that failed LPV/r, and were treated 
with DRV/r.    
3. To perform UDPS   using   the   Roche   454™   Platform, for the detection of 
minor variants for patients that failed LPV/r and thereafter DRV/r.   
4. To generate homology models for both a LPV/r-resistant and a DRV/r-
resistant isolate, using a wild-type subtype C sequence as a template,  
5. To compare overall conformational changes in the both models, in order to 
identify the implications of DRV/r resistance on HIV-1 PR structure 
6. To perform molecular docking, of the PI DRV/r into the LPV/r-resistant, 
DRV/r-resistant and the wild-type model.  
7. To perform MD simulations in AMBER to determine the stability of 








The advent of cART is a milestone in HIV-1 treatment policies; unfortunately the 
emergence of drug resistance mutations undermines its efficacy leading to 
treatment failure (Mugavero and Hicks, 2004, Toledo et al., 2010). Data on the 
mutations seen after first-line failure in SA show a high frequency of NNRTI 
mutations (Marconi et al., 2008, Singh et al., 2011, Manasa et al., 2013, Wallis et 
al., 2014) as opposed to second-line failure studies, which report infrequent LPV/r 
resistance, but a significant accumulation of NRTI/NNRTI mutations (Riddler et al, 
2008, Wallis et al, 2011, Levison et al, 2012, Schoffelen et al 2013). These studies 
attributed non-adherence to be the major cause of treatment failure rather than 
drug resistance. However for those patients that present with resistance, there is 
growing concern around the emergence of additional mutations that may limit the 
efficacy of newer generation ARVs.  
 
Most studies describe LPV/r failure in patients infected with subtype B viruses, 
however C infections dominate the epidemic in Sub-Saharan Africa. The few 
studies describing second-line failure in SA were conducted in the Western Cape, 
Gauteng, Limpopo provinces and other regions in Africa. However, there is no data 
from KZN, the province with the highest prevalence of HIV-1 infection, and the 
highest number of patients receiving ARVs (Kiepela et al, 2014). Lastly, most of 
these studies were based on small cohort sizes, with the exception of one study by 
Van Zyl et al (2013). Here we investigate the contribution of DRMs to PI-inclusive 




2.2 Materials and Methods  
 
2.2.1 Study population  
Patients failing their second-line LPV/r inclusive regimen that were referred to the 
Infectious Diseases Clinic at King Edward VIII Hospital were recruited, having met 
the study requirements. In addition, patients were also recruited from the 
Sinikithemba ARV Clinic at McCord Hospital in Durban, KZN. Patients were 
enrolled if they had a viral load of >1000cpm and were on a PI-inclusive regimen 
for more than six months. Ethical approval for the study was obtained from the 
Biomedical Research Ethics Committee (BF068/08). Subtype C sequences from 
treatment naïve patients were downloaded from the Los Alamos sequence 
database (http://www.hiv.lanl.gov/).  






















Figure 2.1 Sample and control groups used in the study. Accession numbers 
are provided in  




 King Edward Hospital n=155 
 McCord Hospital n=21 
        Paediatrics 
 King Edward Hospital n=26 




 33 samples were rejected – 
due to non-adherence 
issues  
 22 did not amplify 
 3 violated study criteria 
 
Naives 
Three groups of 700 subtype C 
naïve patient derived sequences  
Downloaded from the Los 
Alamos Sequence Database 
Used to compare substitutions in 
Protease to the treated group  
(PCSK Cohort) 
 
 118 valid adult 
genotypes  
 38 valid paediatric 
genotypes 
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2.2.2. Sample collection and processing  
Two tubes of blood (four mls each) were collected in Ethylenediaminetetraacetic 
acid (EDTA) tubes and processed within 24 hours of reception. Tubes were 
centrifuged at 1000 X g for ten minutes at room temperature to allow for the 
separation of the plasma and buffy coat, each of which was then stored in 1.5ml 
cryovials at -80°C until further use. 
 
2.2.3 In-house HIV-1 drug resistance genotyping assay 
The protocol for the in-house drug resistance assay was obtained from the 
National Institute of Communicable Diseases (NICD) and was further optimized 
and validated for use in our laboratory (Pillay et al., 2008). The assay is used to 
detect mutations in the PR and RT regions of the HIV-1 pol gene.  
  
2.2.3.1 RNA extraction  
An RNA extraction involves the isolation of RNA particles from plasma followed by 
purification of the viral RNA. Prior to extraction, 500μl of plasma was added to a 
screw capped 1.5ml tube and labeled with the sample details as well as an 
orientation marking to indicate the position of the pellet after centrifugation.  
Plasma was then centrifuged at 25000 X g at 4°C for one hour in an Eppendorf 
ultracentrifuge. After removal of the supernatant, the RNA was extracted using the 
QiAmp Viral RNA Kit (Qiagen, Valencia, CA) according to the manufacturers 
instructions. Isolated RNA was then stored at -80°C until required.  
 
2.2.3.2 cDNA Synthesis  
The HIV-1 genome was reverse transcribed using a gene specific primer (IN3-
10pmol) and the Superscript III RT enzyme (Invitrogen, Life Technologies, 
Carlsbad, CA). Master mix reactions were prepared in the pre-amplification area. 
All reagents, with the exception of enzymes, were thawed at room temperature. 
Enzymes were kept in the freezer until use. Once thawed, reagents were gently 
vortexed and spun in a minifuge to collect droplets. A mix of one μl of dNTPs 
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(10mM/μl) and one μl of the forward primer IN3 (10pmol/ μl) was prepared in a 
0.2ml tube and kept at room temperature until use. A cDNA master mix was 
prepared in a 1.5ml tube as indicated in Table 2.1. 
 
Table 2.1 Reagents used to prepare a master mix reaction for the cDNA 
synthesis reaction.  
 




5X First Strand Buffer 4 1X 
0.1M DTT 1 5mM 




Final Volume  7  
 
The cDNA master mix was used within 30 minutes of preparation. For the reverse 
transcription   reaction,   ten  μl  of   thawed  RNA  was  added to the mix of primer and 
dNTPs, and was placed in the thermocycler under the reaction conditions indicated 
in Table 2.2  
 
Table 2.2 Thermocycling conditions used for the cDNA synthesis reaction. 
Temperature  Time  Process 
65°C 5 minutes Relax RNA secondary 
structure 
4°C 1 minute  Cool to optimal enzyme 
activity  
Pause manually * 
50°C 60 minutes Reverse transcription 
70°C 15 minutes Inactivates superscript III 
4°C >10 minutes Hold  
*After  the  65°C  step  the  thermocycler  was  paused  and  eight  μl  of  freshly  prepared  
cDNA master mix was added into each tube and mixed well. Tubes were placed 
back onto the thermocycler for the remaining conditions.   
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Once   complete,   one   μl   of   RNase   H   (1U/μl) (Invitrogen, Life Technologies, 
Carlsbad, CA) was added for the degradation of ssRNA at 37°C for 20 minutes, the 
reaction was held at 4°C until further use.  
 
2.2.3.3 PCR amplification  
A nested PCR amplification of PR and RT genes from cDNA was done using the 
Expand Long Template PCR system (Roche Applied Science, Branford, CT, USA) 
making use of four primers as indicated in Table 2.3.  
 
Table 2.3 Primer sequences used for the nested PCR. The locations relative to 
HXB2 are also shown. 
 
Primer name  HXB2 
positioning  
Primer  sequence  (5’-3’) 
G25REV(forward) 1867-1892 GCAAGAGTTTTGGCTGAAGCAATGAG  
AV150(forward) 2036-2062 GTGGAAAGGAAGGACACCAAATGAAAG 
IN3(reverse) 4246-4212 TCTATVCCATCTAAAAATAGTACTTTCCTGATTCC 
POL M4 (reverse) 3892-3870 CTATTAGCTGCCCCATCTACATA 
 
A first round and a second round master mix was prepared in two separate 1.5ml 
tubes and stored in the fridge until required.  An extra reaction containing no 
sample was used as the negative control in all instances.  
 
Table 2.4 Reagents and volumes used for the first round PCR reaction.  
           




DEPC Treated Water  16.3 - 
10 X Buffer + MgCl2 (17.5mM)  2.5 1X 
dNTPs (10mmol/μl) 0.88 0.35Mm 
AV150  (10pmol/μl) 0.25 0.125μm 
IN3  (10pmol/μl)   0.25 0.125μm 
Expand  long  template  (5U/μl) 0.38 1.9U 






Table 2.5 Reagents and volumes used for a second round PCR master mix 
reaction 
 




DEPC Treated Water  39 - 
10 X Buffer + MgCl2 (17.5mM) 5 1X 
dNTPs (10mmol/μl) 1.75 0.35Mm 
G25REV  (10pmol/μl) 0.5 0.125μm 
POL  M4  (10pmol/μl)   0.5 0.125μm 
Expand  long  template  (5U/μl) 0.75 1.9U 
Final  47.50  
 
Once the cDNA program was complete, the tubes were removed from the 
thermocycler  and  centrifuged  in  a  minifuge  to  collect  the  droplets.    Thereafter  4.5μl  
of the cDNA was added into each of the respective first round master mix tubes. 
The reaction was then run under the conditions shown in Table 2.6, with the ramp 
speed  set  to  maximum  and  the  reaction  volume  to  25  μl.   
 
Table 2.6 Thermal cycling conditions used for the first and second round 
PCR reaction. 
 
No of cycles Temperature  Time  Process 
1 94°C 2 minutes Initial Denaturation 
10 94°C 10 seconds  DNA Denaturation  
52°C 30 seconds  Primer annealing  
68°C 2 minutes  Primer extension  
25 94°C 15 seconds  DNA Denaturation  
52°C 30 seconds  Primer annealing  
68°C 2 minutes +20 
sec/cycle 
Primer extension  
1 68°C 7 minutes Final Extension  
 4°C ∞ Hold until ready  
 
Once  the  reaction  was  complete  the  tube  was  spun  down  again  and  2.5  μl  of  the  
first round product was added into the respective second round PCR master mix. 
The  tube  was  placed  in  the  thermal  cycler  and  the  reaction  volume  set  to  50μl.  The  
reaction was run under the same cycling conditions as the first round reaction.  
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2.2.3.4 Gel electrophoresis  
To confirm the size of the product that was amplified, the PCR products were 
electrophoresed on a 1% Agarose gel. Gel loading dye was prepared by adding 
one   μl   of Gel Red (Biotium,   USA)   to   50μl   of   Gel   loading buffer (Sigma-Aldrich, 
USA)   and   vortexed   well   before   use.   Two   μl   of   a   one   kb   ladder (Invitrogen, Life 
Technologies, Carlsbad, CA) was mixed  well  with  two  μl  of  the  Gel loading dye and 
was loaded into the first well  of  the  gel,  two  μl  of  each  PCR  product  was  mixed  with  
two   μl   of   the  Gel   loading   dye   and   loaded   into   the   remaining  wells.   The   gel  was  
placed in an electrophoresis tank containing 1 X TBE (Tris Borate EDTA Buffer) 
(Sigma-Aldrich, USA) and electrophoresed at 100V/cm for 45 minutes on an 
Electrophoresis Power Supply- EPS 301 (Amersham Biosciences, Sweden). The 
gel was then examined under Ultraviolet light using the GelVue UV Trans-
illuminator (SynGene, London).  The negative control well was examined for any 
visible bands apart from primer dimer <100bp, as bands >100bp indicate possible 
contamination and the PCR would have to be repeated. Sizes of the amplified 
products were checked against the ladder and were 1.7kb in size.  Products were 
stored at -20°C until purification.  
  
2.2.3.5 Amplicon Purification  
PCR products were purified using the QIAmp PCR Purification kit (Qiagen, 
Valencia, CA), according to the manufacturers instructions. Purified products were 
run on an Agarose gel once again using a one kb DNA ladder (Invitrogen, Life 




Figure 2.2 One kb DNA ladder showing the different size products on a 1% 
Agarose gel. Taken from the GeneRuler 1kb plus ladder package insert  
(Invitrogen, Life Technologies, Carlsbad, CA).  
 
2.2.3.6 Sequencing reaction  
Once  the  products  were  quantified,  they  were  diluted  to  20ng/μl  using  PCR  grade  
water. Direct sequencing of the PCR amplification products was performed using 
the BigDye Terminator v3.1 cycle sequencing chemistry with six sequencing 
primers as listed in Table 2.7.   
 
Table 2.7 Primer sequences and their relative HXB2 positioning, used during 
the sequencing reaction. 
 





















A master mix was made in separate 0.2ml tubes for each primer and comprised 
the reagents listed in Table 2.8.  
 
Table 2.8 Reagents and volume used to make the sequencing reaction 
master mix  
 
Reagent  Volume for 1 reaction 
(μl) 
Final Concentration 
DEPC treated water  1.6 - 
5X Sequencing buffer  2 1X 
BigDye Terminator 
ready reaction mix 
0.4 - 
Primer  3.2pmol/μl 1 0.256  μM 
Total  5  
 
Thereafter   five   μl   of   each  master  mix   was   aliquoted   into   a   96   well   optical   plate  
(Applied Biosystems, CA. USA) and five  μl  of   the  diluted  sample  was  added   into  
each well according to the designated plate layout. The plate was sealed with 
adhesive foil, gently vortexed and centrifuged to collect droplets. The adhesive foil 
was then removed and replaced with a rubber mat which was secured using an 
applicator to ensure all wells were properly sealed. The plate was then placed in 
the thermocycler and run under the conditions listed in Table 2.9. 
 






No of cycles  Temperature  Cycles Process 
1 96°C 1minute Initial 
denaturation  
35 96°C 10 seconds  DNA 
Denaturation  
50°C 5 seconds  Primer annealing  
60°C 4 minutes Primer extension 
 4°C ∞ Hold until ready  
 54 
2.2.3.7 Purification of sequencing products 
Once the reaction was complete, the sequencing products were purified 
immediately. Prior to beginning the purification, a Sodium Acetate-ethanol mixture 
was   prepared   by   adding   one   μl   of   a   3M   Sodium   Acetate   (pH   5.2)   which   was  
required per well, and 25μl   of   100  %  Absolute   ethanol.   The   plate  was   removed  
from   the   thermocycler   and   one   μl   of   125mM  EDTA (Sigma-Aldrich, USA)   was 
added   into  each  well  using  a  multichannel  pipette   followed  by  26μl  of   the   freshly 
prepared Sodium Acetate-ethanol solution. The plate was sealed with adhesive foil 
and gently vortexed for five seconds and centrifuged at 3000 X g for 20 minutes. 
During this time two sheets were made by folding paper towel into a thick mat, 
matching the size of the 96 well plate. After the 20 minutes the plate was inverted 
onto the paper towel and placed in the centrifuge holder at 150 X g for five 
minutes. During this time a 70% ethanol solution was prepared, and was stored in 
the   fridge   until   use.   Thereafter   35μl   of   freshly   prepared   ethanol   was   added into 
each well using a multichannel pipette. It was important to work quickly at this step 
to prevent drying out of the fragments. The plate was placed in the centrifuge at 
3000 X g for five minutes. After this time the paper towel was placed back on the 
plate for drying and centrifuged at 150 X g for one minute.  Thereafter the late was 
dried in a thermal cycler at 50°C for five minutes and was then stored at -20°C until 
sequenced.  
 
2.2.3.8   Sequencing on the 3130xl Genetic Analyzer  
Prior to sequencing, the dried pellets in each well were reconstituted by the 
addition   of   ten   μl   of   Hi-Di Formamide (Applied Biosystems, CA, USA), and 
denatured on a thermal cycler at 95 °C for five minutes, 10 °C for two minutes and 
4°C on hold. The ABI 3130xl Genetic Analyzer (Applied Biosystems, CA, USA) was 
then prepared for sequencing by the addition of Polymer (POP7) (Applied 
Biosystems, CA, USA) and 10 X EDTA Buffer (Applied Biosystems, CA, USA). The 
plate was then placed into the instrument and sequenced overnight.  
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2.2.3.9 DNA sequencing analysis  
Sequences were obtained from the sequencer in Application Binary Interface (ABI) 
format and was imported into Sequencher v5.0 software (Gene codes, Ann Arbor, 
MI) for analysis. Sequences were trimmed and assembled to form contigs; 
chromatograms were then analyzed for the presence of mixtures and ambiguities. 
The consensus sequence was then exported in FASTA format into ClustalX v2.1 
(Thomson et al, 1994) where sequences were automatically aligned against each 
other and an HXB2 subtype B reference sequence. Alignments were manually 
checked in Bioedit v.5.0.9 (Ibis Biosciences, An Abbott Company, CA. USA).  To 
ensure no cross-contamination occurred between samples, PAUP v4.0 (Swofford 
et al, 2002) was used for the construction of neighbor-joining phylogenetic trees. 
Trees were viewed in Figtree v1.4.1 (http://tree.bio.ed.ac.uk/software/figtree/) and 
were checked for unusual clustering and short branch lengths. Sequences were 
submitted to the Stanford drug resistance database (http:/hivdb.stanford.edu) for 
genotypic interpretation. Reports were generated containing mutations and drug 
susceptibility profiles.  The software interprets the sum of predicted resistance 
scores as being susceptible, potential low-level resistance, low-level resistance, 
intermediate resistance or high-level resistance.  
 
The Viroseq HIV-1 Genotyping system was used for those samples that did not 
amplify by the in-house genotyping assay. 
 
2.2.4 Viroseq HIV-1 Genotyping system  
The Viroseq genotyping system (Celera Diagnostics, CA, USA). is a commercial kit 
used for the identification of mutations within the entire PR gene and approximately 
two thirds of the RT gene in the pol ORF, amplifying a 1.8kb product.   




2.2.4.2 Reverse Transcription PCR  
All reagents were thawed at room temperature, except for the enzymes, these 
were kept in the freezer until use. After thawing, reagents were vortexed gently and 
spun to collect droplets. Enzymes were not vortexed, only spun briefly.  The PCR 
master mix was prepared first in a 1.5ml micro-centrifuge tube according to the 
Table  2.10.  AmpliTaq  Gold  ™  was  used  due   to   its  high  specificity  and  efficiency  
while the Amp Erase Uracil-N-Glycosylate (UNG) has an anti contamination 
chemistry and aids in eliminating false positives. 
 




Final concentration  






 1.0 1U 
Final volume 31.0  
 
 
The mix was vortexed briefly and spun for five seconds to collect droplets and was 
kept in the fridge until required. Thereafter the reverse transcription master mix 
was prepared as listed in Table 2.11. 
  
Table 2.11 Reagents and volumes used to make up the reverse transcription 






HIV RT Mix 8 - 
RNAse  Inhibitor  (20U/μl) 1 20U 




DTT (100mM) 0.4 2mM 
Final Volume 10.4  
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The master mix was vortexed gently and centrifuged for ten seconds to collect 
droplets,  the  mix  was  used  within  30  minutes  of  being  prepared.  Thereafter  ten  μl  
of thawed RNA was added into labeled 0.2ml PCR tubes, the RNA was then 
placed in the thermal cycler and run at 65°C for 30 seconds to relax the RNA 
structure, followed by 42°C for five minutes to cool to optimal enzyme activity, the 
reaction  was  then  paused  and  tubes  were  removed  from  the  machine.  Ten  μl  of  the  
freshly prepared RT master mix was added into each of the RNA tubes and mixed 
well. The tubes were then placed back onto thermal cycler and held at 42°C for 60 
minutes for the reverse transcription reaction and then 99°C for five minutes to 
inactivate the Moloney Murine Leukemia Virus Reverse Transcriptase (MuLV RT) 
enzyme. The reaction was held at 4°C for at least ten minutes until use. Tubes 
were  then  spun  for  ten  seconds  and  30μl  of  the  freshly  prepared  PCR  master  mix  
was added into each tube. Tissue was used to open each tube to prevent aerosol 
contamination. The samples were then loaded onto the thermal cycler and run 
under the conditions listed in Table 2.12. 
 






Temperature Time Process 
1 50oC 10 min UNG activation 
1 93oC 12 min AmpliTaq Gold activation 










1 72oC 10 min Final extension 




     




2.2.4.3 PCR purification  
PCR products were purified using the reagents provided in the Viroseq kit (Celera 
Diagnostics, CA, USA). Briefly a micon-100 spin column is inserted into one of the 
micron  1.5ml  collection  tubes,  300μl of Potassium Chloride (KCl) (200mM) (Celera 
Diagnostics, CA, USA), was added to the top of each column together with the 
entire  50μl  of   the  PCR  product.  The  micro-tube caps were secured to the top of 
each of the column and centrifuged for 15 minutes at 1400-1769 X g. Following 
which,  300μl  of  deionized  water  was  added  to  the  top  of  each  column,  caps  were  
replaced and centrifuged again at the same speed for 15 minutes. For the elution, 
35μl  of  sterile   filtered  water  was  added   to  each  of   the  columns,  which  were   then  
inverted into an empty micron tube and spun for five minutes at 1400-1769 X g. 
The columns were then removed and discarded, leaving behind 40-50μl  of  purified  
PCR product which can be stored for up to two weeks at -20 oC before use. The 
purified  products  were  then  run  on  a  1%  Agarose  gel.  Briefly,  six  μl  of  product  was  
mixed  with  five  μl  of  gel  loading  dye  and  promptly  loaded  into  the  respective  wells.  
Six  μl  of  the  DNA  Mass  Ladder  provided  with  the  kit  was  added  to  one  of the wells. 
The gel was then electrophoresed at 10V/cm for 30 minutes, and was viewed as 
previously described. The concentration of the product was then determined using 
the scale indicated in Table 2.13.  
 
Table 2.13 Band sizes and corresponding concentrations of DNA relative to a 
DNA mass ladder.  
 
Band DNA amount per six µl 
2.0 kb 100 ng 
1.2 kb 60 ng 
0.8 kb 40 ng 
0.4 kb 20 ng 
0.2 kb 10 ng 
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Table 2.14 Concentrations and corresponding dilutions for purified   
samples. 
 
If the intensity of the 1.5 kb 
PCR product band is: 
Dilutions  
> 100 ng Make a 1:10 dilution with sterile filtered H2O  (e.g. 5 µl sample + 45 µl ddH20) 
60 – 100 ng Make a 1: 4 dilution with sterile filtered H2O  (e.g. 13 µl sample + 39 µl ddH20) 
40 – 60 ng Make a 1: 2 dilution with sterile filtered H2O  (e.g. 25 µl sample + 25 µl ddH20) 
20 – 40 ng Adjust the volume of the sample to 50 µl  (minimum volume for sequencing) 
<20 ng 
Sample is not suitable for sequencing , 
however the number of cycles can be 
increased to 35 
 
Once the samples were diluted they were vortexed for five seconds and spun to 
collect droplets, the samples were stored at -20 oC until required.  
 
2.2.4.4 Cycle sequencing reaction  
Twelve  μl   of  each  of   the   custom  primer  mixes  namely  A,  B,  C,  F,  G  and  H  and  
eight   μl   of   the   diluted   sample  were   added  directly   to   a   96  well   optical   plate   into  
each of the respective wells and mixed well. The plate was vortexed for five 
seconds and centrifuged to collect droplets. The plate was then placed in the 
thermocycler and run under the thermal cycling conditions listed in Table 2.15, the 







Table 2.15 Thermal cycling conditions for the sequencing reaction  
 
Temperature  Time  No of cycles  Process  
96 oC 10seconds  
25 
Denaturation  
50 oC 5seconds Primer annealing  
60 oC 4 minutes  Primer extension 
4 oC ∞  Hold 
 
Purification of sequencing products and running of the 3130XL Genetic Analyser 
(Applied Biosystems, was performed as previously described in section 2.2.3.8. 
However the filter set E and BigDye v3 was selected on the sequencer.  
 
2.2.4.5 Analysis of results  
Sequences were analyzed using the Viroseq HIV-1 genotyping system software 
v2.5 (Celera Diagnostics, CA, USA), which assembles the sequences, generating 
a consensus using primers from both PR and RT which are then aligned to an HIV-
1 HXB2 reference sequence. Within the editing window, the codon positions, 
amino acid translation, reference sequence, sample sequence and the 
electropherograms are viewed. Sequences were edited and mixtures called, based 
on the following guidelines i) broad peaks near the beginning of a sequence are 
possibly dye blobs, ii) secondary peaks should be at least 30% of the primary peak 
iii) a sequence is considered a mixture if both the opposite sense sequences 
contain a secondary peak two times above the local noise iv) One sequence 
contains a secondary peak 30% of the primary peak and the sequence in the 
opposite direction contains a secondary peak <30%. In rare situations, a mixture 
will be seen in only one of the two sequences. In these cases, the secondary peak 
must be at least 30% of the primary peak and three times the local noise. 
Subtyping was performed using the REGA HIV-1 Subtyping tool version 3.0 
(www.bioafrica.net/rega-genotype/html/). Thereafter the FASTA sequences were 
submitted to the Stanford drug resistance database for genotypic interpretation. 
Phylogenetic trees were drawn using PAUP v 4.0 and viewed in Figtree v1.4.1, to 
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ensure no cross contamination between samples had occurred as previously 
described in section 2.2.3.9.  
2.2.4.6 Positive selection 
Codon aligned sequences were uploaded to the HyPhy package on the 
Datamonkey webserver (http://datamonkey.org), which determines the rate of 
synonymous (Ds) to non synonymous (DN) amino acid substitutions occurring at 
each site in the sequence. Ds<Dn is indicative of conservation of codon sites while 
Dn>Ds indicates more variability and diversification. The HyPhy package employs 
four approaches to determine sites under a positive selection pressure; here the 
test was performed using the Internal Branch Fixed Effect Likelihood (IFEL) as well 
as the Single Likelihood Ancestral Reconstruction (SLAC) algorithms using the 
HKY84 nucleotide substitution model (0.05 level of significance). SLAC is the most 
conventional counting method that involves reconstruction of the ancestral 
sequences using a single most likely ancestral reconstruction that considers all 
possible ancestral reconstructions or sampling from ancestral reconstructions 
(Kosakovsky Pond & Frost, 2005). The IFEL method determines the selection 
pressure that occurs on the internal branches of a tree.  
 
2.2.4.7 Statistical analysis  
Graph Pad Prism v5.0 (GraphPad Software, California) was used for all statistical 
testing. Descriptive statistical analysis was performed to determine the median and 
interquartile range (IQR) for age  and  viral   load.  Fischer’s  Exact test was used to 
compare the frequency of PR substitutions in treatment naïve and exposed 
patients. A p-value of <0.01 was considered significant (***). The test was 
performed by comparing the treated group to three separate groups of 700 
sequences each. Substitutions with a 0.01 (**) and 0.001 (***) significant difference 




2.3 Results  
 
2.3.1. Patient characteristics 
A total of 156 patients failing their LPV/r inclusive regimen were studied, 
comprising 118 adults and 38 paediatric patients. Amongst the adults, 84 were 
female and 34 were male; the median age was 38 (IQR 32-43).  For the paediatric 
patients, 25 were female and 13 were male; the median age was 12 (IQR 5-14). 
The median viral load for adults and paediatrics following LPV/r therapy was 53862 
IQR (14192-185431) and 64298 (IQR 9753-213494) respectively. The median CD4 
count (cells/μl) in adults (n=102) prior to LPV/r treatment was 135 IQR (72-209) 
and for paediatrics (n= 25) 280 IQR (114-473.5). CD4 data following LPV/r failure 
was not available for these patients. All patients were infected with HIV-1 subtype 
C. The most common treatment regimen amongst the adults was, AZT+ddi+LPV 
(n=66), TDF+3TC+LPV (n=27), while for the paediatric patients AZT+ddi+LPV 
(n=11), d4T+3TC+LPV (n=9) and ABC+3TC+LPV (n=7). In order to assess patient 
adherence, personal interviews were performed by clinicians, as well as records of 
pharmacy collection dates four months prior to genotyping. Consistent pharmacy 
collection dates were only available for 107 adult patients, of which 65 (61%) of 
patients had regular pharmacy collection dates. Most patients were on LPV/r 










2.3.2 Prevalence of Drug Resistance Mutations 




Adults (n=118) Paediatrics (n=38) Adults and Paediatrics  
(n=156) 
*Any DRM  68(58%) 25(66%) 93(60%) 
^PI only  2(2%) 1(3%) 3(2%) 
34(22%) 37 (24%) -PI+other 28(25%) 6(18%) 
§NRTI+other 50 (42%) 20(53%) 70(45%) 
=NRTI DRMs only  2(2%) 5(13%) 7(4%) 
~NNRTI DRMs only  17(14%) 4(11%) 21(13%) 
//NNRTI+other 61(52%) 16(42%) 77(49%) 
--NRTI+NNRTI only  44(37%) 12(32%) 56(36%) 
#NRTI+NNRTI+PI 25(21%) 3(8%) 28(18%) 
 
*Any DRM - refers to patients that had mutations across any of the three drug 
classes 
^PI only- refers to patients that had only PI mutations and no other mutations in the 
NRTI/NNRTI drug classes 
-PI+other – refers to the number of patients that had PI mutations in combination 
with mutations from other drug classes (NRTI+NNRTI). 
§NRTI+other - refers to the number of patients that had NRTI mutations in 
combination with mutations from other drug classes (PI+NNRTI). 
=NRTI DRMs only – refers to the number of patients that had NRTI DRMs only and 
no other DRMs 
~NNRTI DRMs only - refers to the number of patients that had NNRTI DRMS only 
and no other DRMs 
//NNRTI+other – refers to the number of patients that had NNRTI mutations in 
combination with mutations from other drug classes (PI+NRTI). 
--NRTI+NNRTI only - refers to patients that had only NRTI and NNRTI mutations 
and no PI mutations  
#NRTI+NNRTI+PI - refers to patients that had mutations across all three drug 
classes 
 
Within this cohort, 93 (60%) patients presented with any DRM, mostly prevalent in 
the NRTI n=70 (45%) and NNRTI n=77 (49%) drug classes. Amongst those 
patients harbouring resistance mutations, PI mutations were found in 37 (24%) 
patients; 30 were adults and seven were paediatric patients. All except three 
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patients had PI mutations in combination with other DRMs. Interestingly, 36% of 
patients presented with NRTI+NNRTI mutations, suggesting some adherence to at 
least this component of the regimen. 
 
 




Figure 2.3 Frequency of Protease Inhibitor mutations in adult patients 
(n=118). The major mutations are shown in pink and the minor mutations are 














Figure 2.4 Frequency of Protease Inhibitor mutations in paediatric patients 
(n=38). The major mutations are shown in pink and the minor mutations are shown 
in blue. 
 
Figure 2.5 Pattern of Major Protease Inhibitor mutations amongst adult and 
paediatric patients with PI resistance [n=36, 24%]. 





M46I, I47A, I84V n=1
M46I, I54V, V82A n=4
I54V, L76V, V82A n=1
M46L, I47A, N88S n=1
M46L, I54V, L76V, V82A n=1
M46I, I54V, L76V, V82A n=13
M46I, I54L, L76V, I84V  n=1
M46I, I50V, I54V, V82A n=1
M46I, I54V, L76V, I84V n=1
L24I, M46I, I54V, V82A n=1
M46I, I54V, V82A, I85V n=1
M46I, I54V, L76V, V82C, I84V n=2
M46I, I54V, L76V, V82A, N83D n=1
M46I, I47V, I54V, L76V, V82C n=1
L24I, M46I, I54V, L76V, V82A n=1










Amongst the adult patients the most frequent major PI mutations were I54V [n=24, 
20%]. M46I [n=23, 19%], L76V [n=21, 18%], V82A [n=21, 18%]. The most frequent 
minor PI DRMs found were L10F [n=19, 16%] and T74S [n=18, 15%]. Amongst the 
paediatrics studied, the most frequent major PI mutations were V82A [n=7, 18%], 
I54V [n=6, 16%], M46I [n=5, 13%], while the most frequent minor PI mutations 
were T74S [n=8, 21%], L10F [n=5, 13%] and L10V [n=4, 11%].  V82A was the only 
major PI DRM occurring alone, while some patients had up to six PI mutations. 
Interestingly, four of the patients with six PI mutations were on LPV/r for less than a 
year. The most common pattern of mutations was M46I, I54V, L76V and V82A 
(n=13) as shown in Figure 2.3.  V11I was the only minor PI DRM occuring alone. In 
order to identify novel mutations selected as a result of PI drug pressure, a 
comparison between treated and naïve sequences was performed. A significant 
increase in frequency in the treated group were only found at positions known to 
cause  drug  resistance:  L10F,  K20R,  M46I,  I54V,  A71V,  L76V,  and  V82A  (Fischer’s  
exact Test, p<0.001). No novel mutations in PR were identified. 
2.3.4 Reverse Transcriptase Inhibitor mutations 
 
Figure 2.6 Prevalence of Nucleoside Reverse Transcriptase Inhibitor 
mutations amongst adult patients n=118.  
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Figure 2.7 Prevalence of Non-Nucleoside Reverse Transcriptase Inhibitor 
mutations amongst paediatric patients n=38 
Amongst adult and paediatric patients, M184V was the most prevalent NRTI DRM: 
[n=40 (34%)] and [n=12 (32%)], respectively. There were 39 adult patients that 
presented with TAMs: 22 had TAM 2 only, two had TAM 1 only and 15 had both 
TAM1+2.  For the paediatric patients, 12 patients harboured TAMs: seven had 
TAM 2 only, and three had TAM 1 only, while two had both TAM 1 + 2. K65R was 
found in only three adult patients despite 27 patients receiving TDF-inclusive 
second-line treatment. Interestingly, paediatric patients harboured many 
substitutions at codon 215, (T215C/F/I/V/Y). However T215F/Y were the only 




Figure 2.8 Non–Nucleoside Reverse Transcriptase Inhibitor mutations 





Figure 2.9 Non–Nucleoside Reverse Transcriptase Inhibitor mutations 
amongst paediatric patients n=38. The most prevalent NNRTI mutations were 
K103N and V106M.  
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For the NNRTI drug class, 61 (52%) adult patients had NNRTI mutations; K103N 
was the most prevalent occurring in [n=58 (49%)]. While [n=16 (42%)] paediatric 
patients had NNRTI mutations, the most prevalent NNRTI mutations were K103N 
[n=6 (16%)] and V106M [n=5 (13%)]. In addition, F227L was present only in the 
paediatric group.  
 
2.3.5 Positive selection  
 
Table 2.17 A test for positive selection amongst the sample and control 
groups (n=156 and n=423) respectively.  
 
 Subjects 
Algorithm Treated (n=156)                            Naïve (n=423) 
 PR RT PR  RT 
Both SLAC 
and IFEL 12, 19, 63 
36, 48, 123, 
184. 12, 15, 19, 63, 74 
36, 123, 165, 
173, 174 
IFEL only 20, 82 219 None None 




37, 60 48, 162, 166, 200 
 
Positive selection using the IFEL algorithm identified 11 positively and 138 
negatively selected sites amongst the treated patients, while SLAC identified 16 
positively and 173 negatively selected sites. Amongst the naïve patients, IFEL 
detected 22 positively and 381 negatively selected sites, while SLAC found 25 
positively and 394 negatively selected sites. Sites that were selected in the treated 
group only were 20 and 82 in PR and sites 184 and 219 in RT. Most of the other 








In this large cohort of second-line failure patients from KZN SA, 60% of the patients 
harboured any DRM, with only 37 patients (24%) harbouring viruses with major 
LPV/r mutations. While still low, this is higher than reports from other provinces in 
SA  (Wallis et al, 2011, Van Zyl et al., 2013). The prevalence of PI DRMs in other 
studies have been largely attributed to non-adherence (Wallis et al, 2011, Ajose et 
al, 2012, Levison et al, 2012, Osinusi-Adekanmbi et al., 2014). 
 
In addition, it has been shown that for PIs, the time spent in the mutant selection 
window during which drug resistant viruses are rapidly selected is very short, and 
with non-adherence, the wild-type virus rapidly emerges and gains a selective 
advantage (Rosenbloom et al., 2012, Siliciano and Siliciano, 2013). However the 
characteristic higher genetic barrier of LPV/r may also account for the lower 
frequency of PI DRMs. The genetic barrier for the NNRTI and NRTIs are lower and 
would consequently result in a higher frequency of NNRTI/NRTI DRMs (Tang and 
Shafer et al, 2012). A third possibility is the development of PI resistance mutations 
in other parts of the viral genome, such as gag and envelope. 
 
Amongst those patients with PI resistance the most prevalent PI DRMS were M46I, 
I54V, L76V and V82A, all of which are major PI DRMS (Tang and Shafer et al, 
2012). The most frequent minor PI DRMs were L10F, T74S, and A71V. Major 
mutations are often selected first and alter the drug binding site of PR for both the 
drug and the natural substrate, resulting in a less fit virus with reduced infectivity, 
while the accessory mutations play a compensatory role in restoring viral fitness 
(Race, 2001). Two mutational pathways describe LPV/r failure, firstly mutations 
(M46I, I54V and V82A) which retain sensitivity to DRV/r, versus. a second pathway 
described by patients harbouring the L76V mutation, and less commonly (V32I, 
I47A and I50V), this describes a pathway conferring DRV/r cross-resistance (Tang 
and Shafer et al, 2012). The L76V mutation is a distinctive LPV/r DRM in both 
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subtype B and C and has a strong impact on DRV/r resistance (Lambert-Niclot et 
al., 2008).  Interestingly, the major PI DRMs appeared to be accumulated in distinct 
patterns, where V82A was the only mutation that occurred alone, followed by 
V82A+ I54V, then V82A+I54V+M46I. This combination of mutations was seen in 
four patients, and has been previously reported for subtype B and C. The addition 
of L76V to this combination was seen in 13 patients and was accompanied by the 
presence of an accessory PI DRM, L10F in all 13 patients. While this has also 
been observed by Van Zyl et al (2013) in subtype C patients, this is distinctly 
different to subtype B. The L10F mutation could improve replication capacity, as 
shown by Race et al (2001) where variants containing a pattern of 
M48I/L63P/V82T/I84V and L10R/M46I/L63P/V82T/I84V were able to replicate at 
the same at the rate as wild-type virus. (Race et al, 2001). However, more work will 
be required to investigate the fitness costs associated with the most frequent 
pattern of mutations (M46I/V82A/I54V/L76V/L10F) seen in our study. Interestingly 
there were four patients that were able to accumulate six drug resistance mutations 
within less than one year of receiving LPV/r treatment, while seven patients were 
able to accumulate four DRMs between the first and second year of LPV/r 
treatment, largely suggesting that mutations in PR can develop quickly despite the 
drug’s  high  genetic  barrier  (Tang  and  Shafer  et  al,  2012). 
 
To further identify mutations that arose as a result of exposure to LPV/r, a 
comparison of our LPV/r treated patients with downloaded treatment naïve 
sequences was performed. A significant increase in frequency in the treated group 
was found for DRMs: L10F, K20R, M46I, I54V, A71V, L76V, and V82A and no 
novel PR mutations were detected. While, the K20R mutation is regarded as an 
accessory mutation that plays a compensatory role in patients that have other PI 
resistance mutations, other studies have found a high prevalence of K20R in non-B 
treatment naïve patients (Bessong et al, 2008, Descamps et al., 2009). A study by 
Descamps et al (2009) showed that the K20R mutation results in a better 
virological response to a DRV/r containing regimen, as opposed to the K20I 
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mutation (Descamps et al. 2009).  A71V is considered a minor PI mutation and is 
present in (2-3%) of the untreated population and increases in frequency in 
patients receiving PIs. The co-existence of V82A and A71V results in a significant 
increase in viral fitness (Race et al, 2001).   
 
Mutation M184V was the most frequent NRTI mutation amongst both adults and 
paediatric patients, attributed to the use of 3TC/FTC during first or second-line 
treatment. Despite 27 patients receiving TDF-inclusive regimens, only three 
patients harboured the K65R mutation, the presence of the TAMs prevents the 
selection of K65R, and thus may account for the low frequency of this mutation 
(Tang and Shafer et al, 2012).  The high percentage of the NNRTI mutation, 
K103N, is a result of an NNRTI-containing first-line regimen. Many studies have 
shown that K103N can persist between one to three years after stopping NNRTI 
treatment, due to the fitness advantage conferred by this mutation (Cong et al., 
2007). Fortunately, the second-generation NNRTI, ETR would still be a good 
option for the majority of patients, as the presence of K103N does not confer cross-
resistance to ETR (Tang and Shafer et al, 2012).  
 
Positive selection results indicated that the majority of codons in PR were under 
negative selection pressure, suggesting that very little sequence variation can be 
tolerated in order to preserve PR functional activity. (Gordon et al, 2003, Banke et 
al., 2009).  Positively selected sites that were common in both the treated and 
naïve groups are most likely the result of immune selection pressure and not the 
influence of drug pressure. The codons under positive selection in PR (in both 
naïve and treated isolates included: 12, 15, 19, 37, 63 and 74 and in RT: 36, 48, 
123, 162, 165, 166, 173, 174 and 200. Most of these codons are part of the genetic 
signature of C viruses (Banke et al, 2009). The only codons that were positively 
selected in PR in the treated isolates only, were at codons 20 and 82; codon 82 is 
associated with the major PI DRM, V82A, while codon 20 is an accessory PI DRM 
and may also play a compensatory role in improving fitness but also results in a 
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>20 fold decrease in LPV/r susceptibility (Barber et al., 2012). For RT, codons 184 
and 219 were positively selected in the treated group only, and are associated with 
the DRMs M184V and K219E/Q/R/W/N respectively, and are an indication of RT-
inhibitor treatment. It is evident that selection pressure due to ARV therapy is the 
main force driving the development of DRMs in the pol gene (Banke et al, 2009).  
In summary, PI drug resistance does not seem to be the major cause of LPV/r 
failure  given  that  only  24%  of  patient’s  harboured  resistance  to  LPV/r.  Intermittent  
drug-adherence may account for the emergence of PI resistance amongst these 
patients.  
 
Overall non-adherence seems to be the major cause of treatment failure in the 
remaining patients. Measuring the LPV/r concentration using serum levels or hair 
sampling may also help to out rule adherence as the primary cause of failure. 
However sampling at random as opposed to a longitudinal analysis may not be 
completely accurate and is thus subject to variability in these patients. Additionally, 
the high genetic barrier associated with PIs, as well as the presence of DRMs in 
other parts of the viral genome such as gag or env may also be likely contributors 
to treatment failure. For those patients without resistance, LPV/r and recycled 
NNRTIs/NRTIs can still be used in the presence of added adherence counselling. 
Despite the distinct pattern of four PI DRMS (M46I, I54V, V82A, and L76V) 
identified amongst those with PI resistance, most patients still retained 
susceptibility to DRV/r and will thus still be a good third-line option. However, for 
those harboring the L76V mutation cross-resistance to DRV/r is likely, nevertheless 
this drug can still be used, as additional DRV/r resistance associated mutations are 








Drug resistance amongst patients failing both Lopinavir and Darunavir using 
Ultra Deep Pyro-Sequencing. 
 
3.1 Introduction 
Access to third-line ART in SA is limited to patients who have documented 
resistance to LPV/r and must be authorized by an expert committee. For these 
patients, DRV/r and other ARVs such as ETR and RAL, depending  on  the  patient’s  
resistance profile and ART history, are usually prescribed (Department of Health 
and Human Services, 2015). Darunavir is a second-generation PI that was 
developed for use in treatment-experienced patients. Despite this, studies have 
shown that distinct DRV/r resistance associated mutations can develop and 
contribute to treatment failure (Delaugerre et al., 2008, de Meyer et al., 2008, 
Lambert-Niclot et al., 2008, Descamps et al., 2009). This aspect of the study 
describes DRV/r resistance mutations in patients from KZN, and investigates the 
role of low frequency mutations (or minority variants) present at LPV/r failure and 
DRV/r failure. Minority populations are generally missed by Sanger sequencing, 
however the clinical value of detecting these variants is well described in the 
literature (Le et al, 2009, Avidor et al, 2013). Therefore, minority variants that are 
present at LPV/r failure may inherently increase in frequency and contribute to 
DRV/r resistance. Here, the Roche 454 platformTM  (Branford, CT, USA) was used 
to perform UDPS for the detection minority variants in PR, RT and IN. The IN 
sequences serve as baseline data prior to RAL treatment. Given the limited 
availability of treatment options beyond third-line, these drugs must be preserved 






3.2 Materials and Methods  
 
3.2.1 Study population  
Twenty patients from the PCSK cohort were switched to a third-line regimen 
comprising a combination of either DRV/SQV/ATV or 3TC/TDF/AZT, ETR and 
RAL. Of these patients, seven presented with viral loads >1000cpm and were 
genotyped; six of these patients showed distinct DRV/r resistance associated 
mutations while the remaining patients did not show any additional PI mutations. 
Five of the six patients were sequenced using UDPS at LPV/r and DRV/r failure. 
The sixth sample was not available for analysis. 
 
3.2.2 Ultra Deep Pyro-Sequencing 
The Roche 454TM platform  was   used   for   UDPS   according   to   the  manufacturer’s  
instructions. The procedure incudes an RNA extraction, RNA purification, cDNA 
synthesis, PCR amplification, generation of the HIV-1 amplicon library, amplicon 
purification, quantification, qualitation, amplicon pooling, emulsion PCR (emPCR), 
and sequencing. 
 
3.2.2.1 RNA extraction  
The assay recommends using HIV-1 infected plasma with a viral load of  >2000 
copies per ml. Briefly, one ml of each plasma sample was aliquoted into a 1.5ml 
screw capped tube and labeled with an orientation marking indicative of the pellet.  
Tubes were centrifuged in an ultracentrifuge at 25000 X g for two hours at 4°C. 
After removal of the supernatant, RNA was extracted using the QiAmp Viral RNA 
Mini   kit   (Qiagen,  Valencia,  CA)  according   to   the  manufacturer’s   instructions.  The  
final  elution  was  performed  using  50μl  of  Buffer  AVE  supplied  with   the  extraction  
kit. Bacteriophage MS2  carrier  RNA  (10ng/μl)  (Roche  Life  Science,  Branford,  CT,  
USA) was added to the freshly extracted RNA to improve the stability of the RNA.  
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3.2.2.2 RNA purification  
RNA was purified using the Agencourt RNA Clean XP beads (Beckman, Coulter, 
Brea CA). These beads are paramagnetic once placed in a magnetic field, and 
allow the collection and re-suspension of the beads once the magnetic field is 
removed.  The  purification  was  carried  out   in  a  96  well  optical  plate  where  45μl  of  
freshly extracted RNA was added into columns A1-10. Before use, the AMPure 
RNA clean XP beads were thoroughly vortexed for three minutes until a 
homogenous  suspension  was  formed,  following  which  81μl  was  added  into  each  of  
the sample wells and mixed five times. The plate was incubated at room 
temperature for ten minutes and then placed on a 96 well Magnetic Ring Stand 
(MRS) (Life Technologies, Carlsbad, CA) for five minutes.  The supernatant was 
carefully  removed  and  discarded  without  disturbing  the  beads.  Thereafter  200μl  of  
freshly prepared 70% ethanol was added into each of the sample wells and the 
plate was gently swirled five times around the MRS to dislodge the beads. The 
plate was then placed on the MRS for 30 seconds. The supernatant was removed 
and discarded, a total of three 70 % ethanol washes were performed. Following the 
final wash, all ethanol was completely removed and beads were left to air dry for 
no  longer  than  five  minutes.  For  the  final  elution,  15μl  of  nuclease  free  water  was  
added into each of the sample wells and mixed ten times. The plate was placed 
back on the MRS for one minute, during this time the V Type HIV-1 cDNA 1-1 
primer plates (Roche, Applied Science, Mannheim, Germany) containing 
lyophilized primers were centrifuged at 900 X g for 30 seconds to collect droplets 
and was placed on a plate cooler for at least five minutes before use. The plates 
contained   primers   spanning   PR,   RT   as   well   as   IN.   Thereafter,   13.5μl   of   the  
supernatant from the RNA elution was transferred into the corresponding wells of 
the cDNA primer plate. The positive and negative control was included in well 11 
and 12 respectively. The plate was sealed with an adhesive foil and centrifuged at 




3.2.2.3 cDNA Synthesis and PCR amplification  
    The cDNA synthesis was performed using the Transcriptor First Strand cDNA 
synthesis Kit (Roche Applied Science, Mannheim, Germany). All reagents except 
enzymes were vortexed for five seconds and centrifuged for ten seconds before 
use. The cDNA master mix was prepared in a 1.7ml micro-centrifuge tube as 
indicated in Table 3.1.  
 
Table 3.1 Reverse Transcriptase Master Mix 
Reagent   (μl)/well Final Concentration  
5X Transcriptor RT 
Reaction Buffer 
4 1X (8mM) 
dNTPs (10mM) 2 1mM each 






Total Volume  7  
 
The master mix was gently vortexed, spun in a bench top minifuge and placed on 
ice until use. The plate was then obtained and placed on the thermocycler at 65°C 
for  ten  minutes,  and  promptly  cooled  on  ice  for  two  minutes.  Seven  μl  of  the  freshly  
prepared cDNA master mix was added into each of the wells and mixed well. The 
plate was sealed with adhesive foil and centrifuged at 900 X g for 30 seconds. The 
reaction was run on the thermocycler at 50°C for 60 minutes, 85°C for five minutes 
and left on hold at 4°C for no longer than two hours.  Once the reaction was 
complete the plate was centrifuged again and   one   μl   of   RNase H (Life 
Technologies, Invitrogen, Carlsbad, CA) was added to each well.  The plate was 
centrifuged again and placed on the thermocycler at 37°C for 20 minutes and then 
4°C on hold. 
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Multiplex Identifiers (MIDs) were added onto each primer sequence as indicated in 
Figure 3.1. This allows a system of barcoding and an automated software 














Figure 3.1 Illustration of the Multiplex Identifiers. Each well in the primer plate 
contains amplicon specific primers comprising  adaptors  that  are  5’  extensions  with  
binding sites for the forward (A) (Primer A- Key) 5- 
CGTATCGCCTCCCTCGCGCCA and reverse (B) (Primer B – Key)   5’  
CCTATCCCCTGTGTGCCTTGGCAGTC, to which the key sequence (TCAG) is 
attached. The key sequence refers to a known sequence of four nucleotides which 
is followed by the MID.  (Adapted from the Amplicon Library Preparation Method 
Manual, Roche 454TM Life Sciences, Branford, CA, USA). 
 
 
A PCR master mix was made using the Fast Start Hi Fidelity PCR System (Roche 
Applied Science, Mannheim Germany) which encompasses a unique blend of Fast 
Start Taq DNA polymerase and a thermostable chemically modified proofreading 
protein without polymerase activity. The PCR master mix was made as indicated in 











Table 3.2 Composition of the PCR master mix using the Fast Start Hi-Fi Kit. 
Reagent   (μl)/well    Final concentration 
(mM) 
Nuclease Free Water 16.5 - 
Fast Start Hi Fidelity Reaction Buffer 
w/o MgCl2 (10X) 
2.5 1 X   
MgCl2 (25mM) 2.25 2.56 
dNTPs (10mM) 0.5 0.23 
Fast Start High Fidelity Enzyme 
Blend  (5U/μl) 
0.25 1.25U 
Total volume  22  
 
The PCR mix was gently vortexed, centrifuged and placed on ice until use. PCR 
primer plates were prepared as previously described for the cDNA plates in section 
3.2.2.3.  Using  a  multichannel  pipette  22μl  of  PCR  master  mix  was  added  into  each  
well of rows A-E of the PCR primer plate using a new tip for each well. The cDNA 
plate was removed from the thermocycler and centrifuged at 900 X g for 30 
seconds to collect droplets and was placed on a plate cooler. Using a multichannel 
pipette  three  μl  of  cDNA  was  then  transferred  from  row  A into each of the rows (A-
E) of the PCR plate containing the master mix. The PCR plate was sealed, 
centrifuged and run under the following thermal conditions. Once the reaction was 
complete the plate was stored at -20°C until required. 
 
Table 3.3 Thermal cycling conditions for the PCR amplification.  
No of cycles  Temperature  Time  
1 95°C 3 minutes  
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95°C 30 seconds  
55°C 20 seconds  
72°C 50 seconds  
1 72°C 8 minutes 





3.2.2.4 Amplicon purification  
Purification of amplicons was performed using the Agencourt Ampure XP Kit 
(Beckman Coulter, Brea, CA, USA). Firstly, amplicons were immobilized onto a 
new 96 well optical plate-containing  22.5μl  of  molecular  biology  water;;  22.5μl  of  the  
amplicons were transferred into corresponding wells. The bottle of Ampure beads 
was thoroughly vortexed for three minutes to ensure a homogenous suspension 
and  45μl  was  added   into  each  well  and  mixed  at   least   five   times.  The  plate  was  
incubated at room temperature for ten minutes to allow the paramagnetic beads 
containing amplicons to bind. The plate was placed on the MRS for five minutes to 
allow the separation of the beads from the supernatant, which was then removed 
and discarded using a multichannel pipette. The next step involved contaminant 
removal,  where  100μl  of  freshly  prepared  70%  ethanol  was  added  into  each  of  the  
wells. The plate was then swirled five times across the MRS to dislodge the beads 
into the liquid and was placed back on the MRS for one minute. The supernatant 
was removed and discarded; this process was repeated. After the last wash it was 
important to remove as much of the ethanol as possible. The plate was then left to 
air   dry   for   five   to   ten   minutes.   Thereafter,   using   a   multichannel   pipette,   20μl   of  
freshly prepared 1 X Tris EDTA (TE) buffer (Sigma, Aldrich, USA) was added into 
each well. The plate was swirled across the MRS and thereafter incubated for one 
minute at room temperature. Lastly, the clear supernatant was removed and 




Figure 3.2 Amplicon purification using Agencourt Ampure XP beads 
(Beckman Coulter, Brea, CA, USA).  
 
3.2.2.5 Quantification of amplicons 
The Quant-iT Picogreen dsDNA Assay kit (Invitrogen, Life Technologies, Carlsbad, 
CA) employs Picogreen, an ultra-sensitive fluorescent nucleic acid stain for 
quantitating dsDNA. Both the Lambda DNA standard and the Picogreen reagent 
were thawed according to   the   manufacturer’s   instructions.   Lambda   DNA   was  







A       B 
Figure 3.3 A) Serial dilution to quantify the amplicons. This was performed 
using  the  Lambda  DNA  standard,  tube  one  contained  877.5μl  of  I  X  TE  buffer  and  
tubes 2-10  had  450μl  of  1  X  TE  buffer,  at  each  transfer  tubes  were  vortexed  and  
spun for five seconds before transferring into the next tube. B) Final concentrations 
for each of the serial dilutions.  
Tube  Concentration 
(ng/μl) 
Tube  Concentration 
(ng/μl) 
1 250 6 7.81 
2 125 7 3.91 
3 62.5 8 1.95 
4 31.2 9 0.98 
5 15.63 10 0 
877.5ul TE 
























From  each  of  the  serially  diluted  tubes  100μl  was  transferred  into  the  first  row  of  a  
black 96 well Micro plate (Bio-Rad,  Hercules,  CA.  USA)  and  97μl  of  1  X  TE  Buffer  
was added into all the sample wells using a multichannel pipette followed by the 
addition  of  three  μl  of  the  purified  sample.    The  Picogreen  reagent  was  prepared  by  
making   a   1:200   dilution   (three   μl   Picogreen   +   600μl   1X   TE   Buffer)   this   was  
vortexed  well  and  100μl  was  added  into  all  wells  and  mixed  at least five times. The 
plate was read on the Glomax Modulus Micro plate Flourometer (Promega, State 
of Wisconsin, USA) as described by the Quant-It Picogreen dsDNA Assay Kit 
insert. The Comma Separated Values (CSV) file was exported from the Glomax 
and used to construct a standard curve using Relative Fluorescent Units (RFU) 
versus concentration. An R-value of >0.98 was considered acceptable.  
Table 3.4 The DNA standard and the sample values were used to determine 
the concentration of each amplicon in molecules/μl 
Molecules/μl Sample concentration  (ng/μl)  x  6.022  x1023 




Figure 3.4 Standard curve used to quantitate amplicons by the Quant -it 
Picogreen dsDNA assay kit (Invitrogen, Life Technologies, Carlsbad, CA). 
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3.2.2.6 Amplicon qualitation 
Amplicons   that   were   quantified   at   <5ng/μl   were   further   evaluated   on   the   Agilent  
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Procedures 
describing the use of the bioanalyzer is described in Appendix B. The bioanalyzer 
is used to ensure that all amplicons are between 400-500bp. Amplicons with bands 
that are less than 300bp are indicative of primer dimer. If these primer dimer bands 
were less than a 3:1 molar ratio relative to the correct sized products then these 
amplicons were further purified. This was done to prevent the preferential 
amplification of primer dimer during the sequencing reaction.  Primer dimers that 
were greater than a 3:1 molar ratio relative to the product were not included. The 
bioanalyzer also provides an electropherogram which indicates an upper marker 
and a lower marker, the middle peak is indicative of the product at 400-500bp while 
other peaks indicate primer dimer. This is shown in Figure 3.5. 
A B  
Figure 3.5 A) Gel picture generated by the bioanalyzer. All samples showed 
products between 400-500bp, primer dimer was present at 100bp in a few 
samples, however these were <3:1 ratio relative to the products and were thus 
ignored. B) Electropherogram shows slight primer dimer <3 times the height of the 






3.2.2.7 Normalization of amplicons  
All amplicons had to be present at equimolar ratios for the emPCR. Therefore 
amplicons were normalized to 5x109 molecules/μl   based   on   the   concentration 
obtained from the dilution calculator on the my454.com website (my454.com). 
Dilutions were performed using 1 X TE buffer. In a new 96 well plate the required 
volumes of 1 X TE buffer and sample was added. The sample pool was then 
prepared by transferring all the samples from each column into the respective last 
row of each column. The final master pool was prepared by removing the entire 
volume of sample from the last row of the plate and transferring into a single 1.7ml 
eppendorf. The final master pool was diluted from 5x109 to 1x109 molecules/μl  (ten  
μl  of  the  5  x109 master  pool  +  40μl  of  1  X  TE  buffer)  and  was  vortexed  gently.  This  
master pool was then purified to ensure all short fragments were removed before 
the emPCR.  
3.2.2.8 Purification of the master pool.  
In  a  single  well  of  a  new  96  well  plate,  22.5μl  of  molecular  water  +  22.5μl  of   the  
1x109 molecules/μl  master  pool  +  45μl  of  Ampure  XP  beads  and  was  mixed  at  least  
five times to ensure a homogenous suspension, the plate was incubated for ten 
minutes at room temperature and five minutes on the MRS. With the plate on the 
MRS the supernatant was removed and discarded without disturbing the beads 
followed  by   the  addition  of  100μl  of   freshly  prepared  70%  ethanol.  The  plate  was  
swirled across the MRS to wash the bead pellet and thereafter placed back on the 
MRS for one minute.  The supernatant was removed and discarded, the process 
was repeated to obtain a total of two washes after the last wash, as much of the 
ethanol as possible was removed and the beads were left to air dry for five 
minutes. To re-suspend the beads, 22.5μl   of   1   X   TE   buffer  was   added   and   the  
plate was swirled across the MRS followed by an incubation of one minute on the 
MRS. The supernatant was removed and transferred to a new well on the same 
plate,  22.5μl  of  molecular  water  and  45μl  of  Ampure  beads  was  added  and  mixed  
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well. The procedure was repeated as before, once the 1 X TE buffer was added 
the supernatant was removed and transferred to a new 1.7ml tube for 
quantification.  
3.2.2.9 Quantification of the twice-purified master pool 
The twice purified master pool was quantified using the Quant it dsDNA Picogreen 
assay as previously described in section 3.2.2.5. Ten eppendorf tubes were 
labeled 1-10,  and  441μl  of  1  X  TE  buffer  was  added  to the  first  tube  and  225μl  of  1  
X  TE  was  added  into  the  remaining  tubes.  Nine  μl  of  DNA  standard  was  added  into  
the first tube and vortexed for five seconds making a 1:50 dilution of the DNA 
standard,   225μl   from   tube   one   was   transferred   into   tube   two   and   vortexed, the 
serial   dilution   continued   to   tube   nine   where   225μl   was   removed   and   discarded  
leaving   tube   ten   as   the   no   DNA   control.   One   hundred   μl   of   each   standard   was  
transferred  onto  the  black  96  well  Micro  plate,  into  a  single  column  and  90μl  of  1  X  
TE buffer was added into one of the wells. This was followed by the addition of ten 
μl  of   the   twice-purified master pool. A 1: 200 dilution of Picogreen was prepared 
and   100μl   was   added   into   the   respective   wells   containing   the   standard   and   the  
sample. The plate was then read on the Glomax Modulus Micro Plate Flourometer 
as described in section 3.2.2.5. The master pool was then diluted to 2x106 
molecules/μl  using  1  X  TE  buffer,  constituting  the  final  purified  master  pool.   
3.2.2.10  Emulsion PCR  
Emulsion PCR refers to a process of emulsion based clonal amplification whereby 
DNA library fragments are attached to micron sized beads. The emPCR was 
performed on sepharose beads carrying immobilized primers that are 
complementary to the B adaptors of the library. For clonal amplification of a single 
molecule per bead a 1:1 ratio of library fragments to beads is required (Avidor et al, 
2009). Therefore correct library quantitation is crucial, as no readable sequence 
can be obtained from those beads that have no DNA fragments or less than one 
fragment bound. During the initial process of the amplification reaction, the DNA 
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library fragments capture beads, and enzyme reagents are subject to vigorous 
shaking in small cylindrical plastic containers. This creates water droplets around 
the beads, referred to as an emulsion. The water droplets generated by the 
emulsion act as PCR micro-reactors containing biotinlyated primers, buffers, 
nucleotides, salts and DNA polymerases that causes a single and isolated DNA 
fragment in each droplet to be amplified into millions of copies of DNA, which are 
clones of a single library molecule (Roche 454 TM Life Sciences, Branford, CA, 
USA).  The emPCR was performed according to the methods provided in the 
Roche  454  ™  emulsion  PCR  Manual  (my454.com)  and  is described in Appendix C. 
3.2.2.11  Sequencing 
 
The GS Junior uses sequencing by synthesis approach whereby ssDNA is 
synthesized by synthesis of the complementary strand one base pair at a time. The 
reaction utilizes ssDNA as a template, sequencing primers, the enzymes DNA 
polymerase, ATP sulfurylase, Luciferase and Apyrase, as well as two substrates, 
Adenosine  5’  phosphosulfate  (APS)  and  Luciferin.  The  nucleotide  bases  TCAG  are  
flowed sequentially in the same order across the PTP. As one of the four dNTPs is 
added to the sequencing reaction, while the DNA polymerase catalyzes its 
incorporation onto the DNA strand. During this time a phosphodiester bond 
between the dNTPs is formed, resulting in the release of pyrophosphate (PPi).  
ATP sulfyrase converts the PPi to ATP in the presence of APS. ATP is utilized for 
the conversion of Luciferin to Oxyluciferin catalyzed by Luciferase resulting in the 
production of light intensity that is proportional to the amount of ATP used in the 
reaction. This light is then detected by a CCD camera as a peak. The height of the 
peak is proportionate to the number of nucleotides that were incorporated, while 
the intensity of the light signal is proportional to the amount of ATP synthesized, 
which is also proportional to the number of nucleotides added to the growing chain. 
The system is regenerated with Apyrase, which degrades ATP and the un-
incorporated dNTPs (to form dinucleotide monophosphate [dNMP]), thereby 
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eliminating any background noise during the sequencing run. As the process 
continues the complementary DNA strand grows and the nucleotide sequence is 
determined based on the signal peaks seen in the pyrogram.  
3.2.2.12 Sequencing method  
Reagents were supplied as three individual kits from Roche; the GS Junior 
Sequencing Kit Reagents and Enzymes, Sequencing Kit Buffers and the 
Sequencing Kit Packing Beads with Supplement CB (Roche 454 TM Life Science, 
Branford CA, USA).  Kit components were all thawed according to the 
manufacturer’s   instructions.  The  sequencing  reaction  was  performed  according  to  
the  Roche  454™  Sequencing  method  manual  and  is  described in Appendix C.  
3.2.2.13 Post Analysis – using the Amplicon Variant Analyzer (AVA) 
The Amplicon Variant Analyzer (AVA) is a component of the standard GS junior 
software suite used for identifying sequence variants derived from moderate to 
high-depth sequencing.  Before using AVA, the HIV-1 assay extra processing script 
(runAnalysisCollabHIV_v3.0.gz), was installed which acts as an interface for 
downstream analysis software. Its purpose is to automate the generation of an 
appropriately configured AVA project, trigger AVA processing, de-multiplex 
samples, align reads, as well as extract and export the read alignments in FASTA 
format for third party analysis software. Following installation of the script, the 
standard FASTA format (SFF) files were imported into AVA, for the generation of 
an AVA project. The frequency of variants were determined by the proportion of 
reads with a pattern of variation, all of the aligned reads that span the pattern 
provides an estimate of the variant frequency. The frequency of resistance 
mutations were reported in a summary table according to the IAS and the Stanford 
Drug resistance Database algorithms (Avidor et al, 2013).  
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3.2.2.14 Quality control  
Despite the Roche 454TM platform being a powerful and efficient deep sequencing 
tool, with widespread applications, this technology is error prone in several 
aspects. Well documented bias includes errors introduced by stretches of homo-
polymers and GC content; primer related selective amplification and in vitro 
recombination, as well as sampling error due to low template availability, all of 
which can result in substantial uncertainty for rare variants (Knapp et al, 2014). 
Nonetheless many studies have been able to show that 454™ deep sequencing is 
fairly reproducible with an error rate of ~1% (Huse et al, 2007, Mitsuya et al 2007, 





















3.3 Results  
3.3.1 Longitudinal analysis for patients on a DRV/r-inclusive regimens. 
Results below show a longitudinal analysis of patient data, performed using the 
ART-AiDE (Antiretroviral Therapy –Acquisition and Display engine, Version 1.1 












Figure 3.6 Longitudinal Analysis for PID 040 showing mutations and minor 
variants identified. Major PI DRMS are indicated in red, while minor PI DRMs are 
shown in black. NRTI DRMS are shown in black and NNRTI DRMs are shown in 
blue. Opportunistic infections during treatment are indicated in green. Red ( ) 
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Patient 040 was initiated on first-line treatment in 2006, presenting with a CD4 
count of 20cells/μL extra-pulmonary TB, and oral candidiasis. In 2009, a high viral 
load of 150 000cpm prompted a switch to second-line LPV/r treatment. On the 9th 
of February 2011, the viral load still did not suppress and the patient was sent for 
genotyping. Sanger sequencing and UDPS identified major PI DRMs: M46I, I54V, 
L76V, V82C, I84V and one minor PI DRM (Q58E). Other PI mutations found 
included T12S, I15V, L19I, K20R, M36I, R41K, L63P, H69K, and L89M. UDPS 
alone found L10F that was missed by Sanger sequencing; this is an accessory 
mutation that causes reduced susceptibility to certain PIs. In addition to the PI 
DRMs detected, UDPS also detected minor variants (those variants occurring at < 
20% of the circulating virus population), L10I and L23I; these mutations reduce the 
susceptibility or increase the replication of viruses having other resistance 
mutations. L23I is an uncommon non-polymorphic mutation associated with NFV/r 
resistance. Patient 040 had intermediate resistance to DRV/r and high-level 
resistance to all other PIs. Sanger and UDPS found NRTI mutations (M41L, D67N, 
K70R, V75M, T215F, and K219Q). UDPS alone found minor variant T69N (1.19%). 
A combination of these mutations resulted in low-level resistance to 3TC/FTC and 
high-level resistance to all other NRTIs. NNRTI mutations found by both assays 
were (V90I, K103S, V106M, E138A, F227L) thus conferring high-level resistance to 
NVP and EFV, low-level resistance to RPV and potential low-level resistance to 
ETR. After initiating DRV/r treatment in 2011, patient 040 presented with a 
detectable viral load two years later and was thus genotyped again. In addition to 
the PI DRMs found at the first time point, Sanger and UDPS found minor mutations 
L10F, V32I and L33F, conferring high-level resistance to all PIs. UDPS alone 
detected K43T (1.92%); this mutation is associated with TPV/r resistance. Sanger 
and UDPS identified the same NRTI mutations at the previous time point, in 
addition to M184V, which now resulted in high-level resistance to 3TC. Initially 
patient 040 presented with high-level TDF resistance, however at the second 
genotype this changed to intermediate TDF resistance, possibly due to the 
presence of M184V, which increases susceptibility to TDF. Minor variant T69N 
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(11.4%) was detected again by UDPS only, and increased in frequency since the 
first genotype. T69N is a non-polymorphic NRTI resistance mutation that is weakly 
selected in those patients receiving NRTIs; however their effects on NRTI 
susceptibility are not well studied (Tang and Shafer et al, 2012). The NNRTI 
resistance profile did not change from the first genotype. Patient 040 did not 
achieve virological suppression thus a new salvage regimen with DRV+RAL+ETR 
was initiated in January 2014.  This regimen worked well and was able to reduce 
the viral load, resulting in an increase in the CD4 count. Patient 040 continues to 













Figure 3.7 Longitudinal Analysis for PID 071 showing mutations and minor 
variants identified. Major PI DRMS are indicated in red, while minor PI DRMs are 
shown in black. NRTI DRMS are shown in black and NNRTI DRMs are shown in 
blue. Opportunistic infections during treatment are indicated in green. Red ( ) 
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In November 2005 patient 071 initiated first-line treatment with, AZT+3TC+EFV; 
however the viral load never fully suppressed. In October 2010 AZT was stopped 
and TDF was started in addition to the remaining drugs in the regimen. After 
approximately one year, the viral load was still high, reaching 270 0000cpm, with a 
low CD4 count of 28cells/μl.  Patient 071 was switched to second-line LPV/r 
treatment, and the viral load still did not fully suppress. A few months later 
genotyping was performed and both Sanger sequencing and UDPS identified 
major PI DRMs (M46I, I54V, L76V, V82A) and one minor PI DRM (L10F). Other PI 
mutations found were I13V, G16E, L10I, K20R, M36I, R41K, L63H, H69K, L89I 
and I93L. There were no PI minority variants that were detected by UDPS. Patient 
071 had low-level resistance to DRV/r and TPV/r, intermediate-level resistance to 
ATV/r and SQV/r and high-level resistance to the remaining PIs. Both Sanger and 
UDPS detected NRTI mutations (M41L, D67N, K74I, M184V, T215F and K219Q) 
as a result patient 071 now had intermediate resistance to TDF and high-level 
resistance to the remaining NRTIs. In addition to the NRTI mutations detected by 
Sanger, UDPS also detected K70R; this mutation causes intermediate resistance 
to AZT and possible low-level resistance to d4T and TDF. Both Sanger and UDPS 
identified NNRTI DRMs (A98G, K103N and P225H). Fortunately patient 071 was 
still susceptible to ETR and RPV, but had high-level resistance to the remaining 
NNRTIs.  
Virological suppression was not achieved and thus treatment with DRV+TDF+3TC 
was initiated in February 2012, which decreased the viral load only slightly. A few 
months later the viral load began increasing and patient 071 was genotyped again. 
In addition to the PI DRMs found at the first genotype, both Sanger and UDPS 
identified three new major PI DRMS, V32I, I54L and I84V, as well as minor PI 
DRMs V11I, L33F and Q58E. Other PI mutations found were I13V, G16E, L19I, 
K20R, M36I, R41K, K55R, L63H, H69K, L89I and I93L. No minority variants were 
identified at this time point. Patient 071 now had high-level resistance to all PIs with 
the exception of TPV/r (intermediate resistance). The same NRTI and NNRTI 
mutations were present from the first genotype as detected by both Sanger and 
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UDPS, except D67N, which was no longer present, as patient 071 was no longer 
receiving AZT. UDPS alone found, NRTI mutation K65R (1.21%). Despite the 
switch to a DRV/r-inclusive regimen, the viral load did not fully suppress and in 
October 2013 a new salvage regimen with DRV+TDF+3TC+RAL+ETR was 
started. This treatment was effective in reducing the viral load and in March 2014, 
the viral load was <150cpm. The CD4 count also increased to 594cells/μl, patient 












Figure 3.8 Longitudinal Analysis for PID 086 showing mutations and minor 
variants identified. Major PI DRMS are indicated in red, while minor PI DRMs are 
shown in black. NRTI DRMS are shown in black and NNRTI DRMs are shown in 
blue. Opportunistic infections during treatment are indicated in green. Red ( ) 
indicates the emergence of additional mutations between time points. 
 
In 2005 patient 086 presented with a very high viral load of 150 000cpm and a low 





























































initiated, however the viral load still did not suppress and thus genotyping was 
performed again. Both Sanger and UDPS identified major PI DRMs (M46I, I47V, 
I54V, L76V, V82C) and minor PI DRMS (L10F, Q58E, A71V) resulting in high-level 
resistance to LPV/r, IDV/r, NFV/r, FPV/r, intermediate resistance to DRV/r, ATV/r, 
TPV/r and low-level resistance to SQV/r.  Other PI mutations identified were T12S, 
I15V, G16E, L19E, K20T, E35D, M36I, R41K, L63T, H69R, L89M and I93L. No 
minority variants were found at this time point.  
 
Both Sanger and UDPS identified NRTI DRMs, M41L, D67N, T69D, K70R, M184V, 
T215Y, K219Q) which resulted in high-level resistance to all NRTIs with the 
exception of TDF for which patient 086 had intermediate resistance. Only two 
NNRTI DRMs were found by both Sanger and UDPS (K101R and K103N). This 
resulted in high-level resistance to EFV and NVP. UDPS alone found minor 
variants K101P and V108I. This regimen was continued for seven months while 
awaiting a new salvage regimen.  Prior to the new treatment a resistance test was 
performed and the same mutations were found by both Sanger and UDPS, 
however no minor variants were detected. A regimen comprising SQV+3TC+RAL 
was initiated in 2013, which reduced the viral load slightly however the viral load 
was still not fully suppressed. In March 2013, SQV/r was stopped, DRV/r and TDF 
was initiated in addition to the remaining drugs in the salvage regimen. The 
treatment worked well and in March 2014 the viral load decreased to <40 
















Figure 3.9 Longitudinal Analysis for PID 098 showing mutations and minor 
variants identified. Major PI DRMS are indicated in red, while minor PI DRMs are 
shown in black. NRTI DRMS are shown in black and NNRTI DRMs are shown in 
blue. Opportunistic infections during treatment are indicated in green.  
 
Patient 098 initiated first-line treatment in 2005 with d4T+3TC+NVP, less than a 
year later, d4T was switched to AZT, due to peripheral neuropathy. In August 2006 
a high viral load of 16000cpm and a low CD4 of 42cells/μl prompted a switch to a 
second-line LPV/r–inclusive regimen that reduced the viral load to <25cpm. This 
new regimen did not fully supress the viral load and in June 2012 a genotypic test 
was performed. Both Sanger and UDPS identified major PI DRMS (M46I, I54V, 
L76V, V82C, I84V) and one minor PI DRM L10F, resulting in intermediate 













































































found were T12S, I15V, L19V, K20R, M36I, R41K, D60E, Q61H, L63P, H69K, and 
L89M. 
 
UDPS alone identified minor variant L10I, which can cause reduced susceptibility 
to or increased replication of viruses with other PI resistance mutations. NRTI 
mutations M41L, D67N, K70R, V75M, F77L, M184V, T215F, and K219Q were 
identified by both Sanger and UDPS resulting in high-level resistance to all NRTIs. 
NRTI DRM, K65R was found by UDPS only. NNRTI mutations A98G and Y181C 
were detected by both UDPS and Sanger, resulting in intermediate resistance to 
EFV, ETR, RPV and high-level resistance to NVP. UDPS alone found K101H and 
K103N, reflecting prior NNRTI use. 
 
After a nine month delay due to costs associated with salvage drugs within the 
public health care sector, patient 098 was eventually initiated on a third-line 
regimen comprising DRV+ETR+TDF+3TC+RAL. However in August 2014 the viral 
load was still detectable and a genotypic test was performed again. Both Sanger 
and UDPS identified the same PI DRMs from the first genotype and as a result 
patient 098 still maintained intermediate resistance to DRV/r. Other PI mutations 
found were T12S, I15V, L19V, K20R, M36I, R41K, D60E, Q61H, L63P, H69K, and 
L89M. UDPS alone found L10I again however the frequency of this mutation 
decreased since the first genotype. Both Sanger and UDPS found the same NRTI 
and NNRTI mutations since the first genotype. Patient 098 continues to receive this 














Figure 3.10 Longitudinal Analysis for PID 100 showing mutations and minor 
variants identified. Major PI DRMS are indicated in red, while minor PI DRMs are 
shown in black. NRTI DRMS are shown in black and NNRTI DRMs are shown in 
blue. Opportunistic infections during treatment are indicated in green. Red ( ) 
indicates the emergence of additional mutations between time points. 
 
Patient 100 presented with stage IV disease and initiated first-line treatment in 
2009. In November 2011 a high viral load of 8418642cpm and a low CD4 count of 
27cells/μl  prompted  a  switch to a second-line LPV/r inclusive treatment, however 
this did not reduce the viral load. In November 2012, patient 100 was still not doing 
well presenting with a viral load of 1 million cpm and a very low CD4 count of 
24cells/μl. A genotypic resistance test was performed, both Sanger and UDPS 
detected major PI DRMs (M46I, I54V, L76V, and V82A) and minor PI DRMs (L10F, 
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to SQV/r and high-level resistance to all other PIs. Other PI mutations found were 
I13V, K14R, I15V, L19I, K20R, E35D, M36I, N37D, R41K, H69K, L89I and I93L. 
No PI minor variants were detected at this time point. Both Sanger and UDPS 
detected NRTI DRMs (D67N, K70Q, V75M, M184V) resulting in low-level 
resistance to AZT and TDF, intermediate resistance to ABC, ddi, and high-level 
resistance to 3TC/FTC and d4T. NNRTI DRMs detected by both Sanger and 
UDPS included K103N, V106IM, and V179T. These DRMs resulted in resistance to 
all NNRTI drugs, with the exception of ETR and RPV. V179T is a rare non-
polymorphic mutation rarely selected in those patients receiving NNRTIs, and is 
associated with minimal reductions in ETR and RPV susceptibility (Tang and 
Shafer et al, 2012).  
 
As the viral load did not suppress, patient 100 was switched to a third-line regimen 
DRV/r+TDF+3TC in March 2013. This treatment resulted in only a slight decrease 
in viral load and the CD4 count did not change, as a result a resistance test was 
performed again.  Three additional PI DRMs were detected by both Sanger and 
UDPS: V32I, 184IV and T74S and resulted in intermediate resistance to DRV/r and 
TPV/r. Other PI mutations found were I13V, K14R, I15V, L19I, K20R, E35D, M36I, 
N37D, R41K, H69K, L89I and I93L. No minority variants were detected at this time 
point. The NRTI and NNRTI DRMs remained the same from the first genotype as 
detected by both Sanger and UDPS. In August 2013, a new salvage regimen with 
DRV+RAL+TDF+3TC+AZT was administered. The viral load was still relatively 
high and in April 2014, a genotypic resistance tests was performed again. Both 
Sanger and UDPS detected the same PI DRMs. L63P was now present, however 
the I15V and I93L mutations were no longer present. The same NRTI and NNRTI 
DRMs were present from the previous genotype however the NNRTI DRM, V179T 
was no longer present. UDPS found one minor variant V106M reflecting prior 
NNRTI use. Patient 100 continued with this treatment and in May 2014, the viral 
load was <150cpm and the CD4 count was 318cells/μl. Patient 100 is currently 
receiving this treatment. 
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3.3.2 Baseline Integrase substitutions prior to Raltegravir treatment 
  
Table 3.5 Baseline integrase associated polymorphisms detected by Sanger 
sequencing as well as minority variants detected by UDS.  
 
PID  Mutations detected by Sanger sequencing and 
UDS 
Minor Variants 
detected by UDS only 
PID 40R D25E, P30A, M50T, I84L, T93N, L101I, T112V, 
S119P, T122I, T125A, K136Q, V201I, L234I, 
M275V, D278A, S283G 
V72N (7.33%),  
R127K (4.48%), 
PID 71R S17N, D25E, V31I, I84IM, E96D, L101I, T112V, 
T124A, T125A, K136Q, V201I, L234I 
None  
PID 86R D3K, E11K, S17N, A23G, D25E, E35K, M50I, 
I72V, I84M, F100Y, L101I, T112V, I113L, T124A, 
T125A, K136Q, V201I, L234I, D278A, S283G 
R127K (15.39%) 
PID 98R S17N, R20K, V31I, I72V, I89L, F100Q, L101I, 
T112V, T124G, T125A, K136Q, I182V, V201I, 
T206S, L234I, R269K, D278A 
None 
PID 100R E11D, S24N, D25E, V31I, L101I, T112V, K136Q, 
V201I, K215N, L234I, R269K, D278A, S283G, 
D286N, V151I 






All patients harbored major and minor PI DRMS both at LPV/r and DRV/r failure. 
Other PI mutations that were found are subtype C genetic polymorphisms some of 
which are implicated in drug resistance, particularly K20R, L63P, and L89M (Tang 
and Shafer, 2012). The K55R mutation was seen only after DRV/r failure in two 
patients and plays a compensatory role in restoring viral fitness in the presence of 
major PI DRMS, in particular M46L (Margerison et al., 2008). 
 
Following DRV/r treatment patients quickly developed PI mutations, which included 
(V11I, V32I, I54L and T74S) that were not present at LPV/r failure. These 
mutations changed the resistance profile for two patients from low-level DRV/r 
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resistance to intermediate DRV/r resistance. Two patients presented with 
intermediate DRV/r resistance before and after DRV/r treatment; patient 098 
harbored L10F, M46I, I54V, L76V, V82C and I84V interestingly no additional 
mutations were found following DRV/r treatment. Patient 086 harbored the I47V 
mutation in addition to other PI DRMs, which is included in the Tibotec DRV GSS 
(Tang and Shafer et al, 2012) and may account for the intermediate DRV/r 
resistance seen in this patient before treatment. One patient harbored I54L, which 
changed the resistance profile from low-level to high-level resistance, suggesting 
that this mutation is required for complete DRV/r resistance. The presence of these 
mutations in addition to other PI mutations (V11I, V32I, L33F, I47V, I54L, L76V, 
I84V) are important for conferring DRV/r resistance, and have been reported in 
other studies as DRV/r-associated resistance mutations (Clotet et al., 2007, 
Madruga et al., 2007, Lambert-Niclot et al., 2008). All patients harbored L76V, a 
characteristic LPV/r-resistance associated mutation, which is involved in the 
pathway to DRV/r cross resistance, often accompanied by V32I, I47A and I50V 
(Tang and Shafer et al, 2012). A study by Lambert-Niclot et al (2008) suggested 
that the presence of L76V at baseline reduces the risk of accumulating additional 
DRV/r resistance mutations (Lambert-Niclot et al., 2008). This may account for the 
four patients that presented with only intermediate DRV/r resistance despite 
accumulating DRV/r resistance mutations.  
 
Two patients (PID 098 & PID040) presented with minority variants at LPV/r failure, 
which were L10I and L23I. One of these patients (PID 040) presented with L10F 
detected by UDPS only but missed by Sanger sequencing. This mutation was 
detected by Sanger sequencing only after DRV/r failure. Nonetheless patient 040 
already had PI DRMs conferring high-level resistance to all PIs with the exception 
of DRV/r, thus L10F would not have altered the drug susceptibility profile. The 
remaining three patients did not present with any PI minority drug resistant 
variants. These results suggest that Sanger sequencing is sufficient for the 
detection of PI mutations and the added sensitivity provided by UDPS does not 
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impact on the interpretation of resistance profiles. All patients presented with 
resistance to the NRTI component of the regimen, limiting the use of these drugs in 
subsequent regimens. Only three patients presented with NRTI minor variants, 
which were T69N and K65R. Mutation, T69N occurred in a single patient at a 
frequency of (1.19%) and thereafter increased to (11.4%) at the second time point. 
This mutation may have implications for subsequent treatment with ddi. In addition, 
two patients presented with the K65R mutation, given that this mutation occurs 
within a homo-polymeric stretch and is subject to sequencing errors, their presence 
as true variants is debatable (Lessells et al., 2012). 
 
The NNRTI mutation, K103N, persisted from first-line failure in 3/5 patients studied. 
This mutation is well known for its persistence due to the low fitness cost it confers 
(Flys et al., 2005, Loubser et al., 2006, Palmer et al., 2006, Cong et al., 2007). 
Other NNRTI mutations included V90I, A98G, E138A and V106I, which may have 
implications for subsequent treatment with second-generation NNRTIs in salvage 
regimens. The presence of NNRTI minority variants (K103N, K101H, K101P, 
V108I, V106M), reflect the prior use of NNRTIs during first-line treatment.  
Overall, minority variants did not play a significant role in treatment failure. 
However the presence of certain accessory mutations that were found may have a 
compensatory role in viral fitness (Race, 2001). The clinical benefit of maintaining 
PIs in failing regimens is controversial, as it is well-known that resistant viruses are 
associated with diminished viral fitness, reduced infectivity, and incomplete 
processing of viral proteins (Wensing et al., 2010). Despite the superiority of DRV/r 
versus LPV/r, none of the patients were able to achieve complete virological 
suppression. Poor adherence seems to be a major barrier for these patients. 
  
For IN, several baseline substitutions were identified in all patients. Accessory 
mutation, V151I was present in-patient 100 and is a polymorphic mutation selected 
in patients receiving RAL and in vitro by EVG. This mutation appears to have little 
or no effect on INSTI susceptibility in the absence of major INSTI mutations. 
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Patient 086 harbored the accessory mutation M50I, a subtype B polymorphism that 
is seen in 10-25% of INSTI naïve patients (Wares et al., 2014). Other studies have 
found this polymorphism in combination with the R263K mutation in patients failing 
RAL treatment (Wares et al., 2014). However this mutation does not restore the 
loss in HIV-1 infectivity associated with R263K. M50I alone will not negatively 
impact IN strand transfer activity or HIV replication capacity. However some 
studies have shown that it may slightly decrease HIV-1 susceptibility to EVG. The 
clinical relevance of this mutation will require further studies. Other IN 
polymorphisms that were found may have a compensatory role when present with 
other primary mutations; further work in this regard is required (Quashie et al., 
2012).  
 
Patients within this setting urgently require adherence counseling in order to 
preserve current ARVs and prevent the emergence of drug resistance mutations. 
More data, from larger cohorts are required in order to fully understand the 





















Comparison of HIV-1 Protease at LPV/r versus DRV/r failure using 





Within HIV-1 PR, 45 of the 99 residues have been associated with drug resistance 
(Volberding and Deeks, 2010). Eleven of the 45 have been associated with direct 
changes in the active site and are regarded as primary mutations. The remaining 
34 of the 45 residues occur outside the active site and are often regarded as 
secondary mutations that are thought to indirectly interfere with the drug binding 
interaction, while also improving the overall fitness and stability of HIV-1 PR 
(Ragland et al., 2014). Some structural studies have described how these 
secondary mutations affect the drug binding interactions, however data on their 
specific functions and mechanisms of resistance are not extensive (Ragland et al., 
2014). Thus far it has been shown that in the presence of drug resistance 
mutations there is an expansion of the active site; the volume of the amino acid 
side-chains within the active site decreases; there is a loss of van de Waals 
interactions between the inhibitor and HIV-1 PR; there is a reduction in the active 
site specificity; the mobile flaps are found to be further apart; there are structural 
differences between the side-chains due to changes in the amino acid sequence 
and the distance between certain residues occurring in combination differ (Logsdon 
et al., 2004, Kuiper et al., 2015). Many of these studies were based on 
experimental crystal structures of HIV -1 PR derived from X-ray crystallography or 
Nuclear Magnetic Resonance (NMR) spectroscopy. However, it is difficult and time 
consuming to obtain these experimental structures, thus in this study we employed 
homology modeling, a reliable and accurate method for the generation of modeled 
enzyme systems (Xiang, 2006).  
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We use these structures to describe conformational changes in LPV/r-resistant and 
DRV/r-resistant forms of HIV-1 PR. The homology models were generated from a 
single patient presenting with high-level DRV/r resistance following DRV/r failure. 
The drug binding interaction was investigated using molecular docking, and a MD 
simulation was performed to assess the stability of the final structure. This 
component of the study will provide an insight on the impact of LPV/r and DRV/r 
DRMs on PR in the context of subtype C. 
 
4.2 Materials and Methods 
 
4.2.1 Homology modeling 
Sequences from a single patient (PID-071) from the PCSK cohort was used to 
construct homology models at LPV/r and DRV/r failure. Amino acid sequences 
were uploaded onto the SWISS-MODEL server (http://swissmodel.expasy.org/). A 
template search was performed for models that best matched the query sequence 
with the highest percentage identity. The template was selected and the model was 
constructed using built-in algorithms on the SWISS-MODEL server. Structures 
were viewed and analyzed in Chimera v1.8.1 (Petterson et al., 2004). 
 
4.2.2 Structural analysis 
Modeled structures were superimposed onto each other to perform the structural 
comparisons. Firstly, the atomic structures of mutated residues from the LPV/r-
resistant model were visualized and compared to those of the DRV/r-resistant 
model. Secondly, to further understand conformational changes that occur 
between LPV/r and DRV/r failure, the distance between residues of each protein 
chain was measured. Lastly, the LPV/r resistant and DRV/r resistant models were 
compared to a crystal structure of PR bound to DRV (PDB ID: 4DQB); this was 
done to investigate how structural changes between the two time points may alter 
drug binding. The distance between residues in the direct vicinity of DRV were 
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measured for both models.  We also investigated the influence of mutated residues 
within the active site on neighboring residues in both models.  
 
4.2.3 Molecular docking  
To assess changes in the drug-binding interactions between PR and DRV at LPV/r 
failure versus DRV/r failure, DRV was docked into each of the models using the 
CLC   Drug   discovery   Workbench™   v2.4.1   software   package   (CLC Bio-Qiagen, 
Aarhus, Denmark). All ligands were downloaded from the ZINC12 database (Irwin 
et al., 2012) in mol2 format. Briefly, all structures were imported one at a time onto 
the   CLC  Workbench;;   waters   and   hydrogen’s   were   removed   and   each   structure  
was saved as a molecule project.  In order to identify the target region within the 
protein, suitable binding pockets were identified for DRV. This was performed by 
selecting  the  “find  binding  pockets”  option  within  the  toolbox  and  default  parameter  
settings were used (binding pockets with volumes less than 20 Å3 were ignored). 
The desired binding site was shown using green spheres within the center of the 
protein.   Once   the   binding   site   was   found,   the   “set   up   binding   site”   option   was  
selected. Before commencing with docking, the ligand was inspected and 
validated, to ensure that there were proper connections between atoms, bond 
orders, hydrogen atom positions, and atom hybridizations. The selected binding 
sites  and  ligand  were  saved  as  a  “Molecule  project”.    Docking  was  then  performed,  
using  the  “dock  ligands”  option  in  the  drug-design toolbox, and the molecule project 
as an input. The default docking parameters were selected, which included the 
number of iterations for each ligand in the search for an optimal binding mode 
(n=100). This is considered a good balance between search completeness and 
cost. Increasing this number would have lead to more extensive binding mode 
searches, requiring more computational time. The number of docking results 





4.2.4. Molecular Dynamics simulations using Implicit solvation 
The AMBER12 Molecular Dynamics package was accessed remotely via the 
Centre for High Performance Computing (http://www.chpc.ac.za/) and was used to 
perform the MD simulations. The LPV/r-resistant and DRV/r-resistant models were 
used for the simulation as described in section 4.2.1.  
 
4.2.4.1 Preparation of the ligands 
The atomic force field parameters of the ligands were obtained using the 
ANTECHAMBER module, which employs the Generalized Atomic Force Field 
(GAFF) and Bond Charge Correction (BCC) charges. The AMBER force field 
ff99SB was used to perform the MD simulation. The Parmchk program contains a 
database for parameterization calculations and was used to create the physico-
chemical parameters of the solvation box. The resultant parameter file is employed 
by tleap in AMBER12 to add hydrogen atoms to the ligand. The receptor was then 
loaded in PDB format for the formation of the complex (ligand+receptor). The 
default radii angles were set and the ligand, receptor and complex topology files 
were saved. Additional Chlorine ions were added wherever necessary, in order to 
neutralize the system and balance the charge of HIV-1 PR. The protein was then 
placed in the center of the cubic box with TIP3PBOX8.0, which was used as the 
water model for this solvation. This water model specifies that the molecule should 
have a buffer of at least 8.0Å between the structure and the periodic box wall. 
Lastly the final solvated topology and coordinate files were saved (Simmerling et 
al., 2002).  
 
4.2.4.2 Energy minimization and equilibration 
Energy minimization was performed to obtain the most favorable configuration of 
the model. Each of the parameters that was used to perform the minimization is 
provided in detail in Appendix D.  Briefly, the solvated complex was equilibrated by 
performing an energy minimization using the SANDER module in a constant 
volume by 2500 cycles of steepest descent minimization; this was followed by 750 
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cycles of conjugated gradient minimization. The systems were then gradually 
heated from 0K to 300K over 50ps of heating, 50ps of density equilibration with 
weak restraints on the complex followed by 0.25ns of constant pressure 
equilibration at 300K.All simulations were run using the Shake algorithm to 
constrain the bonds that contained hydrogen atoms, and the temperature was 
controlled using the Langevin thermostat. The backbone Root-Mean-Square-
Deviation (RMSD), (which is a measurement of how the internal atomic co-
ordinates change relative to the minimized molecular structure co-ordinates) 
(Coutsias et al., 2004), was determined using the PTRAJ module in AMBER. 
PTRAJ is a comprehensive program used to analyze MD trajectories. The program 
requires a topology file as well as a perl script specifying the input and output 
requirements. These are shown in Appendix D. Average summaries for the 
density, temperature and the total energy were obtained using the 
process_mdout.perl script provided in the Amber Tools package. This data was 
used to generate separate plots for the RMSD, density, and equilibration versus 





4.3.1 Homology modeling 
The LPV/r resistant model harbored polymorphisms: I13V, G16E, L19I, K20R, 
M36I, R41K, K55R, L63H, H69K, L89I, I93L as well as major (M46I, I54V, L76V 
and V82A) and minor (L10F) PI resistance mutations. The DRV/r-resistant model 
harbored the same polymorphisms. In addition, major (V32I, M46I, I54L, L76V) and 
minor (L10F, V11I, L33F and Q58E) PI DRMs, were also present. However, the 
patient no longer had the V82A mutation. Both these sequences were modeled 
using a South African wild-type HIV-1 subtype C virus (PDB ID: 2R5Q) resolved by 
X-ray crystallography (2.3Å) as a template. The final modeled structures are 
indicated in Figure 4.1.  
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Figure 4.1 Three-dimensional model of HIV-1 Protease. The LPV/r-resistant 
model is shown by purple traces with pink side-chains and the DRV/r-resistant 
model is shown by light blue traces with blue side-chains. The model was 
generated in SWISS MODEL and visualized in Chimera v1.8.1. 
 
4.3.2 Structural analysis 
Residues that differed between the LPV/r-resistant and the DRV/r-resistant models 
are indicated in Figure 4.2 and Figure 4.3.  
A  B  C  D  
Figure 4.2 Major PI mutations that differed between the LPV/r-resistant (pink 
side-chains) and DRV/r-resistant (blue side-chains) models. A) Mutant V32I is 
a substrate cleft mutation that makes direct contact with the inhibitor; the mutant 
form appears slightly larger than the un-mutated form. B) The I54L/V residue is a 
flap-tip mutation, the 154L mutant form seems slightly larger than the I54V mutant 










than the un-mutated form. D) The I84V mutant is also a substrate cleft mutation 
and has shorter amino acid side-chains in comparison to the un-mutated form.  
 
A  B  C  
 
Figure 4.3 Minor PI mutations that differed between the LPV/r-resistant (pink 
side-chains) and DRV/r-resistant (blue side-chains) models. A) Residue V11, 
occurs within the distal regions of the enzyme and thus does not seem to have 
direct contact with the inhibitor/substrates within the active site, the mutant side 
chains appear to be longer than the un-mutated chains. B) The L33F mutant shows 
a large aromatic side chain that protrudes into the hydrophobic pocket of the 
enzyme, occupying more space than the un-mutated form. C) The Q58E mutant is 
located distally and distinct structural changes can be seen in comparison to the 
un-mutated form.  
 
 
4.3.2.1.Distances between side-chains in the absence of the inhibitor 
The distance between the side-chains of certain residues in the LPV/r-resistant 
model and the DRV/r-resistant model was measured. This comprised all mutated 
residues present in both models as well as those residues that were not mutated 
















Table 4.1 Distance between the protein chains of selected mutated and un-
mutated residues of both models studied.  
 
LPV/r-resistant model DRV/r-resistant model  
Difference in 
distance between 






A and B (Å) 
Residue  Distance between 
chain A and B 
(Å) 
L10F 30.505 L10F 30.504  
V11 24.500 V11I 24.553  
D25 4.720 D25 4.701  
D29 18.641 D29 18.646  
V32 19.778 V32I 20.108  
L33 32.124 L33F 31.191 0.9333  
M46I 25.417 M46I 25.413  
L50 11.168 L50 11.040 0.128  
F53 18.376 F53 18.378  
I54V 14.315 I54L 13.986 0.329  
L76V 26.476 L76V 26.211 0.265  
V82A 18.296 V82 18.172 0.124  
I84 11.315 I84V 14.165 2.85  
Q58 36.544 Q58E 39.593 3.049  
*We considered a 0.1Å difference as a notable change in conformation between 
the two structures. Those with a 0.1Å difference that were also mutated are shaded 
in green, while the residues that were not mutated but showed a (>0.1Å) difference 
are shaded in grey. Those that were mutated/un-mutated that showed only slight 
differences (<0.1Å
or decreased from LPV/r to DRV/r failure. 
 
Amongst those residues that were mutated and showed a noted change in 
distance, V32I, resulted in an increase in distance from LPV/r to DRV/r failure. 
Other residues that increased in distance (>0.1) from LPV/r to DRV/r failure 
included residues 58 and 84, I84V appeared shorter than the un-mutated form, 
thus would occupy less space making the structure wider. The remaining residues 
(33, 54, 76, and 82) decreased in distance between the two models. Each of these 
residues in their mutated states seemed to occupy more space than the un-
mutated forms, thereby reducing the distance between the two protein chains. 
Residue 50 was not mutated, but the distance between the protein chains with this 
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residue showed a reduction from LPV/r to DRV/r failure. The remaining residues 
showed very slight differences in distance between the protein chains.  
 
4.3.2.2 Distance between side-chains in the presence of the inhibitor.   
The distance between some of the residues likely to make direct contact with the 
inhibitor was measured, as shown in Figure 4.4.  
 
Figure 4.4 Three-dimensional model of HIV-1 PR with Darunavir bound. The 
LPV/r-resistant model is shown by purple traces the DRV/r-resistant model is 
shown with grey traces, the inhibitor Darunavir is shown within the active site in 
orange. The model was generated in SWISS MODEL and visualized in Chimera 
v1.8.1.  
 
A B  
Figure 4.5 Residue D25 side-chain interactions with the PI-DRV shown in 
orange. (A) LPV/r-resistant model, side-chains are indicated in pink (B) DRV/r-
resistant model, side-chains are shown in blue. The distances between each of the 




A B  
Figure 4.6 Residue D29 side-chain interactions with the PI-DRV shown in 
orange (A) LPV/r-resistant model, side-chains are indicated in pink (B) DRV/r-
resistant model, side-chains are shown in blue. The distances between each of the 
side-chain interactions with the inhibitor differed only slightly.  
 
 
A B  
 
Figure 4.7 Residue D30 side-chain interactions with the PI-DRV shown in 
orange (A) LPV/r-resistant model, side-chains are indicated in pink (B) DRV/r-
resistant model, side-chains are shown in blue. The distances between each of the 
side-chain interactions with the inhibitor differed only slightly.  
 
A B  
Figure 4.8 Residue V32 side-chain interactions with the PI-DRV shown in 






resistant model, side-chains are shown in blue. The distances between each of the 
side-chain interactions with the inhibitor differed.  
A B  
 
Figure 4.9 Residue V82 side-chain interactions with the PI-DRV shown in 
orange (A) LPV/r-resistant model, side-chains are indicated in pink (B) DRV/r-
resistant model, side-chains are shown in blue. The distances between each of the 
side-chain interactions with the inhibitor differed.  
 
A B  
Figure 4.10 Residue I84 side-chain interactions with the PI-DRV shown in 
orange (A) LPV/r-resistant model, side-chains are indicated in pink (B) DRV/r-
resistant model, side-chains are shown in blue. The distances between each of the 
side chain interactions with the inhibitor differed. 
 
4.3.2.3 Interactions with surrounding residues  
 
The interaction of certain active site residues that were mutated were visualized in 
sphere form, to gauge the interactions with neighboring residues. Those having 
more interactions with surrounding residues may affect their locations and thus will 





A B  
 
Figure 4.11 Mutant V32I, interactions with surrounding residues. A) Side chain 
of V32 (pink spheres) in the LPV/r-resistant model, shows interactions with 
surrounding residues (red spheres) are slightly less in comparison to B) V32I (blue 
spheres), in the DRV/r-resistant model, the mutant moves closer into the active site 
compared to the un-mutated form. This indicates that the mutant form will have 
more interactions with the surrounding residues in comparison to the un-mutated 




A B  
 
Figure 4.12 Mutant L33F, interactions with surrounding residues. A) Side 
chain of L33 (pink spheres) in the LPV/r-resistant model show that there are fewer 
interactions with surrounding residues in comparison to the B) DRV/r-resistant 
model with blue side chains, this mutant form tends to have more interactions with 
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the surrounding residues, thus occupying more space. There seems to be more 
interactions with the I15V residue in particular 
 
A B  
 
Figure 4.13 Mutant V82A, interactions with surrounding residues. A) Side 
chain of V82A (pink spheres) in the LPV/r-resistant model, shows that this mutant 
form looses interactions with surrounding residues and occupies less space in the 




A B  
 
Figure 4.14 Mutant I84V, interactions with surrounding residues. A) Side-chain 
of I84 (pink spheres) in the LPV/r-resistant model appears larger thus occupying 
more space and has more interactions with neighboring residues in comparison to 
B) the DRV/r-resistant model shown by (blue spheres), here the 184V mutant form 
appears smaller and has fewer interactions with neighboring residues.  
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4.4 Molecular docking  
 
Table 4.2 Binding scores derived from molecular docking for the LPV/r-
resistant and DRV/r-resistant models.  
 
 
These results show that the wild-type model had the lowest binding score 
indicative of the most stable complex. For the LPV/r-resistant model and the 
DRV/r-resistant model the binding scores increased, suggesting that the inhibitory 
potency was lowered.  
 
 
4.5.Molecular Dynamics simulations  
Following energy minimization, the RMSD versus time was plotted. This was done 
for each of the models studied as shown in Figure 4.15. 
 
 
Structures  Ligands Binding scores 
(kcal/mol) 
Wild-type model (2R5Q) DRV -20.04 
LPV/r failure model DRV -13.36 
DRV/r failure model DRV -11.56 
___ Wild-type DRV complex 
___ LPV/r resistant-DRV complex 
___ DRV/r resistant-DRV complex 
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Figure 4.15 RMSD values versus time for the wild-type-DRV complex (red), the 
LPV/r-resistant-DRV complex (green) and the DRV/r-resistant –DRV bound 
complex (blue).  
 
Equilibrium was reached in each of the structures after a 0.25ns simulation at an 
RMSD of 0.79A. 1.04A, 1.15A for the wild-type, LPV/r-resistant and DRV/r-
resistant complexes respectively. The equilibrium seemed to converge well for the 
wild-type-DRV complex, as opposed to the other two models. Larger fluctuations in 
the latter models may be attributed to the presence of DRMs that seem to 




The emergence of drug resistance mutations in PR enables the enzyme to evade 
inhibition and maintain biological function (Ragland et al., 2014).  Structural studies 
have revealed resistance mechanisms amongst mutated residues in HIV-1 PR. For 
example, the role of the M36I mutation in regulating the size of the active site, by 
shifting the L33 and V77 residue inward (Ode et al, 2007), or the asymmetrical 
changes caused by the L76V mutant, where one side of the active site constricts 
and the other side widens (Ragland et al., 2014). Our study investigated how the 
HIV-1 PR structure is altered following LPV/r-inclusive second-line treatment and 
DRV/r-inclusive third-line treatment. Distinct differences were found in each of the 
mutated residues in the DRV/r-resistant model; where some side-chains (V82, 
I84V) appeared smaller and shorter, while others (V11I, V32I L33F and I54L) were 
larger and longer occupying more volume. Some of these side-chain changes also 
resulted in distinct differences in the width between dimers of the LPV/r-resistant 
and DRV/r-resistant structures. The presence of V32I, Q58E and I84V in the 
DRV/r-resistant model caused the dimers to be further apart in comparison to the 
LPV/r-resistant model. The short side-chains of I84V occupy less space and results 
in a slight expansion of the active site cavity. Other studies report that in the 
presence of both I84V and V82A, there is a profound expansion of the active site 
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(Logsdon et al, 2004), however given that our DRV/r model lacks the V82A 
mutation, active site expansion in this model is minimal. Residues with larger side-
chains (L33F, I54L, and V82) resulted in the dimers being closer together. These 
results clearly show that following DRV/r failure there are significant structural 
alterations in PR that contribute to DRV/r resistance.  
 
Distances between the active site residues (D25, D29, D30) and DRV differed only 
slightly. This was probably because DRV was designed to form more hydrogen 
bonds with the main chain atoms of Asp29 and Asp 30, which are not easily 
disrupted and can withstand minor structural alterations caused by resistance 
mutations (Lui et al., 2008). In our study the V32I mutant showed increased 
interactions with the inhibitor compared to the un-mutated form. This mutant 
appeared to move inward toward the active site and had more interactions with 
surrounding residues.  
 
In the DRV/r-resistant model the I84V mutant had shorter side-chains, thus losing 
its interactions with DRV, and also appeared to have fewer interactions with 
surrounding residues. This could be attributed to the possible rearrangements with 
the 80s loop caused by V32I, that is known to push DRV away from the I84 residue 
and toward the 50s region (Ragland et al., 2014). Similarly the mutant form of 
V82A in the LPV/r-resistant model also appeared shorter in comparison to its un-
mutated form, thus loosing interactions with DRV and surrounding residues. Other 
residues that do not make direct contact with DRV can also result in overall 
structural rearrangements within PR. This is especially true for the L33F mutant 
that presented with bulky aromatic side chains thus having increased interactions 
with residues within the hydrophobic pocket, defined by residues (I13, I15, K20, 
A22, T31, M/V36, L38, I64, I66, V75, V77, N83, and I85). These increased 
interactions causes the structure to become rigid and loose flexibility and as a 




Docking results showed that the potential inhibitory potency of DRV was lowered in 
both the LPV/r and DRV/r resistant models. Despite the absence of DRV/r-
resistance associated mutations in the LPV/r-resistant model, DRV did not bind as 
efficiently as it was bound to the wild-type model. This is largely attributed to the 
presence of certain LPV/r mutations that contribute to DRV resistance, specifically 
the L76V mutant that is known to confer DRV/r cross-resistance (Barber et al, 
2012). The worst drug binding score was returned for the DRV/r-resistant model, 
suggesting that the drugs inhibitory potency is greatly lowered in the presence of 
multiple resistance mutations. However, the results obtained from molecular 
docking need to be further confirmed by performing an end state energy analysis 
on generated MD trajectories using the MMPBSA.py script. This approach has 
been shown to be more accurate than other scoring methods (Rastelli et al., 2010).  
Molecular Dynamics simulations showed that the wild-type complex was more 
stable than the LPV/r-resistant and DRV/r-resistant models. The fluctuations seen 
on the RMSD plots can be attributed to the presence of DRMs that alter the 
enzyme dynamics.   
 
Despite the superiority of DRV for highly treatment-experienced individuals, we find 
that its efficacy is considerably affected by the presence of DRMs. A combination 
of these structural alterations amongst certain localized residues, as well as those 
occurring in a variety of positions collectively contribute to the shape and flexibility 
of the overall structure and are thus likely to contribute to drug resistance (Ragland 










General discussions and conclusions 
 
HIV-1 PR is an ideal drug target owing to its vital role in proteolytic processing 
(Tomasselli et al., 1990). The inclusion of PIs in cART, is the standard of care for 
HIV-1 treatment globally. Here in South Africa, LPV/r is a key component of the 
second-line regimen, and DRV/r is recommended for third-line treatment 
(Department of Health, 2013). Unfortunately, the selection of PI-resistant viral 
variants leads to drug resistance and poor treatment responses (Tang and Shafer 
et al., 2012). However, to date second-line failure studies report a low frequency of 
LPV/r DRMs with a significant accumulation of RT-inhibitor DRMs (Riddler et al., 
2008, Wallis et al., 2011, Levision et al, 2012). These studies ascribed treatment 
failure to non-adherence as opposed to drug resistance.  
 
From our cohort of 156 second-line failures from KZN, only 24% harboured LPV/r 
DRMs, thus we also attribute non-adherence as the primary reason for treatment 
failure. Despite this low occurrence of PI DRMs, our findings are higher in 
comparison to other regions (Wallis et al, 2011, Van Zyl et al, 2013). Interestingly, 
we also observed a distinct pattern of PI DRMs, where V82A occurred alone, 
followed by V82A+I54V then V82A+I54V+M46I, and lastly 
V82A+I54V+M46I+L76V+L10F, representing the most prevalent PI DRM pattern. 
For the RT-inhibitor drug class, the NRTI mutation M184V was the most prevalent 
attributed to 3TC/FTC treatment. In the NNRTI drug class the K103N mutation was 
most frequent, and is known to persist from first-line failure (Tang and Shafer et al., 
2012). 
 
For those patients presenting with high-level LPV/r resistance, the third-line 
regimen usually consists of DRV/r and a combination of ETR, RT-inhibitors and or 
RAL (Department of Health, 2013). Amongst those patients in our cohort that were 
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switched to DRV/r, five patients failed their third-line treatment within less than a 
year of receiving DRV/r.  We longitudinally assessed these five patients using 
UDPS to investigate the possibility of drug resistant minority variants at LPV/r 
failure that may predict DRV/r failure. Other studies have reported that the 
presence of resistant minority variants can influence treatment outcomes in 
patients (Fisher et al., 2012, Nicot et al., 2012, Avidor et al., 2013, Gianella et al., 
2013). In our study we found, that 2/5 patients presented with PI minority variants 
at LPV/r failure (L10I and L23I). These were not seen at DRV/r failure. One patient 
presented with minor variant K43T at DRV/r failure only. These variants are 
compensatory mutations and are not known to cause DRV/r failure. For the RT-
inhibitor class the K65R variant occurred in 2/5 patients this mutant occurs within a 
homo-polymeric region and is possibly a sequencing artifact. Several NNRTI 
varaints were identified that have persisted from first-line failure, the persistence of 
these mutations has also been reported elsewhere (Fisher et al.,2012).  
 
Our results established that minority variants at LPV/r failure did not influence 
DRV/r failure. However distinct DRV/r resistance mutations were selected relatively 
quickly in majority virus populations, despite the drugs high genetic barrier. 
Exceptionally high viral loads were seen in each of these patients despite DRV/r 
treatment, inferring that DRV/r was unable to suppress viral replication. However 
this could also be attributed to non-adherence. Nonetheless, most (80%) of 
patients developed additional DRV/r resistance mutations, implying that these 
patients did take their medication intermittently. Furthermore the presence of LPV/r 
resistance mutations conferring cross-resistance to DRV/r could have influenced 
DRV/r failure.  
 
In the single patient that presented with high-level DRV/r resistance, we 
investigated the structural implications on viral PR before and after DRV/r 
treatment. Structural differences between the LPV/r-resistant and the DRV/r-
resistant model were evident. We showed that resistance mutations caused 
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alterations to the side-chains at certain residues that influenced the width between 
the dimers in each model.  
 
However, the distance between the active site residues (D25, D29, D30) and 
DRV/r differed only slightly, despite various other conformational changes in these 
structures. In contrast the I84V mutant had reduced interactions with the inhibitor, 
further contributing to resistance. Mutated residues such as V32I had increased 
interactions with DRV/r, however these interactions tend to have detrimental 
effects for other residues (Ragland et al., 2014). Additionally the L33F mutant 
protrudes deeply into the hydrophobic regions, and has increased interactions with 
surrounding residues, consistent with the findings of Kuiper et al (2015). In 
summary, mutations located within the active site as well as in other regions of the 
enzyme contribute to the overall conformation and drug binding interaction of viral 
PR. Each of these conformational changes account for the high-level of drug 
resistance experienced by this patient at DRV/r failure.  
 
Molecular docking studies confirmed these findings, as the inhibitory potency of 
DRV/r was lowered in the DRV/r-resistant model and to a lesser extent in the 
LPV/r-resistant model. The binding scores of the LPV/r-resistant model was similar 
to the DRV/r-resistant model. This is attributed to the presence of certain LPV/r 
resistance mutations that are involved in the pathway to DRV/r cross-resistance, 
that inherently confer baseline DRV/r resistance prior to treatment. Molecular 
Dynamics simulations showed that LPV/r and DRV/r-resistant models seemed to 
fluctuate more than the wild-type model, indicating that PI DRMs contributed to the 
overall stability of the structure. Our results confirm that drug resistance 
considerably compromises the drug binding interaction within viral PR. Despite the 
potency and ability of DRV/r to withstand a certain degree of mutations, multiple 
mutations of this kind can severely compromise its efficacy. Studying these 
physical impacts of mutations on drug binding affinity provides a detailed 
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perspective on how the enzyme can accommodate such changes but also provides 
a basic platform for the design of new and improved PIs. 
 
Patients within our setting urgently require adherence counseling to preserve 
current ARVs and prevent the emergence of drug resistance mutations. One of the 
major limitations of our study was that we could not accurately measure drug levels 
for either LPV/r or DRV/r at the relevant time points in order to fully assess patient 
adherence. Furthermore, CD4 data for the majority of these patients were not 
available; thus we do not know the full clinical profile of these patients. Additionally, 
while   longitudinal   analysis   of   patient’s   revealed valuable information, a larger 
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AB285763 AB285803 AB285843 AF527292 AM071436 AY165226 AY228557 
AB285764 AB285804 AB356162 AF527294 AM071437 AY165230 AY267321 
AB285765 AB285805 AB356179 AF527305 AM071438 AY165235 AY331723 
AB285766 AB285806 AB356180 AF527340 AM071439 AY165252 AY359695 
APPENDIX A 
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AY359696 AY463228 AY515759 AY515800 AM071414 AM071453 AY036394 
AY359697 AY463229 AY515760 AY515801 AM071415 AM071454 AY036395 
AY390076 AY463230 AY515761 AY515802 AM071416 AY007730 AY036396 
AY390079 AY463231 AY515762 AY515803 AM071417 AY007731 AY036397 
AY390080 AY463232 AY515763 AY515804 AM071418 AY007732 AY036398 
AY390081 AY463233 AY515764 AY515805 AM071419 AY007733 AY036399 
AY390188 AY463234 AY515765 AY515806 AM071420 AY007734 AY036401 
AY390190 AY463236 AY515766 AY515807 AM071421 AY007735 AY036404 
AY390191 AY463237 AY515767 AY515808 AM071422 AY007736 AY036405 
AY390193 AY515728 AY515768 AB285829 AM071423 AY007737 AY036406 
AY390194 AY515729 AY515769 AB285831 AM071424 AY007738 AY036407 
AY390195 AY515730 AY515771 AB285832 AM071425 AY007739 AY036408 
AY390196 AY515731 AY515772 AB285833 AM071426 AY007740 AY136954 
AY390198 AY515732 AY515773 AB285834 AM071427 AY007741 AY136955 
AY435389 AY515733 AY515774 AB285835 AM071428 AY007742 AY136956 
AY444208 AY515734 AY515775 AB285836 AM071429 AY007743 AY136957 
AY444209 AY515735 AY515776 AB285837 AM071430 AY007744 AY136958 
AY444210 AY515736 AY515777 AB285838 AM071431 AY007746 AY136959 
AY444211 AY515737 AY515778 AB285839 AM071432 AY036312 AY136960 
AY444212 AY515738 AY515779 AB285840 AM071433 AY036313 AY136961 
AY444213 AY515739 AY515780 AB285841 AM071434 AY036314 AY136962 
AY444214 AY515740 AY515781 AB285842 AM071435 AY036315 AY136963 
AY444215 AY515741 AY515782 AB285843 AM071436 AY036316 AY136964 
AY444216 AY515742 AY515783 AB356162 AM071437 AY036317 AY136965 
AY444217 AY515744 AY515784 AB356179 AM071438 AY036325 AY136966 
AY444218 AY515745 AY515785 AB356180 AM071439 AY036326 AY136967 
AY444219 AY515746 AY515786 AB356214 AM071440 AY036327 AY136968 
AY444220 AY515747 AY515787 AB356260 AM071441 AY036328 AY136969 
AY463217 AY515748 AY515788 AB356269 AM071442 AY036329 AY136970 
AY463218 AY515749 AY515789 AB356345 AM071443 AY036330 AY136971 
AY463219 AY515750 AY515791 AB356365 AM071444 AY036377 AY136972 
AY463220 AY515751 AY515792 AB356375 AM071445 AY036378 AY136973 
AY463221 AY515752 AY515793 AB442231 AM071446 AY036379 AY136974 
AY463222 AY515753 AY515794 AB442233 AM071447 AY036380 AY136975 
AY463223 AY515754 AY515795 AB442259 AM071448 AY036381 AY136976 
AY463224 AY515755 AY515796 AB640061 AM071449 AY036382 AY136977 
AY463225 AY515756 AY515797 AB640066 AM071450 AY036391 AY136978 
AY463226 AY515757 AY515798 AB640073 AM071451 AY036392 AY136979 
AY463227 AY515758 AY515799 AB640195 AM071452 AY036393 AY136980 
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AY136981 AY165216 AY213521 AY463218 AY515749 AY515789 AB356345 
AY136982 AY165219 AY213522 AY463219 AY515750 AY515791 AB356365 
AY136983 AY165220 AY213525 AY463220 AY515751 AY515792 AB356375 
AY136984 AY165223 AY213542 AY463221 AY515752 AY515793 AB442231 
AY136985 AY165224 AY213550 AY463222 AY515753 AY515794 AB442233 
AY136986 AY165225 AY228556 AY463223 AY515754 AY515795 AB442259 
AY136987 AY165226 AY228557 AY463224 AY515755 AY515796 AB640061 
AY136988 AY165230 AY267321 AY463225 AY515756 AY515797 AB640066 
AY136989 AY165235 AY331723 AY463226 AY515757 AY515798 AB640073 
AY136990 AY165252 AY359695 AY463227 AY515758 AY515799 AB640195 
AY136991 AY165253 AY359696 AY463228 AY515759 AY515800 AB640318 
AY136992 AY165255 AY359697 AY463229 AY515760 AY515801 AB640380 
AY136993 AY165257 AY390076 AY463230 AY515761 AY515802 AB640496 
AY136994 AY165260 AY390079 AY463231 AY515762 AY515803 AF527205 
AY136995 AY165263 AY390080 AY463232 AY515763 AY515804 AF527207 
AY136996 AY165266 AY390081 AY463233 AY515764 AY515805 AF527211 
AY136997 AY165272 AY390188 AY463234 AY515765 AY515806 AF527213 
AY136998 AY165281 AY390190 AY463236 AY515766 AY515807 AF527217 
AY136999 AY196498 AY390191 AY463237 AY515767 AY515808 AF527222 
AY137000 AY196499 AY390193 AY515728 AY515768 AB285829 AF527230 
AY137001 AY196500 AY390194 AY515729 AY515769 AB285831 AF527240 
AY137002 AY196501 AY390195 AY515730 AY515771 AB285832 AF527242 
AY137003 AY196502 AY390196 AY515731 AY515772 AB285833 AF527246 
AY137004 AY196503 AY390198 AY515732 AY515773 AB285834 AF527248 
AY137005 AY196504 AY435389 AY515733 AY515774 AB285835 AF527250 
AY137006 AY196505 AY444208 AY515734 AY515775 AB285836 AF527256 
AY137007 AY196506 AY444209 AY515735 AY515776 AB285837 AF527264 
AY137008 AY196507 AY444210 AY515736 AY515777 AB285838 AF527266 
AY165186 AY196508 AY444211 AY515737 AY515778 AB285839 AF527272 
AY165187 AY196509 AY444212 AY515738 AY515779 AB285840 AF527277 
AY165196 AY196510 AY444213 AY515739 AY515780 AB285841 AF527284 
AY165205 AY196511 AY444214 AY515740 AY515781 AB285842 AF527286 
AY165207 AY196512 AY444215 AY515741 AY515782 AB285843 AF527292 
AY165208 AY196513 AY444216 AY515742 AY515783 AB356162 AF527294 
AY165209 AY196514 AY444217 AY515744 AY515784 AB356179 AF527305 
AY165211 AY196515 AY444218 AY515745 AY515785 AB356180 AF527340 
AY165213 AY196516 AY444219 AY515746 AY515786 AB356214 AJ287005 
AY165214 AY196517 AY444220 AY515747 AY515787 AB356260 AM040985 
AY165215 AY213437 AY463217 AY515748 AY515788 AB356269 AM040991 
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AM041004 AM071443 AY036329 AY136970 AY165186 AY196508 AY444211 
AM041006 AM071444 AY036330 AY136971 AY165187 AY196509 AY444212 
AM041011 AM041002 AY036377 AY136972 AY165196 AY196510 AY444213 
AM041013 AM071445 AY036378 AY136973 AY165205 AY196511 AY444214 
AM041017 AM071446 AY036379 AY136974 AY165207 AY196512 AY444215 
AM041034 AM071447 AY036380 AY136975 AY165208 AY196513 AY444216 
AM041050 AM071448 AY036381 AY136976 AY165209 AY196514 AY444217 
AM071412 AM071449 AY036382 AY136977 AY165211 AY196515 AY444218 
AM071413 AM071450 AY036391 AY136978 AY165213 AY196516 AY463217 
AM071414 AM071451 AY036392 AY136979 AY165214 AY196517 AY463218 
AM071415 AM071452 AY036393 AY136980 AY165215 AY213437 AY463219 
AM071416 AM071453 AY036394 AY136981 AY165216 AY213521 AY463220 
AM071417 AM071454 AY036395 AY136982 AY165219 AY213522 AY463221 
AM071418 AY007730 AY036396 AY136983 AY165220 AY213525 AY463222 
AM071419 AY007731 AY036397 AY136984 AY165223 AY213542 AY463223 
AM071420 AY007732 AY036398 AY136985 AY165224 AY213550 AY463224 
AM071421 AY007733 AY036399 AY136986 AY165225 AY228556 AY463225 
AM071422 AY007734 AY036401 AY136987 AY165226 AY228557 AY463226 
AM071423 AY007735 AY036404 AY136988 AY165230 AY267321 AY463227 
AM071424 AY007736 AY036405 AY136989 AY165235 AY331723 AY463228 
AM071425 AY007737 AY036406 AY136990 AY165252 AY359695 AY463229 
AM071426 AY007738 AY036407 AY136991 AY165253 AY359696 AY463230 
AM071427 AY007739 AY036408 AY136992 AY165255 AY359697 AY463231 
AM071428 AY007740 AY136954 AY136993 AY165257 AY390076 AY463232 
AM071429 AY007741 AY136955 AY136994 AY165260 AY390079 AY463233 
AM071430 AY007742 AY136956 AY136995 AY165263 AY390080 AY463234 
AM071431 AY007743 AY136957 AY136996 AY165266 AY390081 AY463236 
AM071432 AY007744 AY136958 AY136997 AY165272 AY390188 AY463237 
AM071433 AY007746 AY136959 AY136998 AY165281 AY390190 AY515728 
AM071434 AY036312 AY136960 AY136999 AY196498 AY390191 AY515729 
AM071435 AY036313 AY136961 AY137000 AY196499 AY390193 AY515730 
AM071436 AY036314 AY136962 AY137001 AY196500 AY390194 AY515731 
AM071437 AY036315 AY136963 AY137002 AY196501 AY390195 AY515732 
AM071438 AY036316 AY136964 AY137003 AY196502 AY390196 AY515733 
AM071439 AY036317 AY136965 AY137004 AY196503 AY390198 AY515734 
AM071440 AY036325 AY136966 AY137005 AY196504 AY435389 AY515735 
AM071441 AY036326 AY136967 AY137006 AY196505 AY444208 AY515736 
AM071442 AY036327 AY136968 AY137007 AY196506 AY444209 AY515737 
 EF369085 AY036328 AY136969 AY137008 AY196507 AY444210 AY515738 
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AY515739 AY515780 AY515821 AY589844 AY746363 AY772700 AY829302 
AY515740 AY515781 AY515822 AY589845 AY746364 AY787492 AY829303 
AY515741 AY515782 AY515823 AY589846 AY746365 AY787522 AY829304 
AY515742 AY515783 AY515824 AY589847 AY746366 AY787532 AY829305 
AY515744 AY515784 AY515825 AY589848 AY746367 AY787535 AY829306 
AY515745 AY515785 AY515826 AY589849 AY746368 AY787536 AY829307 
AY515746 AY515786 AY515827 AY589850 AY746369 AY829268 AY829308 
AY515747 AY515787 AY515828 AY589851 AY746370 AY829269 AY829309 
AY515748 AY515788 AY515829 AY589852 AY746371 AY829270 AY829310 
AY515749 AY515789 AY515830 AY589853 AY746372 AY829271 AY829311 
AY515750 AY515791 AY515831 AY589854 AY746374 AY829272 AY829312 
AY515751 AY515792 AY515832 AY589855 AY746375 AY829273 AY829313 
AY515752 AY515793 AY515833 AY589856 AY746376 AY829274 AY829314 
AY515753 AY515794 AY515834 AY589857 AY746377 AY829275 AY829315 
AY515754 AY515795 AY515835 AY589858 AY746378 AY829276 AY829316 
AY515755 AY515796 AY515836 AY589859 AY746379 AY829277 AY829317 
AY515756 AY515797 AY515837 AY589860 AY746380 AY829278 AY829318 
AY515757 AY515798 AY515838 AY589861 AY746381 AY829279 AY829319 
AY515758 AY515799 AY515839 AY589862 AY746382 AY829280 AY829320 
AY515759 AY515800 AY515840 AY589863 AY746383 AY829281 AY829321 
AY515760 AY515801 AY515841 AY589864 AY746384 AY829282 AY829322 
AY515761 AY515802 AY515842 AY589865 AY746385 AY829283 AY829323 
AY515762 AY515803 AY515843 AY589866 AY746386 AY829284 AY829324 
AY515763 AY515804 AY515844 AY589867 AY746387 AY829285 AY829325 
AY515764 AY515805 AY515845 AY589868 AY746388 AY829286 AY829326 
AY515765 AY515806 AY515846 AY589869 AY746389 AY829287 AY829327 
AY515766 AY515807 AY515847 AY611649 AY746390 AY829288 AY829328 
AY515767 AY515808 AY515848 AY611650 AY749171 AY829290 AY829329 
AY515768 AY515810 AY515849 AY611651 AY749174 AY829291 AY829330 
AY515769 AY515811 AY585264 AY611665 AY749177 AY829292 AY829331 
AY515771 AY515812 AY585265 AY703908 AY772690 AY829293 AY829332 
AY515772 AY515813 AY585266 AY703909 AY772691 AY829294 AY829333 
AY515773 AY515814 AY585267 AY703910 AY772692 AY829295 AY829334 
AY515774 AY515815 AY585268 AY703911 AY772693 AY829296 AY829335 
AY515775 AY515816 AY589839 AY739911 AY772694 AY829297 AY829336 
AY515776 AY515817 AY589840 AY739912 AY772695 AY829298 AY829337 
AY515777 AY515818 AY589841 AY739913 AY772696 AY829299 AY829338 
AY515778 AY515819 AY589842 AY746361 AY772698 AY829300 AY838565 
AY515779 AY515820 AY589843 AY746362 AY772699 AY829301 AY838566 
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AY838567 AY900850 AY901978 DQ060213 DQ164109 DQ222264 DQ275664 
AY838568 AY900853 AY901979 DQ060215 DQ164110 DQ222265 DQ351216 
AY878054 AY900855 AY901980 DQ060216 DQ164111 DQ222266 DQ351217 
AY878055 AY900858 AY901981 DQ060218 DQ164112 DQ222267 DQ351218 
AY878056 AY900898 AY945738 DQ060219 DQ164113 DQ222268 DQ351219 
AY878057 AY900899 DQ011165 DQ060220 DQ164114 DQ222269 DQ351220 
AY878058 AY900900 DQ011166 DQ060221 DQ164115 DQ222270 DQ351221 
AY878059 AY900901 DQ011167 DQ060224 DQ164116 DQ222271 DQ351222 
AY878060 AY900902 DQ011169 DQ060225 DQ164117 DQ222272 DQ351223 
AY878061 AY900903 DQ011170 DQ060226 DQ164118 DQ222273 DQ351224 
AY878062 AY900904 DQ011171 DQ060227 DQ164119 DQ222274 DQ351225 
AY878063 AY900905 DQ011172 DQ060228 DQ164121 DQ222275 DQ351226 
AY878064 AY900906 DQ011173 DQ070553 DQ164122 DQ222276 DQ351227 
AY878065 AY900907 DQ011174 DQ093585 DQ164126 DQ222277 DQ351228 
AY878068 AY900909 DQ011175 DQ093586 DQ164127 DQ222278 DQ351229 
AY878070 AY900912 DQ011176 DQ093587 DQ164129 DQ222279 DQ351230 
AY878071 AY900914 DQ011177 DQ093588 DQ205288 DQ222280 DQ351231 
AY878072 AY900915 DQ011178 DQ093589 DQ207941 DQ222281 DQ351232 
AY900740 AY900917 DQ011179 DQ093590 DQ222243 DQ222282 DQ351233 
AY900750 AY900920 DQ011180 DQ093591 DQ222244 DQ275642 DQ351234 
AY900752 AY900936 DQ013271 DQ093592 DQ222245 DQ275643 DQ351235 
AY900759 AY900953 DQ013277 DQ093593 DQ222246 DQ275644 DQ351237 
AY900760 AY900954 DQ056302 DQ093594 DQ222247 DQ275645 DQ369976 
AY900774 AY900955 DQ056404 DQ093595 DQ222248 DQ275646 DQ369977 
AY900775 AY900956 DQ056405 DQ093596 DQ222249 DQ275647 DQ369978 
AY900777 AY900957 DQ056406 DQ093597 DQ222250 DQ275648 DQ369979 
AY900780 AY901965 DQ056408 DQ093598 DQ222251 DQ275649 DQ369980 
AY900782 AY901966 DQ056409 DQ093599 DQ222252 DQ275650 DQ369981 
AY900785 AY901967 DQ056410 DQ093600 DQ222253 DQ275651 DQ369982 
AY900787 AY901968 DQ056411 DQ093601 DQ222254 DQ275652 DQ369983 
AY900797 AY901969 DQ056412 DQ093602 DQ222255 DQ275653 DQ369984 
AY900806 AY901970 DQ056413 DQ093604 DQ222256 DQ275654 DQ369985 
AY900832 AY901971 DQ056414 DQ093605 DQ222257 DQ275655 DQ369986 
AY900834 AY901972 DQ056415 DQ093607 DQ222258 DQ275656 DQ369987 
AY900835 AY901973 DQ056416 DQ164104 DQ222259 DQ275657 DQ369988 
AY900836 AY901974 DQ056417 DQ164105 DQ222260 DQ275658 DQ369989 
AY900837 AY901975 DQ056418 DQ164106 DQ222261 DQ275659 DQ369990 
AY900839 AY901976 DQ060209 DQ164107 DQ222262 DQ275660 DQ369991 
AY900843 AY901977 DQ060212 DQ164108 DQ222263 DQ275661 DQ369992 
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DQ369993 DQ396399 DQ660000 DQ660048 DQ826607 EF186941 DQ660066 
DQ369994 DQ445631 DQ660001 DQ660050 DQ826608 EF186942 DQ660067 
DQ369995 DQ445632 DQ660003 DQ660051 DQ826609 EF186943 DQ660068 
DQ369996 DQ445633 DQ660004 DQ660052 DQ826610 EF186944 DQ660069 
DQ369997 DQ445634 DQ660005 DQ660053 DQ826611 EF186945 DQ660070 
DQ396364 DQ445635 DQ660006 DQ660054 DQ826612 EF186946 DQ660071 
DQ396365 DQ445637 DQ660007 DQ660055 DQ826613 EF186947 DQ660073 
DQ396366 DQ659965 DQ660008 DQ660056 DQ826614 EF186948 DQ660074 
DQ396367 DQ659966 DQ660009 DQ660057 DQ826615 EF186949 DQ660075 
DQ396368 DQ659967 DQ660013 DQ660058 DQ826616 EF186950 DQ666390 
DQ396369 DQ659968 DQ660014 DQ660059 DQ826617 EF186951 DQ826595 
DQ396370 DQ659969 DQ660015 DQ660060 DQ826618 EF186952 DQ826596 
DQ396371 DQ659970 DQ660016 DQ660061 DQ826619 EF186953 DQ826597 
DQ396372 DQ659972 DQ660017 DQ660062 EF064480 EF186954 DQ826598 
DQ396373 DQ659973 DQ660019 DQ660063 EF120244 EF195277 DQ826599 
DQ396374 DQ659974 DQ660020 DQ660064 EF120254 EF368549 DQ826600 
DQ396375 DQ659975 DQ660021 DQ660065 EF120336 EF368642 DQ826601 
DQ396376 DQ659976 DQ660022 DQ660066 EF120337 EF368697 DQ826602 
DQ396377 DQ659977 DQ660023 DQ660067 EF122539 EF368731 DQ826603 
DQ396378 DQ659978 DQ660024 DQ660068 EF143496 EF368743 DQ826604 
DQ396379 DQ659979 DQ660025 DQ660069 EF143499 EF368805 DQ826605 
DQ396380 DQ659980 DQ660026 DQ660070 EF143501 EF368807 DQ826606 
DQ396381 DQ659982 DQ660027 DQ660071 EF143502 EF368846 DQ826607 
DQ396382 DQ659983 DQ660028 DQ660073 EF143518 EF368925 DQ826608 
DQ396383 DQ659984 DQ660029 DQ660074 EF143521 DQ660051 DQ826609 
DQ396384 DQ659985 DQ660031 DQ660075 EF143527 DQ660052 DQ826610 
DQ396385 DQ659986 DQ660032 DQ666390 EF143528 DQ660053 DQ826611 
DQ396386 DQ659987 DQ660033 DQ826595 EF143529 DQ660054 DQ826612 
DQ396387 DQ659988 DQ660035 DQ826596 EF143532 DQ660055 DQ826613 
DQ396388 DQ659989 DQ660036 DQ826597 EF143533 DQ660056 DQ826614 
DQ396389 DQ659990 DQ660037 DQ826598 EF157888 DQ660057 DQ826615 
DQ396390 DQ659991 DQ660038 DQ826599 EF186933 DQ660058 DQ826616 
DQ396391 DQ659992 DQ660039 DQ826600 EF186934 DQ660059 DQ826617 
DQ396392 DQ659993 DQ660041 DQ826601 EF186935 DQ660060 DQ826618 
DQ396393 DQ659994 DQ660042 DQ826602 EF186936 DQ660061 DQ826619 
DQ396394 DQ659995 DQ660043 DQ826603 EF186937 DQ660062 EF064480 
DQ396395 DQ659996 DQ660045 DQ826604 EF186938 DQ660063 EF120244 
DQ396396 DQ659998 DQ660046 DQ826605 EF186939 DQ660064 EF120254 















































EF120337 EF368697 EF407704 EF407743 
EF122539 EF368731 EF407705 EF407744 
EF143496 EF368743 EF407706 EF407745 
EF143499 EF368805 EF407707 EF407746 
EF143501 EF368807 EF407708 EF407747 
EF143502 EF368846 EF407709 EF407748 
EF143518 EF368925 EF407710 EF407749 
EF143521 EF369040 EF407711 EF407750 
EF143527 EF369043 EF407712 EF407751 
EF143528 EF369057 EF407713 EF469243 
EF143529 EF369085 EF407714 EF491925 
EF143532 EF369163 EF407715 EF491926 
EF143533 EF369173 EF407716 EF491927 
EF157888 EF379154 EF407717 EF491928 
EF186933 EF379159 EF407718 EF491929 
EF186934 EF379168 EF407719 EF491930 
EF186935 EF379171 EF407720 EF491931 
EF186936 EF379174 EF407721 EF491932 
EF186937 EF379176 EF407722 EF491933 
EF186938 EF379177 EF407723 EF491934 
EF186939 EF379178 EF407724 EF491935 
EF186940 EF379181 EF407725 EF491936 
EF186941 EF379191 EF407726 EF491937 
EF186942 EF379193 EF407727 EF491938 
EF186943 EF379195 EF407728 EF491939 
EF186944 EF379198 EF407729 EF491940 
EF186945 EF379199 EF407730 EF491941 
EF186946 EF379203 EF407731 EF491942 
EF186947 EF379204 EF407732 EF491943 
EF186948 EF379206 EF407733 EF369040 
EF186949 EF379207 EF407734 EF369043 
EF186950 EF379208 EF407735 EF369057 
EF186951 EF379209 EF407736  
EF186952 EF379211 EF407737 
EF186953 EF379212 EF407738 
EF186954 EF379213 EF407739 
EF195277 EF407701 EF407740 
EF368549 EF407702 EF407741 





Use of the Agilent 2100 Bioanalyzer 
The DNA 1000 Kit was used to carry out the assay. Reagents were thawed and 
prepared   according   to   the   manufacturer’s   instructions.      Briefly,   the   chip   priming  
station together with the syringe kit, base plate and syringe clip were set up 
according to the manufacturer’s  instructions.  A  new  DNA  1000  chip  was  removed  
from its seal and placed on the chip priming station; nine μl  of  the  gel  dye  mix  was  
pipetted to the bottom of the well-marked with a G. The plunger was positioned at 
the one ml marking, the chip priming station was closed the plunger was pressed 
down and held by the syringe clip for 60 seconds. This allows the distribution of the 
gel throughout each of the wells through a pressurization action. Thereafter the clip 
was released allowing the plunger to move back to its one ml position. The chip 
priming station was opened and nine μl   of   the   gel-dye mix was added into the 
remaining  two  wells  marked  with  a  G.  Five  μl  of   the  DNA  marker  was  added   into  
the well-marked with the ladder symbol as well as into each of the 12 sample wells. 
One  μl  of  the  DNA  ladder  was  added  to  the  well with the ladder symbol, and one μl  
of each amplicon was added into the respective sample wells, one μl  of  deionized  
water was added to any remaining empty wells. The chip was then removed from 
the chip priming station and placed on the IKA vortex (Roche, Life Sciences, 
Branford, CT, USA) at 2400rpm for 60 seconds. The chip was inserted into the 
Agilent Bioanalyzer and run within five minutes on the DNA 1000 series assay, 
after 30 minutes the gel and an electropherogram were viewed on the Agilent 









1. Preparation of Mock Mix and Pre-Emulsion 
Reagents were obtained from the GS Junior Titanium emPCR Kit (Lib-A) (Roche 
Applied Sciences, Mannheim, Germany) and were thawed according to the 
manufacturer’s  instructions.  A  1 X mock mix was prepared using molecular grade 
water. The provided emulsion oil was vortexed well and poured into the IKA Turrax 
Stirring Tube (Roche Applied Science, Mannheim, Germany) two mls of the freshly 
prepared 1 X mock mix was added. The Ultra Turrax Tube Drive (UTTD) (Roche 
Applied Science, Mannheim, Germany) was set at 4000rpm for five minutes. 
During this time two Live Amplification mixes were prepared in 1.7ml micro-
centrifuge tube as indicated in Table 1 the tubes were stored on ice until required.  
Table 1. Preparation of Live Amp Mix A and B for the emulsion PCR. 
Reagent (Amp A)  Volume  (μl) Reagent (Amp B) Volume  (μl) 
Molecular Biology 
Grade Water 
205 Molecular Biology 
Grade Water 
205 
Additive  260 Additive  260 
Amp Mix  135 Amp Mix  135 
Amp Primer A  40 Amp Primer A  40 
Enzyme mix  35 Enzyme mix  35 
Ppiase  1 Ppiase  1 
Total  676 Total  676 
 
2. DNA library capture 
Capture beads have oligonucleotides that are complementary to adaptor A and B 
of the amplicons bound on their surface. Each of the capture beads A and B were 
washed twice with a freshly prepared 1 X Wash buffer by a spin rotation (quick spin 
the tube in one orientation, rotate the tube and quick spin again), the supernatant 
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was then removed.  An input library of one copy per bead corresponding to the 
addition  of  2.5μl  of  sample  was  added  to  capture  bead  A  and  2.5μl  to  capture  bead  
B.  Six  hundred  μl  of  Live  Amp  Mix  B  was  added  to  the tube of captured library B, 
this was vortexed and transferred to the Turrax stirring tube set at 2000rpm for five 
minutes.  Thereafter  600μl  of  the  Live  Amp  Mix  A  was  added to the tube of captured 
library A and vortexed at the same conditions. Thereafter,   100μl  of   the  emulsion  
was dispensed using a combitip into a new 96 well optical plate. The plate was 
sealed with strip capped sealers and placed on the thermocycler under the 
following reaction conditions, one cycle of 94°C for four minutes, 50 cycles of 94°C 
for 30 seconds, 58°C for 4.5minutes, 68°C for 30 seconds; the reaction was held at 
10 °C until use. The plate was left in the thermocycler for no more than 16 hours.   
3. Bead Recovery 
The beads were recovered by breaking the water in oil emulsion using isopropanol 
and ethanol solutions. The recovered beads represent a heterogeneous population 
comprising several null beads which are those beads that have no library 
fragments captured, mixed beads that have captured more than one fragment as 
well as the DNA beads that have correctly captured a single library fragment. Null 
beads and mixed beads will not produce any readable sequence data and are 
therefore removed. The emulsion was aspirated into a 50 ml tube using a vacuum 
assisted transpette provided in the GS Junior Oil and Breaking Kit (Roche. 454TM 
Science,  Branford,  USA).    The  wells  were  washed  twice  with  100μl  of  isopropanol  
per well and the amplified beads (approximately 15ml) were collected in a 50 ml 
falcon tube.  
4. Bead Washes  
In order to recover the collected emulsion, beads were washed as described below 
and all centrifugation steps were performed at 930X g for five minutes. The 50ml 
tube of collected emulsions was vortexed well and washed by adding isopropanol 
to a final volume of 35ml.The pellet was vortexed again, then centrifuged and the 
 170 
supernatant was carefully poured out. Ten mls of enhancing buffer was added to 
the tube and vortexed well. It was important to completely re-suspend the bead 
pellet and ensure all aggregates were completely broken. The beads were washed 
again by re-suspending in a final volume of 40ml of isopropanol, vortexed and 
centrifuged. An additional wash using isopropanol followed by ethanol, both to a 
final volume of 35ml was performed, the supernatant was removed and enhancing 
buffer to a final volume of 35ml was added. Following centrifugation the 
supernatant was removed, leaving behind at least two mls. The pellet was re-
suspended and the final DNA bead suspension was transferred to a 1.7ml 
siliconized micro-centrifuge tube provided in the kit. Following a spin rotation the 
supernatant was removed and discarded and the remaining bead suspension was 
added to the tube and the spin rotation repeated. The 50ml tube was rinsed with an 
additional one ml of enhancing buffer and added to the 1.7ml tube. The bead pellet 
was thoroughly rinsed twice with one ml of enhancing buffer by spin rotation and 
discarding of the supernatant.  
5. DNA library bead enrichment  
A 10N Sodium Hydroxide (NaOH) (Sigma Aldrich,St Louis, Missouri, USA) solution 
was prepared by dissolving 2g of NaOH in five mls of Molecular biology water. This 
was   used   to   prepare   a   Melt   solution,   with   125μl   of   10N   NaOH   and 9.875ml of 
molecular biology grade water. Beads were washed twice with one ml of Melt 
solution followed by a two-minute incubation at room temperature. After a spin 
rotation   the   supernatant   was   removed,   discarded   and   45μl   of   annealing   buffer,  
15μl  of  enrich  primer  A  and  15μl  of  enrich  primer  B  was  added  to   the  beads  and  
vortexed well. The tube was placed on a heated block at 65°C for five minutes and 
then promptly cooled on ice for two minutes. The beads were washed with one ml 
of enhancing buffer for a total of three washes; each wash was followed by a spin 
rotation and removal of the supernatant 
.  
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6. Preparation of enrichment beads  
Enrichment beads were vortexed thoroughly for one minute to re-suspend the 
beads. Beads were washed by placing the tube on the Magnetic Particle 
Concentrator (MPC) (Invitrogen, Life Technologies, Carlsbad, CA) for three 
minutes,   removing   the   supernatant   and   adding   500μl   of   Enhancing   buffer.   The  
enrichment tube was then placed on the MPC to pellet the beads and the wash 
was repeated. Following  the  final  wash,  80μl  of  enhancing  buffer  was  added  to  the  
beads and vortexed. All of the washed enrichment beads were added to the 1.7ml 
tube of DNA beads and vortexed. The tube was placed on the lab rotator at room 
temperature for five minutes and thereafter pelleted on the MPC for five minutes, 
followed by removal of the supernatant. DNA beads were washed between six to 
ten times with one ml of Enhancing buffer to remove the white beads that do not 
contain DNA until the aspirated supernatant was clear i.e. no white beads were 
present. The  enriched  DNA  beads  were  washed  twice  with  700μl  of  Melt  solution,  
vortexed for five seconds and then pelleted on the MPC. The supernatant 
containing enriched DNA beads was transferred to a new 1.7ml tube. After a spin 
rotation the supernatant was removed and discarded and one ml of annealing 
buffer  was  added  for  a  total  of  three  washes.  Finally,  100μl  of  annealing  buffer  was  
used to re-suspend the beads. 
7. Bead counting  
After the enrichment, beads were counted on the GS Junior emPCR Bead Counter 
v2 (Roche, 454 TM Life Science). The recommended input for a sequencing run is 
500 000 enriched DNA beads. The bead counter was held at eye level, and the 
position of the pellet was noted. Ideally the pellet should be located within the 
window and above the bottom edge, indicative of 500 000 beads. If the number of 
positive beads was too high and the enrichment exceeded the threshold parameter 
of 20%, this indicated that the bead population contained too many beads and was 
discarded. 
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8. Sequence primer annealing  
To   anneal   the   sequencing   primers,   15μl   of   sequencing   primer   A   and   15μl   of  
sequencing primer B was added to the 1.7ml tube and vortexed. The tube was 
placed on a heating block at 65°C for five minutes and promptly cooled on ice for 
two minutes. The beads were washed twice with one ml of enhancing buffer and 




Before beginning the sequencing run, the instrument fluidics was thoroughly 
washed by performing a Pre-wash,   according   to   the   manufacturer’s   instructions  
(GS Junior Titanium Series, Sequencing Method Manual). 
2.  Preparation of the Bead Deposition Device (BDD) 
The BDD was washed twice using Nano Pure water and left to air dry. The PTP 
plate  was  then  installed  onto  the  BDD  according  to  the  manufacturer’s  instructions  
(GS Junior Titanium Series, Sequencing Method Manual).  
3. Preparation of Bead Buffer 2 (BB2) 
From the sequencing kit buffers, 6.6ml of Supplement CB was added to the Buffer 
CB bottle and thoroughly mixed by inverting the bottle ten times. Forty mls of this 
mix was transferred to a 50ml falcon tube and labeled Bead Buffer 2 (BB2); this 
was placed on ice until required. The tube of Apyrase was thawed and centrifuged 
at  9300  X  g  for  five  seconds  and  6.5μl  was  added  to  BB2  and  was  gently  inverted  
ten times to mix the contents and thereafter placed on ice. Using a single motion, 
380μl  of  BB2  was  pipetted  into  the  loading  port  of  the BDD and centrifuged for five 
minutes at 1620 X g. It was important to ensure that the centrifuge was correctly 
balanced with the provided adaptors during the centrifugation process.  
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4.  Preparation of the bead layers 
Four kinds of beads were prepared and loaded onto the PTP  
 Preparation of DNA beads  
Control beads XLTF were centrifuged in a micro-centrifuge for five seconds at 
9300 X g and was resuspended by pipetting up and down at least five  times.  Six  μl  
of the control   beads   and   500μl   of   BB2   were   added   to   the   previously prepared 
enriched DNA beads. After gentle vortexing the tube was sealed with parafilm and 
placed on the Lab Rotator for 20 minutes at room temperature. 
 Preparation of the packing beads  
Packing beads were washed three times by adding one ml of BB2 and vortexing at 
high speed until a homogenous suspension was formed. The tube was centrifuged 
at 9300 X g for five seconds following which the supernatant was carefully 
removed and discarded. After the final wash,  200μl  of  BB2  was  added,  vortexed  
and kept on ice until use. 
 
 Preparation of the enzyme and PPiase Beads  
Enzyme beads and PPiase beads were washed three times in parallel by the 
addition of one ml of BB2, care was taken not to mix tips. The tubes were vortexed 
at medium speed and placed on the MPC for 30 seconds thereafter the 
supernatant  was  carefully   removed  and  discarded.  After   the   third  wash,  400μl  of  
BB2  was  added  to  the  Enzyme  beads  and  410μl  of  BB2  was  added  to  the  PPiase  
beads and vortexed at medium speed. PPiase beads were then placed on ice until 
use. Enzyme Pre-Layer and Enzyme Post-layer were prepared as indicated in 







Table 2 Preparation of enzyme beads Pre-Layer and Post-Layer for the 
sequencing reaction 
 
Reagent  Enzyme Beads 
Pre-Layer  (μ/l) 
Enzyme Beads 
Post- Layer (μ/l) 
Total volume 
(μ/l) 
BB2 300 180 410 
Enzyme Beads  110 230 410 
 
 Preparation of the DNA and Packing Beads  
The DNA bead tube was removed from the Lab Rotator and centrifuged at 9300 X 
g for five seconds to pellet the beads. BB2 was removed leaving behind 
approximately  50μl.  Polymerase  and  Polymerase  Cofactor  tubes  were  centrifuged  
at  9300  X  g  for  five  seconds.    Forty  μl  of  Polymerase,  20μl  of  Polymerase  Cofactor  
and  65μl  of  BB2  was  added  to  the  tube  of  DNA  beads.  The  mixture  was  vortexed  
at medium speed for five seconds and incubated on the Lab Rotator for ten 
minutes at room temperature. The tube of Packing Beads was vortexed at high 
speed  and  175μl  of  packing  beads  was  added  to  the  DNA  mixture,  vortexed  at  low  
speed and incubated on the Lab Rotator for five minutes at room temperature.  
 
5. Preparation of Buffer CB  
The tube of 0.1M DTT was thawed, vortexed at high speed for five seconds and 
one ml was added to the bottle of Buffer CB and was inverted ten times. Using a 
serological pipette, 44ml of Substrate TW was transferred to the bottle of Buffer 
CB. The bottle was inverted ten times to mix and thereafter placed in the dark.  
 
6.  Priming the GS Junior  
The   GS   Junior   was   primed   following   the  manufacturer’s   instructions   in   the   user  
handout (Roche, 454 Life Science, Branford, CA, USA). The bottle of Buffer CB 
and the cassette containing sequencing reagents were placed in the instrument.  
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7.  Deposition of bead layers  
Beads  were  deposited  onto   the  PTP  by  pipetting  350μl  of  each  bead  suspension  
through the loading port of the BDD. Using centrifugal sedimentation, beads were 
packed to the bottom of the wells of the plate. After each layer was centrifuged, the 
supernatant was removed before the next layer was added.  
8. Initiating the sequencing run  
The GS Junior Titanium, PTP Kit Cartridge was prepared according to the 
manufacturer’s   instructions,   full   processing   for   amplicons   was   selected   at   200  
cycles, the plate was loaded onto the instrument and the sequencing run was 
started. The instrument fluidics were calibrated for 30 minutes followed by the 


























Input files for the Molecular Dynamics simulation 
 
Energy minimization  Heating Stages  
minimize ras-raf 
 &cntrl 
  imin=1,maxcyc=2500,ncyc=750, 
  cut=8.0,ntb=1, 
  ntc=2,ntf=2, 
  ntpr=100, 
  ntr=1, restraintmask=':1-242', 




  imin=0,irest=0,ntx=1, 
  nstlim=25000,dt=0.002, 
  ntc=2,ntf=2, 
  cut=8.0, ntb=1, 
  ntpr=500, ntwx=500, 
  ntt=3, gamma_ln=2.0, 
  tempi=0.0, temp0=300.0, 
  ntr=1, restraintmask=':1-242', 
  restraint_wt=2.0, 
  nmropt=1 
  ig= -1 
 / 
 &wt TYPE='TEMP0', istep1=0, 
istep2=25000, 
  value1=0.1, value2=300.0, / 
 &wt TYPE='END' / 
Density  Equilibration 
heat ras-raf 
 &cntrl 
  imin=0,irest=1,ntx=5, 
  nstlim=25000,dt=0.002, 
  ntc=2,ntf=2, 
  cut=8.0, ntb=2, ntp=1, taup=1.0, 
  ntpr=500, ntwx=500, 
  ntt=3, gamma_ln=2.0, 
  temp0=300.0, 
  ntr=1, restraintmask=':1-242', 
  restraint_wt=2.0, 




  imin=0,irest=1,ntx=5, 
  nstlim=1000000,dt=0.002, 
  ntc=2,ntf=2, 
  cut=8.0, ntb=2, ntp=1, taup=2.0, 
  ntpr=1000, ntwx=1000, 
  ntt=3, gamma_ln=2.0, 
  temp0=300.0, 




Script: Calculation of the RMSD using PTRAJ 
 
Trajin equil.mdcrd.gz 1:250 1 
Reference sample_solvated.inpcrd 
 177 
















Residue  Location Distance  Residue Location Distance    
D25 O18-OD1 2.443 D25 O18-OD1 2.434 0.009 
  O18-CG 2.803   O18-CG 2.793 0.01 
  OD2-O05 2.561   OD2-O05 2.561 0 
D29 C29-OD2 4.204 D29 C29-OD2 4.205 0.001 
  C29-CG 4.34   C29-CG 4.34 0 
  C29-OD1 4.669   C29-OD1 4.667 0.002 
  C29-CB 4.809   C29-CB 4.808 0.001 
D30 C25-OD2 4.846 D30 C25-OD2 4.844 0.002 
  C25-CG 5.151   C25-CG 5.149 0.002 
  C25-OD1 6.219   C25-OD1 6.217 0.002 
V32I  C15-CG1 8.125  V32I C15-CG1 8.422 0.297 
  C15-CB 9.623   C15-CB 9.898 0.275 
  CG2-C15 10.167   CG2-C15 10.478 0.311 
I50 CG1-C3 6.444 I50 CG1-C3 6.447 0.003 
  CD1-C3 7.537   CD1-C3 7.557 0.02 
  CB-C3 6.326   CB-C3 6.325 0.001 
V82 CB-C15 4.324 V82A CB-C15 4..284 0.04 
  CB-C14 5.695   CG2-C15 4.588 1.107 
  CA-C15 5.531   CG1-C15 4.643 0.888 
I84 CG2-C15 6.191 I84V CG2-C15 6.463 0.272 
  CB-C15 6.07   CB-C15 6.129 0.059 
  C15-CG1 7.034   C15-CG1 4.711 2.323 
